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Sumnary
The first section of this thesis reviews the literature 
dealing with the biological activities k n o m  to be present 
in the terpenoids, and in the main treats the subject in 
terms of the usual chemical classification of terpenoids 
as mono-, sesqui-, di- and tri-terpenoids. Selected 
examples are also given in order to illustrate how the 
group fits in with modern concepts of drug action, such as 
structural specificity, the supporting moiety theory and 
the theory of metabolite displacement. Certain representative 
members of each chemical sub group are discussed in detail 
but others are covered in a more general manner in order to 
lend perspective to the field.
The second section is concerned with the synthesis of 
certain terpenoid hemisuccinates as potential general 
anaesthetic agents. The preparation of these compounds is 
justified in terms of theories of general anaesthesia 
which are briefly discussed. Pharmacological testing showed 
that the compounds were inactive and this fact is compared 
with evidence previously reported which indicates that the 
steroidal general anaesthetics may be structurally specific 
agents unlike the simple gaseous anaesthetics which are 
believed to act by a ’’physical" or structurally non-specific 
mechanism.
The third section of the thesis describes the s^mthesis 
of structurally rigid acetylcholine-like bornane derivatives 
and the reasons for their preparation. Also included is a 
summary of present day knowledge of the role of acetylcholine 
in the animal body and of the different classes of drugs 
mimicking or antagonising this neurohormone at its various 
sites of action. A brief discussion of other biologically 
active bornane derivatives is also given.
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INTRODUCTION
1.
Despite the ready availability and widespread 
occurrence of the terpenoids very few members of the 
group are of any great pharmacological significance.
In view of the detailed knowledge of their chemical 
properties and molecular structures now available it 
seemed a worthwhile endeavour to carry out investigations 
as to the suitability of various terpenoids as starting 
materials for the synthesis of new potentially 
biologically-active molecules and the results of these 
studies are reported in this thesis. Two lines of 
investigation were pursued. In the first,various 
representative terpenoids possessing an alcoholic 
function were converted to the corresponding 
hemisuccinates in order to assess such derivatives for 
general anaesthetic potency and in the second,the 
bornane skeleton was utilized as a rigid molecular 
framework with which to investigate activity in 
conformationally rigid acetylcholine-like molecules.
A detailed discussion of the theoretical justifications 
for these studies is given in sections II and III 
of this thesis. In order to place these studies in 
clearer perspective in relationship to the biological
2.
properties of the terpenoids as a whole, a review of 
biological activity in the terpenoids and their 
derivatives is included as section I of the thesis. 
This review is necessarily far from complete both on 
account of the extremely large number of studies 
reported in the literature and because a considerable 
number of studies have been reported in relatively 
inaccessible publications. Nevertheless a serious 
attempt has been made to ensure that the survey is as 
representative as possible.
Section I.
3*
I. BIOLOGICAL ACTIVITY OF THE TERPENOIDS AND THEIR 
DERIVATIVES .
The terpenoids constitute one of the largest 
groups of naturally-occurring compounds being 
characterised by their extremely widespread distribu 
-tion in both the plant and animal kingdoms and by 
their great diversity of chemical structure (1). 
Extensive biological investigations have been carried 
out within the group and a number of terpenoids and 
their derivatives have seen medicinal application.
Some are in use today, whereas others have disappeared 
from the pharmacopoeias and so the group affords many 
illustrations of the progress in clinical medicine. 
Other terpenoids are of considerable pharmacological 
interest, and still others are of value in horticulture 
and agriculture where they are employed as pesticides 
and fungicides. Many terpenoids and their derivatives 
are also of the greatest importance to the perfume 
and cosmetic industries.
4-.
THEORETICAL CONSIDERATIONS 
Structural Specjflcity
In general, compounds showing biological activity are 
conveniently divided into two classes - the structurally 
specific and the structurally non-specific (2) - and 
one of the interesting features of the terpenoids as a 
class is the variation in the degree of structural 
specificity within the group. Although most members 
would appear to have little or no structural specificity 
(which serves to eyplaln their relative unimportance 
in modern medicine with its emphasis on highly specific 
drugs), there are, nevertheless, some terpenoids of 
pronounced structural specificity. Examples are provided 
by the Erythrophleum alkaloids, mecamylamine and the 
vitamins A and K. As might be expected, terpenoids 
with a relatively simple chemical constitution tend to be 
non-specific whilst the more complex compounds tend to 
show greater specificity.
Compounds which are completely structurally 
non-specific exhibit biological activity solely by 
virtue of their favourable physical properties in 
accordance with the principle so elegantly established 
by Ferguson (3)5 and their biological properties
5*
are entirely independent of their functional groups and 
stereochemistry. Such compounds may be expected to 
satisfy two criteria. Firstly they should exert an effect 
on a variety of biological phenomena and secondly their 
relative potencies should be independent of the test 
system employed. Although considerable work has been 
done in relating the potency of structurally non-specific 
agents of various chemical classes (which are active as 
general anaesthetics, insecticides, bactericides etc.) 
to thermodynamic activity, few quantitative studies have 
been carried out with the terpenoids. Most investigators 
have concentrated their efforts on such groups as the 
paraffins, simple ethers, ketones, inert gases and 
highly chlorinated compounds. In particular, much 
attention has been devoted to the homologous primary 
alcohols (4). Since one of the consequences of Ferguson’s 
Principle is that optical antipodes should be equipotent, 
the neglect to include terpenoids in the quantitative 
study of non-specific agents is surprising in view of 
the fact that many of the simpler terpenoids are readily 
available from natural sources in both enantiomorphic 
forms. Di- and tri-terpenoids, however, appear to occur in 
nature in only one antipodal form - with the notable 
exception of the diterpene kaurene (5)«
6 .
For compounds acting by a structurally specific 
mechanism, current theory postulates that biological 
activity is the result of interaction between the drug 
molecule and a specific receptor to form a drug-receptor 
complex. In the majority of cases the forces involved 
in the formation of the complex are of the nature of 
electrostatic and van der Waal’s forces. Optimum 
conditions for complex formation will therefore be 
greatly dependent upon the functional groups and 
3 -dimensional geometrical properties of the drug 
molecule. The more dissimilar a given set of receptors 
are in their nature to all other receptors and the 
greater the restrictions imposed by these receptors on 
the achievement of adequate "fit", then the more 
structurally specific a drug which satisfies these 
restrictions will be*
Terpenoids as Metabolite Displacing Agents
Often a structurally specific drug exerts its action 
by competing successfully with some metabolite of the 
organism, to which it is closely related in chemical 
and physical properties, for a receptor. It thus denies 
the natural agent access to the site where it
7.
initiates the characteristic train of events which is 
observed as a biological response. In such cases of 
metabolite displacement the drug can be expected to 
intensify, mimic or oppose the action of the natural 
metabolite depending upon its affinity for the receptor 
and upon its intrinsic activity (6), a term introduced 
as a measure of the ability of the compound to evoke a positive 
physiological response once the receptor-complex has been 
formed. In favourable circumstances, where rigid 
molecules are involved, it should be possible to deduce 
something of the physical nature of the receptor-site 
from a consideration of the geometrical properties and 
electric charge distribution of those molecules capable 
of complexing with it and of those which lack this 
ability. Most of the work along these lines in the 
terpene field appears to have been carried out with 
triterpenoids, having been inspired by the similarity 
in chemical structure between these compounds and the 
steroids. For example compound I, prepared :
o
HO
8.
from lanosterol (7)5 has been shovn to exhibit 
progestational activity, but compound II, prepared 
from the triterpenoid dipterocarpol, is without such
HO
II
activity (8).
Unfortunately the case of compound I is complicated 
by the fact that the steroid hormones are formed in the 
body via lanosterol and it is conceivable that pathways 
exist for the in vivo conversion of this compound into 
progesterone. No similar ambiguity exists in the case of 
compound II however. As this substance does not 
antagonise the action of progesterone, or is not at 
least a powerful antagonist (9)> it would seem that 
it owes its lack of activity to an inability to undergo 
complex-formation with the receptor (zero affinity) 
rather than to a low intrinsic activity. Thus the 
shape of the receptor may be such as to accommodate the 
flat steroid nucleus but not the deformed nucleus - ,
9.
of II. with the strong non-bonded interaction between the 
methyl groups on C-8 and C-10.
Similarly compound III, which was also prepared from
OH
III
dipterocarpol (8), was found to be inactive as a male 
sex hormone and to lack appreciable antagonism to its 
analogue testosterone.
Another steroid analogue derived from a 
triterpenoid which is worthy of mention is the 
lanosterol analogue of provitamin (IV) (10), 
although it is without biological action as is the 
8,l4 seco 8[26],9[l3] ,12-triene derived from 
methyl ursolate (11).
HO
IV
10*
The receptor site is^ however, only one of three 
sites which must be taken into account when considering 
interference between a metabolite-displacing agent and 
the natural metabolite. Often the metabolite is held in 
an inactive or bound form in the cell and the displacing 
agent could conceivably effect release of the metabolite 
by a replacement reaction. Again the metabolite- 
displacing agent may compete for the site at which the 
normal metabolite undergoes inactivation with 
consequent prolongation of the action of the metabolite. 
Indeed there would seem to be good evidence that 
certain tri terpenoids do act in this manner by 
preventing the inactivation of adrenocortical steroid 
hormones. The greatest attention has been paid to 
glycyrrhetinic acid (12), (syn glycyrrhetin) (V),
COOH
HO
V
its synthetic derivatives (13)? and glycyrrhizinic 
acid (syn glycyrrhizin), which is derived from 
glycyrrhetinic acid by combination with two ‘
11 •
molecules of glucuronic acid. These triterpenoids are 
obtained from liquorice and the earlier investigators 
employed crude liquorice extracts. Other triterpenoids, 
including synthetic derivatives, have also been 
examined for adrenocorticoid activity (1^).
The early work with the triterpenoids from liquorice 
led to many conflicting claims as to their mineralo- 
corticoid, glucocorticoid and anti-inflammatory 
properties (1?), and it was not until Atherden (16) 
demonstrated that glycyrrhetinic acid acted in vitro 
as a powerful inhibitor of the enzymes responsible for 
the inactivation of 11-deoxycorticosterone and 
progesterone that any clarification of the position 
was achieved. This evidence - taken in conjunction 
with the numerous clinical observations that 
glycyrrhetinic acid or glycyrrhizinic acid are active 
only in patients still retaining functional adrenal 
tissue (17), or are of value only as adjuncts to 
cortisone or hydrocortisone therapy (18) - would strongly 
indicate that the triterpenoids are themselves without 
adrenocortical activity but are able to interfere with 
the destruction of the steroidal hormones. Still further 
evidence is afforded by the demonstration that
12.
ammonium glycyrrhizinate depresses the excretion of 
urinary 17-ketosteroids (19) and produces a rise in the 
plasma levels of hydroxycorticosteroids (20). The other 
actions of glycyrrhetinic and glycyrrhizinic acids, 
such as the ability to depress the secretion of 
adrenocorticotrophic hormone (21), the ability to 
produce hypertension in unilaterally nephrectomized 
rats (22) and the cortisone-like anti-leukaemic action 
(23) ? can also be explained by an inhibition of the 
biotransforniatlon of adrenocortical steroids.
Glycyrrhetinic acid has been shown to produce an 
inhibition of oestrogen-induced uterine growth, but the 
inhibition is grossly non-competitive (2^). It is not 
possible to deduce whether this is due to irreversible 
competitive antagonism or whether it is due to different 
receptors being involved.
Supporting Moiety Theory
Another interest in the terpenoids arises from the 
light which they cast on the "supporting moiety" theory. 
This theory, first formally stated by Cavallini (2^), 
postulates that the molecules of substances possessing 
pharmacological activity consist of two portions, the 
supporting moiety which confers affinity for the site
13.
of action ( and which could also he involved in 
transportation mechanisms etc. ) and the radical moiety 
which determines the type of activity displayed. The 
broad scope of the theory is readily apparent from a 
consideration of the important role which groups such as 
the hydroxyl and amino functions play in determining the 
activity of so many diverse drugs. Strong support for the 
theory has been provided by studies in the terpenoid 
field, excellent examples being afforded by the 
Erythrophleum alkaloids and the vitamin K.
The Erythrophleum alkaloids which exhibit pronounced 
positive inotropic cardiac activity are esters of certain 
c<,p- unsaturated tricyclic diterpene acids and
dimethylaminoethanol or p- methylarainoethanol. The 
aminoalcohols themselves show the same qualitative action 
on the heart as do the derived alkaloids, but are some 
800 times less potent on a molar basis (26). Thus the 
chemical combination of the diterpene acid moiety (the 
supporting moiety) with the alkanolamine (radical moiety) 
reinforces the biological property already characteristic 
of the radical moiety.
Replacement of the natural tricyclic diterpene acids 
by other acids, including the diterpenoid abietic •
14-.
acid and the triterpenoid sarsasapogenoic acid has been 
shown in general to lead to reduction of activity (27)*
It is of interest that saturation of the double bonds 
in the supporting moieties of the natural alkaloids also 
leads to loss of activity (28). As reduction of the 
double bond of the unsaturated lactone ring of the 
steroidal cardiac glycosides is well known to lead to 
loss of potency there may be some biological 
correspondence between the «r, p-unsaturated ester system 
of the Erythrophleum alkaloids and the oc, p -unsaturated 
lactone ring of the cardiac glycosides, although the 
steric relationships of these unsaturated functions to 
the rest of their molecules are quite dissimilar.
Vitamin (VI) is 2-methyl-3-phytylnaphtho-1,4-quinone 
and therefore can be regarded as a diterpene derivative.
o
VI VII
It was found, however, that on a molar basis the synthetic 
compound 2-methyInaphtho-1,4— quinone ( menadione )
15-
(VII) in the form of its soluble sodium bisulphite 
addition compound had greater antihaemorrhagic activity 
than the natural vitamin following oral administration 
to dogs or chicks (29)• Thus it would appear at first 
glance that the quinonoid moiety is more active without 
the addition of a diterpenoid supporting moiety. However
ih.
work with C labelled menadione in the rat has shown that 
menadione is converted by the addition of a diterpenoid 
side-chain into 3-(geranylgeranyl)-2-methylnaphtho-1 , 
^-quinone or vitamin [zo] (30)# The apparent higher 
activity of menadione as compared to that of vitamin 
is therefore probably due to the better absorption and 
penetration of the simpler compound prior to its 
biotransformation into vitamin K2 [2(^  • Support for this 
assumption is provided by studies on the ability of 
menadione and various 3-polyisoprenoid-substituted 
menadiones to antagonise the action of anticoagulants, 
Isler et al. (31) having firmly established that a side 
chain of a certain minimum length is necessary for this 
activity. Later work by the same school (32) has shown 
that biological activity in the vitamin K-deficient 
chick is also dependent upon the length of the 
polyisoprenoid side chain attached to the quinonoid 
moiety.
16.
Much other work having a bearing on the supporting 
moiety theory has been reported in the terpenoid field.
For example Reinhard et al. (33) pointed out that the 
p -dimethylaminoethyl group formed an integral part of 
the molecular structure of many anti spasmodic, local 
anaesthetic, sympathomimetic and antihistaminic drugs. 
Treating this function as the radical moiety, they 
investigated the effects of changing the supporting moiety. 
They discovered that thymyl-f -dimethylaminoethyl ether
(VIII) and menthyl-p -dimethylamlnoethyl ether (IX)
OCHgCHgN
CH
H
CH
VIII IX
possessed pronounced anti spasmodic activity. Similar 
considerations inspired the pharmacological investigation 
of the B -diethylaminoethyl ester of cumic acid (X) ' '
COOCH^CHgNC^^ "^^^3  
CH2CH3
X
17-
(3^) which in the form of its hydrochloride is claimed 
to be equipotent with procaine hydrochloride as a local 
anaesthetic. A further example is afforded by two isomeric 
2-hydroxy-3-methylaminocamphanes, prepared during an 
investigation of the pharmacological importance of the 
^-methylamino- -hydroxyethyl radical, which were shown 
to have pronounced action on the respiratory centre of 
rabbits (35)*
With the discovery that certain thiosemicarbazones and 
acid hydrazones possess marked antituberculous properties 
a great deal of attention has been devoted to the 
preparation and screening of drugs belonging to these two 
classes. Included in these studies were the isonicotinyl 
hydrazone of cumaldehyde (36), the o-hydroxybenzoyl 
-hydrazone of perillaldehyde (37) ^nd the thiosemicarba 
-zones of citronellal (38) and cumaldehyde (39)* 
Thiosemicarbazones derived from p -ionone (XI) and the
o
XI XII
isomeric y -ionones (e.g. XII) are claimed as anti 
tuberculous agents in the patent literature (4-0).
18.
Although strictly speaking the ionones are not true 
terpenoids they are customarily included in the group 
as they are simple condensation products of citral and 
cyclocitrals with acetone.
The ionones can be used to furnish other examples of 
the supporting moiety concept. For instance studies with 
various ionylamines (4-1 ) have shown that, in contrast to 
the p- ionylamines, the ^ -ionylamines have a high 
spasmolytic activity in vivo, thus providing a good 
illustration of how minor changes in the supporting 
moiety can have a major effect on the activity displayed.
Further examples which may be quoted are the preparation 
of the geranyl, citronellyl and linaloyl esters of 
chaulmoogric acid (4-2) in attempts to increase the 
efficacy of chaulmoogra therapy for leprosy and the 
synthesis of terpenoid esters of piperonylic acid as 
potential insecticides (4-3).
In addition, certain chemical features possessed by 
various biologically active terpenoids have inspired the 
preparation and biological testing of other molecules 
possessing the same structural unit. This approach can 
be regarded as a special aspect of the supporting moiety 
theory in which attempts are made to isolate the ' ' '
1 9.
active radical moiety and combine it with other 
supporting moieties. An example of such work has been the 
preparation and testing of lactones (4-4-) as potential 
anthelmintics since the sesquiterpenoid anthelmintic, 
santonin, possesses a lactone function.
Biotransformation
Terpenoids have played an important role in studies of 
biotransformation and metabolism of compounds foreign to 
the body. Because many terpenoids can be considered as 
normal constituents of animal food, the ability of the 
animal organism to metabolise them into compounds more 
easily excreted and eliminated has not had as great an 
impact on scientific thinking as has the ability of 
animals to effect biotransformation of the newer 
synthetic compounds to which life could never have been 
exposed in the whole course of evolution. Nevertheless, 
now that it is recognised that the liver microsomes are 
capable of adaptive enzyme-formation to metabolise to a 
greater or lesser degree innumerable compounds foreigh 
to the body (4-5) ? the accumulated information on the 
biotransformations of the terpenoids achieves a new 
significance. An excellent summary of the
20.
biotransformations undergone by monoterpenoids is to be 
found in the book by Williams (46).
In general the main type of biotransformation suffered 
by mono terpenoids in the animal body is conjugation to 
glueuronides, with or without accompanying oxidations 
and reductions. The excretion of monoterpenoids as 
glucuronides has been proposed as the basis of a test 
of liver function (4y), and another interesting 
application of the glucuronic detoxication mechanism was 
devised by Williams (48) who utilized it to resolve 
dl. menthol.
Other Interests in Terpenoids
Other interests in the terpenoids arise from the part 
that the quinonoid derivatives of some of the higher 
members, such as the ubiquinones and vitamin K, appear 
to play in the electron transferring system in 
respiratory chain phosphorylation (49,%) and from the 
role which the carotenoids and chlorophyll play in the 
energy transfer processes of photosynthesis in plants. 
These will not, however, be discussed here.
21.
CLASSIFICATION
The terpenoids are customarily classified according 
to the number of carbon atoms present in the molecule, 
giving rise to four main groups. These are the 
monoterpenoids, which are derivatives of certain C^^ 
hydrocarbons, the sesquiterpenoids, which are derivatives 
of certain hydrocarbons, the diterpenoids, which are 
derivatives of certain C2Q hydrocarbons, and the 
triterpenoids, which are derivatives of certain C^q 
hydrocarbons. In addition a fifth group, the carotenoids, 
which are derivatives of certain Cj^ q hydrocarbons, are 
sometimes referred to as tetraterpenoids. Further 
subdivision within these groups is made according to the 
number of carbocyclic rings present in the molecule. 
Occasionally certain derivatives of isoprene (XIII) are
A.
XIII
termed as hemiterpenoids.
All the terpenoids are elaborated in nature from 
acetate units via the key intermediate mevalonic acid 
(XIV) which can be considered to be the ' . V .
22.
OH
OH
 COOH
XIV
’active isoprene precursor" responsible for the validity 
of the isoprene rule (51), long recognised by organic 
chemists as applying to these compounds. In fact the 
criterion which determines the inclusion of a compound 
as a terpenoid is that its carbon skeleton obeys the 
isoprene rule^ or is formally derived in a simple fashion 
from a carbon skeleton which does obey the isoprene rule 
by bond migration, loss or gain of carbon atoms, or 
through condensation with other simple molecules. Recent 
progress in the elucidation of the steps involved in the 
biogenesis of natural products has clearly shown that 
many compounds not formerly regarded as terpenoids are 
derived in nature from terpenoids by processes such as 
those just enumerated. One important group so related is 
the steroids (including vitamins D) which are formed in 
the plant or in the animal body by a route involving the 
triterpenoids squalene and lanosterol as intermediates 
(52,53)* It is not proposed, however, to discuss the 
biological properties of the steroids in this ■
23,
review. General accounts of the importance of steroids 
in pharmacology and medicine have appeared (54) and 
numerous specialised reviews dealing with specific 
classes of steroids are available in such publications 
as Vitamins and Hormones.
It is to be noted in passing that it is perhaps 
conceivable that the various terpenoid intermediates 
known to be involved in steroid biosynthesis may prove to 
be of some practical application in cases of steroid 
deficiency. In this connection it has been shown that 
administration of squalene maintained lactation in rats 
which otherwise lactated poorly on a squalene-free 
diet (55).
Many naturally-occurring compounds of biological 
interest are known which are elaborated by a mixed 
biogenesis where one portion of the molecule arises via 
the isoprenoid route vhile the remainder of the molecule 
is formed via linear polyacetate route or shikimic acid 
route. In some cases a complete terpenoid unit is involved 
but in the other cases single isoprenoid units are 
utilized. A case of incorporation of a monoterpenoid 
is afforded by the isomeric tetrahydrocannabinols which 
are the active principles of cannabis (marihuana).
2^ -.
the structure of one of which is shown in XV. It has
OH
CH2CH2CH2CH2CH3
XV
been postulated (56) that these compounds are formed by 
the condensation of a menthatriene with olivetol. 
Analogous reactions employing pulegone have been 
successfully performed under laboratory conditions (57)*
Despite intensive research (58) the action of 
cannabis on the central nervous system in man is still 
not well understood. Several reviews dealing with 
cannabis addiction in the United States of America have 
been published (59) and leading references to the 
investigations of the biological properties of cannabis 
are given by Sollmann (60) and Goodman and Gilman (61).
A considerable number of synthetic tetrahydrocannabinol- 
like compounds have been prepared for pharmacological 
study (62).
The vitamins K and E represent examples of mixed 
biogenesis incorporating diterpenoid units, and 
fumagillin can probably be regarded as the product of 
mixed biogenesis involving a se squi terpenoid \
25.
unit. These substances will be discussed more fully 
later in this review.
Examples of natural products in which separate isoprene 
units have been incorporated are afforded by humulone 
and lupulone (XVI ), which have been shown to be
OH
OH
XVI
antibacterial agents(63). Recently lysergic acid has been 
demonstrated to arise in nature by condensation of moieties 
derived from tryptophan and mevalonic acid (6^), and a 
mixed biogenesis for the plant oestrogen miroestrol (XVII)
OH
OH
HO
XVII
has been proposed in which an isoprene unit and
26.
an Isoflavenoid moiety are involved (65). Fumerons other 
examples could be given (66) but it is not within the 
scope of this review to discuss these compounds further.
In reviewing such a broad field as the biological 
activities of the terpenoids, any treatment which is to 
be concise must necessarily be highly selective. No 
attempt has been made to cover the literature pertaining 
to galenical preparations which are either Imovm or 
suspected to contain terpenoids, although isolated 
examples will be given. The coverage afforded to pure 
compounds is also far from exhaustive and many 
contributions to the literature must go unacknowledged.
It is hoped, however, that the present review will serve 
to provide a perspective and that the references cited 
will serve as adequate keys to the voluminous literature.
NO woterpenoids
Essential Oils
The majority of monoterpenoids are obtained from the 
essential oils of plants where they often occur in 
admixture with volatile compounds of other chemical 
groups (67). As a large number of investigations have 
been carried out with essential oils rather than
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with their pure components, it is necessary to devote 
some attention to the biological properties of 
essential oils.
In nature the essential oils appear to play a 
considerable role in the economy of the vegetable 
kingdom. Their pronounced attraction for certain insects 
favours pollination whilst their repellant action towards 
other insects may serve to protect the plant against 
otherwise harmful species. Most essential oils and 
their constituent, monoterpenoids are characterised by 
their agreeable odours and their palatable flavours and 
so monoterpenoids are of importance in the perfumery and 
cosmetic industries and are employed in pharmacy as 
flavouring agents to mask the disagreeable taste of 
certain medicines. Although odour and the closely related 
phenomenon of taste are properly regarded as manifestations 
of biological activity, it is not proposed to consider 
the use of the terpenoids as flavouring agents and 
perfumes in this review. A number of key references to 
the odoriferous properties of terpenoids and their 
derivatives are to be found in various reviews (68) and 
in the monograph published by the Society of Chemical 
Industry (69). The compositions of various '
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cosmetics and perfumes containing monoterpenoids are 
given in the book by Poucher (70).
It is to be noted, however, that substances possessing 
strong odours are able to produce reflex medullary 
stimulation resulting in increased respiration and a 
transient rise in blood pressure and so various essential 
oils have on occasion been used to revive the patient in 
cases of fainting, though more pungent substances such as 
ammonia are of greater value in this respect. Certain 
mixtures containing monoterpenoids have also been used 
as sedatives in cases of hysteria, their effect presumably 
being mediated by olfactory and psychic reflexes. One such 
preparation is valerian prepared from the dried roots and 
rhizomes of Valeriana officinalis and which contain 
bornyl valerate as well as other terpenoid derivatives*
At one time the essential oils saw considerable 
application in medicine, the Dispensatorium Valeri Cordi 
of 1592, listing some 60 different oils, as was pointed 
out by de Mayo (7I ). In recent times, however, the 
essential oils and monoterpenoids have become less and 
less important medicinally and a recent text book on 
therapy (72) gives no reference at all to essential oils 
as therapeutic agents and only one or two minor '
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references to monoterpenoids as constituents of lotions. 
Their main application today is as carminatives.
In general the essential oils and their constituent 
monoterpenoids are structurally non-specific agents acting 
on virtually all organs of the body and on a variety 
of biological systems. Thus when Eadie et al. (73) were 
seeking a drug conforming to Ferguson ' s principle with 
which to destroy infusoria in the sheep’s rumen they 
turned to various monoterpenoids. Quite often the 
pharmacological action shown by monoterpenoids and 
essential oils is characterized by stimulation in low 
dosages and depression at higher dosages. For instance
various monoterpenoids and essential oils have been shown
to both stimulate and depress the gastro-intestinal 
tract (7^). Similarly, although the principal central
effects are reflex, in large enough doses the essential
oils may exert a direct action on the central nervous 
system producing a depression which in some cases is 
preceded by stimulation.
Other actions shown by essential oils are at the 
neuromuscular junction where they produce a paralysis 
of the muscle (75), and on the heart, where there is 
again a stimulation and depression. Further ' ' *
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evidence of the non-specific nature of their actions is 
afforded by their anti-inflammatory properties (76), 
their haemolytic action (77), their ability to produce 
•methaemoglobin (78) and their ability to inhibit serum 
cholinesterase (79). Recently work has been published 
which indicates that various essential oils may have the 
ability to stimulate the cellular defence mechanism of 
guinea pigs as evidenced by their beneficial influence 
on the outcome of experimental tuberculosis (80) and by 
the India ink and Trypan blue tests for phagocytosis (81).
Perhaps the most characteristic property of many 
essential oils is their irritant activity and to this may 
be traced many of their former clinical applications.
For example the use of essential oils in stomachic 
mixture was due to the feeling of warmth produced on 
irritation of the mucous membranes of the mouth and 
digestive tract and to the increased salivation. Similarly 
the former use of such essential oils as vOil of juniper 
as diuretics depended upon.the irritation produced in the 
kidneys. It is of some interest that the active principle 
of oil of juniper has recently been identified as 
^-terpineol (82). With some oils, e.g. oil of pennyroyal 
and oil of savin, the irritation of the kidneys and 
bladder can be so great as to set up reflex
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uterine contractions and so these oils have on occasion 
been used as emmanogogues and abortifacients. There is, 
however, no direct action on the uterus (83).
Externally the essential oils can be used as 
counter-irritants and rubefacients in the form of 
embrocations and liniments. They produce an initial 
feeling of warmth and smarting which is often followed by 
a mild local anaesthesia. Such preparations have been used 
to relieve rheumatic pain, neuralgia and pleurisy and 
in the treatment of the common cold and bronchitis. 
External application may produce dermatitis especially 
in hypersensitive individuals (84). Oxidation products 
formed from various olefinie constituents appear to be 
the causative agents (85).
The use of certain essential oils in the relief of the 
symptoms of acute bronchitis stemmed from their mild 
expectorant action (86) resulting from irritation of 
the bronchial glands.
The essential oils and the monoterpenoids are mild 
antibacterial (87) and antifungal (88) agents and in 
nature these properties probably protect the plant against 
noxious bacteria and fungi. The utilization of their 
antiseptic potency by man is, however, limited by ' '/
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their sparing solubility in water although various 
techniques can be employed to increase their solubility (89) 
A claim has been made that the protisticidal potency of 
essential oils is related to their dehydrogenase 
arresting properties (90).
Several essential oils have seen use as urinary 
antiseptics (91) but they have long been regarded as 
being of little real clinical value (92) and are never 
used today with the availability of sulphonamides and 
antibiotics. The use of essential oils such as oil of 
eucalyptus in the treatment of pulmonary infections is 
likewise of no value. The mild antiseptic properties of 
monoterpenoids are perhaps of value in toothpastes where 
their rubefacient action on the gums is also of benefit. 
Reviews have been published on the antiseptic properties of 
essential oils (93) and there is also a review of the 
pine-oil disinfectants (94).
It has been reported that ultraviolet (95) and 
X-ray (96) irradiation of essential oils increase the 
anti-bacterial activity and it will be interesting to 
learn the exact nature of the chemical changes involved 
and whether or not terpenoids are implicated.
Oil of chenopodium formerly saw specialised use :
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as an anthelmintic against hookworm (97) in both medical 
and veterinary practice. In this case the activity is due 
to the presence of one particular compound, ascaridole 
(XVIII). Unfortunately ascaridole is very toxic to the
XVIII
host as well as to Ascaris spp and its use in human 
medicine has been strongly opposed for a number of years 
(98). Attempts have been made to overcome its toxicity to 
the host by subsequent administration of physiological 
detoxifying agents such as ascorbic acid and glucuronic 
acid (99).
A detailed description of the pharmacological and 
toxicological properties of different essential oils are 
to be found in various text-books (100,101), and an 
account of their former use in the treatment of wounds 
has been published (102). The biological studies of 
essential oils have not been confined to animals. Their 
action on plants has also been studied (103).
Table I lists several essential oils which 
have been used therapeutically. The examples
TABLE I
ESSENTIAL OILS USED MEDICINALLY
Oil Source
Monoterpenoids 
 present
Sesqulterpenoida 
 present______
Other
Compounds Application
Bill Oil
Aniseed Oil
Ripe fruits of 
Anethum graveolens
Ripe fruits of 
Pimpinella anisum
Chinese Star Ripe fruits of 
Anise Oil Illicium verum
=r ■
Eugenia 
caryophyllata
Ig Oil Seed kernels of 
lAvristica 
fragrans
Bark of 
Cinnamonum 
zeylanicum
Mi^Alwood The wood of 
Oil Santalum album
Garyone
(+) a-Phellandrene 
Limonene
p-Cymene
T- )a-Phellandrene 
(+)p-Phellandrene 
(-)Limonene 
vDipentene 
^-Carene 
(+)a-Pinene 
(+)a-Terpineol 
l;8-Cineole
Bisabolene
Cadinene
«
Billapoil
2 -Cresol
Isoanethole
Anethole
Homoguaiacol
Hydroquinone
Anisalcohol
Anisaldehyde
Anisyl ketone
£-Methoxybenzoic acid
Acetaldehyde
Isoanethole
Anethole
Poeniculin
Hydroquinone monomethyl 
ether
Anisaldehyde
Anisylketone
Decanoic acid
Tiglic acid
Benzoic acid
£-Methoxybenzoic acid 
3 ,4-Dlhydroxybenzoic acid
Carminative.
In gripe water
Carminative as 
anise water
Carminative,
ySphyllene 
Humulene
Caryophyllene oxide
ife f.
^2-Hep^ fano 
2-Nonanol 
Eugenol
Benzyl alcohol 
Vanillin
Methyl amyl ketone 
Methyl heptyl ketone 
Diacetyl 
Benzoic esters 
a-Purfuryl alcohol 
Furfural
5-Methylfurfural 
4,5-DimethyIfuran-3-aldehyde
spasmodic 
Carminative 
Antiseptic 
and relief of 
toothache
p-Cymene
Dipentene
(+la-Plnene
(+1 Camphene
(+) Linalool
p-Menth-l-en-4-ol
(+) Borneol
p-Cymene
(-)P-Phellandrene 
f-)a-Pinene 
(-) linalool 
Cuminaldéhyde
Santene 
Teresantalol 
Santenone 
Teresantalic acid
Santalene 
Santalol
Isoeugenol 
Myristicin 
Octanoic acid 
Decanoic acid 
Dodecanoic acid 
Tetradecanoic acid
Eugenol
Cinnamic alcohol 
n Nonanol
5henylpropionaldehyde 
Cinnamic aldehyde 
Methyl amyl ketone 
Benzoic acid 
Cinnamic acid 
Furfural
Isovaleric aldehyde
Carminative
Carminative, 
also in 
treatment of 
catarrh and 
influenza
Urinary
disinfectant
W
Oil of 
Cajuput
Peppermint
Oil
leaves and twigs of Dipentene 
Melaleuca (+)a-Knene
leucadenTron
Flowering tops 
of Mentha 
piperita
( + )a-!ferpineol 
1,8-Cineole
(+ ) a-Phellandrene
(-)Limonene
(-)a-Pinene
(-Menthol
(+)Neomenthol
(-)Menthone
(+)Isomenthone
(+)Piperitone
Piperitenone
Isopiperitenone
1,8 Cineole
Peperinic acid
Menthofuran
Cadinene
Caryophyllene
Eugenol methyl ether 
Butyraldéhyde 
Valeraldehyde 
Benzaldehyde 
Propionic acid 
Isovaleric acid
Isoamyl alcohol
(+)Octanol
cis Hex-3-en-l-ol
Acetaldehyde
Isovaleric aldehyde
J asmone
Isovaleric acid 
Hex-2-en-l-oic acid 
Phenylacetic acid 
Dimethyl sulphide
Carminative. 
Also applied 
externally in 
relief of 
rheumatism.
Carminative.
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have been selected at random to illustrate the great 
variation in their constituents (104) and to show the 
diverse sources from which they are obtained. Included 
in the table to emphasize the structurally non-specific 
nature of the monoterpenoids is aniseed oil which, 
although containing no monoterpenoids has been used 
interchangeably with Chinese star anise oil. It is to be 
emphasized that not all the components shown in the table 
were necessarily isolated from the same specimen of oil. 
It is well established that the nature and relative 
quantities of the constituents of essential oils vary 
with geographic location and climatic conditions (105)* 
Also portions of the plant other than those used to 
produce the medicinal oil often elaborate essential oils 
of quite different nature.
In addition to the oils listed in Table I countless 
others have been employed medicinally both in western 
medicine and the folk medicine of primitive peoples.
Among these are Roman chamomile oil, fennel oil, 
cardamom oil, caraway oil, coriander oil, eucalyptus oil, 
oil of bay, oil of pimenta, oil of cubebs, oil of 
cascarilla, oil of lemon grass and oil of juniper.
Because of the non-specific nature of most of
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the monoterpenoids many of the pure compounds have little 
biological interest apart from their ability to replace 
essential oils in the therapeutic applications already 
mentioned for the latter. The most commonly encountered 
are terpin hydrate (XIX), 1,8-cineole (syn eucalyptol 
(XX) which are occasionally employed in expectorant
OH
XIX XX
mixtures; thymol (XXI) and carvacrol (XXII) which are
OH
OH
XXI XXII
used as antiseptics; menthol (XXIII) which is sometimes 
used as a mild local anaesthetic and as an acongestant 
in nasal drops; and camphor (XXIV) which is still 
employed to some extent as a counter-irritant. It is
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to be noted that thymol and carvacrol, in addition to
OH
XXIII XXIV
fulfilling the criteria for classification as 
monoterpenoids, are also phenols and so represent 
examples of the large class of phenolic disinfectants.
Thymol at one time saw some use as an anthelmintic (106).
Camphor
In surveying the biological properties of the various 
monoterpenoids it is necessary to devote considerable 
space to camphor for this compound has been more intensively 
investigated than any single monoterpenoid, there being 
well over ^00 publications concerned with its biological 
properties. Well documentated summaries of much of this 
work are available (107)*
A considerable portion of the biological experiments 
conducted with camphor would appear to have been inspired 
by the desire to provide a rational basis for its former 
extensive use in clinical practice. Camphor had been 
introduced into Western medicine in mediaeval . .
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times after a long history of use in ancient Chinese 
remedies, and was at one time, without definite proof, 
thought to possess beneficial cardiovascular and 
respiratory stimulant properties. The results of the 
numerous animal experiments with camphor, although often 
conflicting, have however indicated that such properties, 
if they do indeed exist, are so unpronounced as to render 
the compound of little value as a therapeutic agent. It 
is now generally agreed that any observed clinical 
improvements produced by camphor were brought about as 
the result of reflex actions caused by the painful local 
irritation produced by the injection of the agent (108).
Besides its clinical use as a "stimulant" camphor also 
saw former medical application as a disinfectant of burns 
and wounds and was at one time used in the treatment of 
pulmonary tuberculosis and pneumococcal pneumonia, 
although again it would appear to have been of little 
value. Similarly animal experiments failed to support 
the contentions that camphor possessed antipyretic 
properties (109), or that it would prevent post-partum 
engorgement of the breast (110). The claim by Kawasaki 
(111) that camphor decreased the temperature of normal 
dogs only when given access to the liver and pancreas 
might indicate that a biotransformation product of 
camphor possesses antipyretic properties.
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A survey of the literature pertaining to the 
biological properties of camphor is useful as it 
represents an almost complete course in pharmacology in 
miniature. Thus the investigations with camphor have 
clearly shown how the effect produced can vary with the 
physical state of the drug (112), the dose (113), the 
route of administration (114), the temperature (115) and 
the dietary history (116), age (11?) and the state of 
health (118) of the experimental animal. The studies have 
also provided examples of tolerance (119), and 
idiosyncrasy (120), and species (121), racial (122) and 
individual (123) variations.
The biological actions of camphor have been studied 
in a wide range of species among the more unusual of 
which are the squid (124), the pike (125), the tench 
(126), the earthworm (127), the predaceous diving beetle 
(Dvtiscus marginalis (128), the leech (129), the tortoise 
(130) and the crab (I3I).
Camphor possesses the irritant properties typical of 
so many monoterpenoids. The irritation which it produces 
on the cerebral cortex leads to central excitation (132). 
Several other monoterpenoid ketones (133) including 
thujone (XXV) (134), which is thought to be responsible 
for the convulsions sometimes seen in chronic absinthe
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XXV
drinkers, also possess central nervous system stimulant 
properties but they are all too unreliable to be useful 
as clinical analeptics.
The studies on camphor have covered virtually every 
conceivable pharmacological action, but the major portion 
of the work dealt with its effects on the blood pressure, 
the heart and the central nervous system.
The effect of camphor on the blood pressure has been 
the subject of many conflicting reports, but resolution 
of the differences may be possible when its effects at 
several sites of action are taken into account. For 
instance, camphor is known to dilate certain blood 
vessels (135>'*36) and to procure the release of 
adrenaline (137) so that any observed change in blood 
pressure must be a summation of these effects together 
with those due to its actions, both reflex and direct, 
on the central nervous system.
Much of the conflicting evidence concerning the 
effect of camphor on the heart (138) may be explained
40
by the claim that d-trans Tf-oxocamphor (XXVI), a
XXVI
biotransformation product of camphor, stimulates the 
heart whilst camphor itself depresses it (139), although 
this contention has been denied (140).
Camphor has been shown to lower blood viscosity (141), 
to affect erythrocytes (142) and to act as an anti 
-haemorrhagic agent (143). It has also been shown to 
depress the isolated intestine (144), an action which 
has been classed as parasympathicolytic (145), and to 
produce an initial excitation followed by a depression 
of skeletal muscle (146). VJhen applied to the rabbit eye 
camphor produces an initial mydriasis which is followed 
by miosis (147). Like picrotoxin camphor has been 
claimed to check insulin convulsions (148). Camphor has 
been claimed to possess weak androsterone-like activity 
as have borneol, menthol and menthone (149). Other 
studies include the effect of camphor on antitoxin 
production (150), on cilial movements (151) and on the 
secretion of gonadotropic hormones (152).
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Camphor has seen considerable investigation as a 
potential bactericide (153) and insecticide (154), its 
former use as a moth-proofing agent being well-known.
Another interesting application has been its incorpora 
-tion into poison dusts and sprays as a bee repellent, 
to minimise the destruction of these insects (155)» It 
is claimed that camphorated oil increases the in vitro 
potency of the antibiotics streptomycin and the tetracyclines 
(1 56) and it has also been claimed that camphor promotes 
phagocytic activity (157).
A further property of camphor is its ability to 
produce polyploid forms in various microorganisms (158).
It is also reported to induce the formation of structures 
resembling copulation tubes in yeasts, although nuclear 
fusion does not occur (159)* It is noteworthy that 
other monoterpenoids, containing a carbonyl function, 
such as citral, ci tronellal and hydroxycitronellal have 
been shown to induce or select for mutations in 
Drosonhila melanomaster (160).
Considerable attention has been paid to the biochemical 
effects of camphor. Thus its effect on amino acid 
excretion (161), phosphorus turnover (162), glycolysis 
(163) and acetylcholine metabolism (164) have been
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determined as has its effect on the distribution of 
potassium and calcium ions in the central nervous 
system (165). Other studies have been concerned with its 
influence on the carbohydrate metabolism of the heart 
(166)5 on Vitamin C. metabolism (167), on the ammonia 
content of the central nervous system (168), and with 
its effects on the enzymes acetylcholinesterase (169)? 
cytochrome oxidase (170) and oxolacetic and pyruvic 
carboxylases (17I)#
On the pharmaceutical side camphor has inspired 
studies on new solvent combinations on account of its 
relatively low solubility in water (172) and there is 
an extensive literature devoted to assay procedures for 
this compound (173)#
Numerous detailed toxicological studies with camphor 
are on record (174) as are many detailed biotransforma 
-tion studies (175).
Camphor has also been utilized in admixture with 
other agents (176) and its ability to antagonise or 
support the action of various drugs has been well 
investigated (177)#
Considerable attention has been paid to structure 
action investigations and numerous comparative studies
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between camphor and closely related compounds have been 
reported. To cite a few specific instances the 
pharmacological actions of camphor have been compared 
with those of epicamphor (]OCVII) (178), d-verbenone 
(XXf/'III) (179)5 1-pinocamphone (X^dX) (179) 5 fenchone 
(XXX) (180)5 thujone (181), menthol (182) and 
hetocineole (183). Other compounds which have seen
XXVII XXVIII XXIX XXX
detailed comparison with camphor include 3-methyl-5- 
isopropylcyclohex-2-en-'1 -one (hexetone) (184), 
methylsantenone (185) and 6-0x0fenchone (186). The 
pharmacology of various biotransformation products of 
camphor have also seen attention (187).
From the preceding account it is readily apparent 
that camphor is a structurally non-specific drug, and it 
is interesting to note that it will intensify urethane 
narcosis (188) and that its dose-response curve on the 
toad heart is very similar to that of et.her (I89).
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As was mentioned earlier, the optical antipodes of 
structurally non-specific drugs should show identical 
biological properties. In the case of camphor the 
evidence on this point is conflicting. Several workers 
(190) have claimed that the ^  and 1 isomers are 
indistinguishable pharmacologically and Joachimoglu (191) 
in careful studies employing several pharmacological 
preparations concluded that the d, 1. and dl isomers 
showed identical activity. Other workers (192), however, 
contended that the 1 form is more active than d form, 
whilst a third group (193) maintain that d-camphor is 
the more active pharmacologically. Toxicity studies have 
tended to show that the 1 isomer is more toxic than the 
d isomer (194). As the mammalian organism is known to 
effect biotransformation and elimination of optical 
antipodes at different rates (195)5 these results may 
merely reflect the length of time to which the animal is 
exposed to the particular enantiomorph or to its toxic 
transformation products rather than any difference in 
potency between the two optical isomers. In this 
connection it is to be noted that the urine of animals 
fed dl camphor has been reported to be richer in 
laevorotatory "campherol" (196), an observation which
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was interpreted to mean that 1 camphor is less readily 
degraded in the body than the d isomer. As this work was 
conducted before the demonstration that "campherol" is a 
mixture, the subject would bear detailed re-investigation.
Derivatives of Camphor
Various synthetic derivatives of camphor have been 
prepared, both in attempts to improve its solubility 
characteristics and for the study of structure-action 
relationships. The extravagant claims sometimes 
accompanying the initial introduction of these agents 
followed by the inevitable re-evaluation of their worth, 
is unhappily even at the present day an all too familiar 
phenomenon linked with the marketing of new drugs.
Among the derivatives prepared and tested were 
camphor-10-sulphonic acid (XXXI) and its derivatives.
CHgSOgOH
XXXI
The biological properties of camphor-10-sulphonic acid 
have been well reviewed elsewhere (197).
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As the 10-camphorsulphonate anion is virtually devoid 
of any significant pharmacological activity, it has seen 
considerable utilization as a solubilising anion (198). 
Among the many salts which have been subjected to 
biological screening may be cited the 10-camphorsulphonates 
of p-hydroxyphenylaminoethanol (199), ephedrine (200,201), 
emetine (202), sparteine (203)j quinine (204), antipyrine 
(205), pyrimadone (205), theophylline (206), dihydroxy 
-codeine (201), scopolamine (201), sulphanilamide (207) 
tetraethylammonium (208) and diethyl- (hydroxyethyl)- 
méthylammonium (209). More recently a potent ganglion- 
blocking agent, trimetaphan camphorsulphonate (XXXII), 
has been introduced into clinical practice (210), and
P h C  H 2 "N
O
N-CHgPk
/ ' ®
XXXII
©
CH2S03
N - ( 2i^ -hydroxy-f-methyl-2-phenylethyl ), N -methy 1- 
camphorsulphonamide (XXXIII) is reported to be a potent 
analeptic (211).
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Camphoric acid (XXXTV) which is formed by oxidation of 
camphor has been particularly well investigated
:0
■Pfrv
COOH
A A A I I I  XXXIV
pharmacologically (212). It was at one time used against 
the night sweats of phthisis (213) but closer experimental 
investigation showed that it was of little value (214).
Like isofenchonic acid, camphoric acid is said to 
stimulate the growth of haemolytic StreptococcL in low 
concentrations (215).
Many derivatives of camphoric acid have been prepared 
and tested including various substituted camphorimides 
(216). Several substituted 4-chlorophenyl hydrogen- 
caraphorates are claimed to be of value in the trea.tment 
of athlete*s foot (217), and the salt formed between 
camphoric acid and hexamethylene; tetramine has been used 
as an alternative to hexamethy1enetetramine mandelate in 
combatting urinary infections (218). Hexamethylenetetramine 
camphorate is also reported to be effective in the 
treatment of hard-pad in dogs (219).
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The sodium salt of the monoester formed between 
2-tolylmethylcarbinol and camphoric acid is reported 
to be a cholagogue (220) and recently there has been 
considerable interest in the diethanolamine salt of the 
same monoester because of experiments showing that it 
inhibits serum and tissue cholesterol elevation in 
cholesterol-fed cockerels (221). It also hastens the 
regression of atherosclerotic lesions in birds reverting 
to a normal diet. In rats, however, the compound 
increases the plasma cholesterol level (222).
The derivatives of camphoric acid which are probably 
of the greatest interest are those in which the 
camphoric acid part of the molecule can be regarded as 
a supporting moiety, as for example in the bismuth 
therapy of syphilis. The mercurial diuretics, mercaptomerin 
(XXXV) and mercurophylline (XXXVI) are two other examples 
of the utilization of camphoric acid as a supporting 
moiety (223), and it is claimed that the positional
C O O N a
SCHjCOONa
OCH3
XXXV
isomer, (XXXVII) has greater diuretic potency than
f^9.
mercurophylline (,22k). In these diuretics a definite
OoN<?^
ONHCH2ÇHCH2HJOH
OCH,
CH,
#
CH3
CONHCH2ÇHCh2<-«^ ^
-COONo-
XXXVII
function can be assigned to the organic portion of the 
molecule in that it ensures slow production of ionic 
mercury which then inactivates the enzymes responsible 
for the tubular reabsorption of chloride ions by 
combination with the sulphydryl groups.
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Compounds of type XXXVIII which can be regarded as 
analogues of succinylcholine, formed by replacement of
©
COOCHj C H j N 
COOCHjCHj N ^
XXXVIII
the succinic acid moiety by camphoric acid, have been 
shown to be active as neuromuscular blocking agents
(225). Other interesting camphoric acid derivatives are 
camphorylsulphathiazole which is said to be active
in vitro against a strain of Mycobacterium tuberculosis
(226), and the C-21 hemicamphorate of cortisol which was 
prepared in search for esters of cortisol possessing 
greater clinical potentiality than cortisol itself (227).
In the course of an investigation of the piperidine 
group as an active antitussive moiety, Kase and Yuizono 
(228) utilized esters of camphor-trans-IT-carboxylic 
acid (syn isoketopinic acid) as the supporting moiety 
to give compounds of type XXXIX. Indeed these compounds 
turned out to be active antitussives. Similar derivatives
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possessing a morpholine ring or a piperazine ring in 
place of the piperidine ring were investigated by 
Yoshimoto (229) as potential hypotensive agents. The
\
XXXIX
derived methiodides were studied as well.
Camphor itself has been utilized as a supporting 
moiety in the form of its isonicotinyl hydrazone, which 
was prepared as a potential anti-tuberculous agent (230)
Of the other derivatives of camphor investigated for 
biological activity it will ■ suffice to mention the 
hydroxycamphors (231), camphor oxime (232,233), 
isonitrosocamphor (233), camphorquinone (234), 
camphor-3-carboxylic acid (235), basic bismuth 
camphocarboxylate (236), and 3-carbamoyloxy-2-hydroxy 
-camphane which was recently been shown to possess 
potent anticonvulsant activity (237).
52.
Biologieally-active monoterpenoids from insects
As yet this group is relatively small, but it is 
nevertheless of considerable interest.
Various species of ants are reported to use 
odoriferous secretions in attack and defence against 
other insects and in the laying of odour trails from 
food to the nest, and an interesting monoterpenoid, 
iridomyrmecin (XL) possessing antibacterial and
I
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insecticidal activity (238) has been isolated from the 
workers of the Argentine ant (Iridomyrmex humilis ) in 
which it occurs to the extent of 1^ of the body weight. 
The pharmacology of this compound has been investigated 
by Pavan (239) and it would appear to be without 
significant activity. Two other compounds, iridodial 
(XLI) and isoiridomyrmecin (syn iridolactone) which are 
closely related chemically to iridomyrmecin have been
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isolated from other species of ant (2^ -0), and an
CHO
 ^CHO
XLI
unidentified compound which may be closely akin 
chemically occurs in fire ant venom (2^ -1).
Another active principle which is obtained from 
insects, and which can probably be regarded as a 
monoterpenoid is cantharidin (XLII) the vesicant principle 
occurring in various beetles# At first sight this
. XLI I
optically-inactive compound would appear to result 
from the tail-to-tail coupling of two isoprene units, 
but, theoretically at least an alternative 
bios},aathetic pathway exists by which
5^ .
it could arise through rearrangement of a normal 
monoterpenoid skeleton of the ^-cyclocitral type 
bearing suitable substituènts as in XLI11. Like
OH
W
XLI II
iridomyrmecin cantharidin exhibits insecticidal 
properties {2h2) towards some insects. Towards others, 
it exhibits a pronounced attraction. Its action on plants 
is also reported to parallel that of iridomyrmecin (2^3)*
Cantharidin possesses the irritant properties so 
characterStic of monoterpenoids in general, but to a 
very much more pronounced degree. Thus it causes 
inflammation (244) and inhibits the growth of fibroblasts 
in tissue culture (245) in a similar way to turpentine.
It has been sho-vmi. to produce vessication in the skin of 
corpses (246). Cantharidin has in fact been termed a 
"cell poison" (247).
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At one time cantharidin was used medicinally to 
produce prolonged counterirritation in the treatment of 
neuralgic and rheumatic pains, but this use was dangerous 
because of the risk of toxic effects arising from 
absorption of the drug. Cantharidin has a marked toxicity 
for epithelial tissue and the kidneys are especially 
sensitive to it (248). Small doses produce dilation of 
of the glomeruli with albuminuria (249), and larger doses 
affect the epithelium of the convoluted tubules producing 
severe nephritis.
There are reports in the literature that cantharidin 
can successfully inhibit tumour induction by carcinogenic 
tar (250). This action may well be a result of its 
toxicity to the epithelial cells with consequent 
sloughing of the carcinogen and embryonic tumour. There 
is also a report of a successful destruction of a 
cancer in man (251).
Cantharidin has been used as an aphrodisiac in cattle 
breeding, as it produces a reflex erection through its 
irritation of the urethral mucous membrane (252), but 
its use is not without risk as effective doses may 
produce nephritis. It is of some interest that various 
essential oils and monoterpenoids have quantitatively
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similar but less intense action.
Claims have been advanced that cantharidin will 
initiate oestrus in castrated female rats and infantile 
mice (253) and produce an increase in the urinary 
excretion of oestrogens and progesterone in female 
rabbits (2?^), but the results of other workers (255) 
indicate that cantharidin is without oestrogenic action. 
Detailed pharmacological studies have been performed on 
cantharidin (256) and these have shown remarkable species 
differences in sensitivity to the drug (257)*
Various analogues and derivatives of cantharidin have 
been prepared synthetically. Thus, 1 ,2-dimethyl-1, 
2-dihydrophthalic anhydride is reported to have 
cantharidin-like activity (258) whilst various heavy 
metal salts of the condensation product of cantharidin 
and ethylene diamine are claimed to possess bactericidal 
properties (259). More recently compounds of type XLIV 
have been claimed to be anti-hypertensive agents (260).
CH3
CH3
XLIV
57.
The Pvrethrlns
Various naturally-occurring monoterpenoids or their 
derivatives possess insecticidal properties (261) and 
of these the most potent are the pyrethrins I and II 
and the cinerins I and II which occur in the flower heads 
of Chrysanthemum cineriifolium♦ These four compounds, 
which are conveniently represented by the general 
formula XLV, are not always classified as monoterpenoid 
derivatives but they can be so regarded because of the
p
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obvious formal relationship of chrysanthemic acid 
(XLVI) and chrysanthemum dicarboxylic acid (XLVII) to 
car-^-ene (XLVIII) which is a true monoterpenoid.
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Indeed it is tempting to think that chrysanthemum
HOOC HOOC
XL VI XLVII XLVIII
dicarboxylic acid arises by oxidative cleavage of the 
2,3 double bond in 2 ,^-caradiene with subsequent 
épimérisation at original carbon atom 1 to give the 
trans relationship of the substituents on the 
cyclopropane ring.
The pyrethrins and cinerins find wide application in 
fly sprays and as horticultural insecticides on account 
of their low toxicity to warm-blooded animals and their 
ability to achieve quick "knockdown”, a term used to 
describe the rapidity with which the insects are 
paralysed. In addition to their insecticidal properties 
they also possess anthelmintic activity (262). The early 
work on the physiological action of the pyrethrins is 
described in the book by Gaudin (263) and their 
toxicology and pharmacology are discussed by Feinstein 
and Jacobsen (26^) who also refer to several synthetic
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rethrins. Examples of such synthetic rethrins which are 
of commercial importance are allethrin (XLIX) (265) which 
is the allyl homologue of cinerin I, cyclethrin (L) (266) 
and furethrin (LI) (267). Besides these commercially
ooc
XLIX
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important synthetic compounds many others have been 
prepared (268), among which are several terpenoid esters of 
chrysanthemic acid (269).
The precise mechanism of action of the rethrins on 
insects is still obscure, and they are usually vaguely 
described as neuromuscular or nerve poisons producing 
degenerative changes in the cells of the nerve ganglia. 
Structure action relationships in the rethrin series are 
discussed by Sexton (270) and in greater detail in the 
excellent review by Elliot (271).
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Thu.japli clns
The resistance of certain heartwoods to attack by- 
fungi and insects is often at least partly due to the 
presence of toxic compounds. One such group are the 
OC-, p- and r -  thujaplicins (LII-LIV), which - although 
not obeying isoprene rule - are mentioned in this survey
OH
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because they are generally considered to arise in nature 
from terpenoid precursors (272). Erdtman (273) has 
proposed a detailed scheme whereby a monoterpenoid 
precursor undergoes ring expansion to generate the 
tropolone ring of these compounds.
The thujaplicins have been shown to possess strong 
antifungal activity (27^) and beta-thujaplicin, also 
knoim as hinokitiol, has been shorn to have potent 
antibacterial properties (275)5 in some cases 
exhibiting a higher potency than the common antibiotics 
(276). The interesting claim has been made that bacteria
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do not readily acquire resistance to hinokitiol (277)*
In the form of its sodium salt, hinokitiol shows 
leptospiricidal action (278).
The pharmacological properties of p-thujaplicin (279) 
and T-thujaplicin (280) have seen detailed investigation 
These compounds would appear to produce mixed depression 
and stimulation of the central nervous system and so 
have been compared to camphor with respect to their 
biological properties. The sodium salt of p -thujaplicin 
shows pronounced hyporglycaemic and diuretic properties, 
but these actions are accompanied by considerable tissue 
damage (281). The effects of hinokitiol on respiratory 
enzymes have been studied in detail (282), and 
garnma-thujaplicin has been reported to possess tumour- 
damaging properties (283)#
Synthetic derivatives prepared from hinokitiol have 
been subjected to biological studies. These include 
certain derivatives of hinokitiol-7-sulphonic acid which 
have been shown to stimulate the guinea pig uterus (28^). 
The thujaplicins can be readily converted into azulenes, 
azaazulenes and oxaazulenes (285) and several such 
compounds have been claimed to suppress plant growth
(286) or to be of value in the treatment of infant asthma
(287).
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Amino Derivatives of Monoterpenes
Relatively few monoterpenoid alkaloids appear to 
exist in nature. Apart from actinidine (288) (see p. 72) 
only-one member of the group appears to have seen biological 
investigation and this is chaksine which occurs in the 
seed kernels of Cassia absus. Linn., long used in India 
in the treatment of skin infections and as a cathartic, 
and whose structure has recently been established as 
LV (289).
N H
N  M
LV
Chaksine has been the subject of several 
pharmacological investigations but the results do not 
appear to be completely concordant. One group employing 
chaksine iodide claim that this salt produces a fall in 
blood pressure by capillary dilation, stimulates smooth 
muscle and exhibits atropinic and weak curariform properties 
(290). Other workers employing the sulphate or the 
free base state that the alkaloid is a general 
depressant of the central nervous system and of smooth
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muscle (291)• Chaksine has further been reported to 
possess antibacterial properties (292).
Numerous synthetic amino derivatives of monoterpenes 
are known, but it is only in recent years that any great 
interest has been shown in the biological properties of 
such compounds. The earlier work had, however, shown 
that CJ -aminopinane possessed germicidal properties (293) 
and that thymoxyethylallylamine (LVI) possessed
O C H g C H g N H C H g C H  = :C H
LVI
adrenergic blocking properties (29^). The pharmacology 
of camphenilylamine was also investigated (295) and 
1 :10-bis-(geranylamino)-decane dihydrobromide (LVII)
N H
LVII
•2HB7
-I 2
was shown to possess a high potency as an amoebicide
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in vivo (296) whilst menthyl aminoacetate was claimed 
to possess anaesthetic properties (297). More recently 
experiments with various 3-d.ialkylaminoacylaminocamphors 
and diethylaminoethylhornylether have shown that these 
compounds possess central and smooth muscle depressant 
properties (298). Certain bis quaternary diamines derived 
from ^-ionone are bacteriostatic (299), and certain 
derivatives of 2-amino-1-£-menthanol which were 
synthesised from d-limonene possess fungicidal properties 
(300), although they are without physiological activity.
The recent interest in amino-terpenoids has resulted 
from the demonstration that several such compounds 
possess ganglion-blocking properties and so have 
application as anti-hypertensive agents. For instance 
trimethyl-1-menthylammonium iodide (LVIII) and 
trimethyl-d- bornylammonium iodide (LIX) have been shown 
to markedly lower blood pressure (301), a property which
l O
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is shared to some extent by various simple terpenoid 
primary, secondary and tertiary amines (302,303)* 
Unfortunately, however, these compounds also possess a 
degree of curarimimetic activity and so are not as 
specific in their action as is to be desired* As 
ganglion-blocking activity is usually associated with 
quaternary nitrogen atoms, especially where the molecule 
is relatively simple in its chemical structure, the 
quaternary terpenoid derivatives are of interest from 
the supporting moiety concept.
In general quaternary ammonium salts are poorly and 
irregularly absorbed on oral administration, so the 
introduction into clinical practice of the orally-active 
competitive ganglion-blocking agent 3-niethylaminoisocamphane 
hydrochloride (LX) (syn mecamylamine) marked a distinct 
advance in the treatment of hypertension* This terpenoid 
derivative is characterised by its high potency and 
prolonged duration of action (30^), but like all 
ganglion-blocking agents so far tested it does not show
LX
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complete specificity for sympathetic ganglia and 
consequently it produces the usual undesirable side 
effects resulting from blockade of the parasympathetic 
ganglia. Mecamylamine also exhibits a direct depressant 
action on smooth muscle.
The encouraging results obtained with these simple 
amino-terpenoids has led to the search for other similar 
compounds. Besides the various analogues of mecamylamine 
which have been prepared and tested (305)» amino- 
terpenoids which have been investigated include 
N-allyl-2-aminoisocamphane (306), N-methylcamphidine 
(303) and quaternary salts derived from camphidine (307)*
Synthetic Insecticides Derived from Monoterpenoids
In addition to monoterpenoid insecticides of natural 
occurrence such as the pyrethrins mentioned previously, 
various synthetic monoterpenoid.derivatives have seen 
widespread application as insecticides and pesticides. 
Because the number of publications describing the 
efficacy of these agents against various species of 
insects or describing their toxicity to man and livestock 
is so great, no attempt can be made to give a comprehensive 
account here* Certain key references to commercially 
available terpenoid insecticides are to be found in the
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handbook published by the Canada Department of Agricul 
-ture (308)5 as well as in other specialized monographs 
(309). With the introduction of the phosphate 
insecticides the importance of the terpenoid insecticides 
would appear to be on the decline.
4
The synthetic terpenoid derivatives which have been 
shown to possess insecticidal properties cover a wide 
range of chemical diversity and include simple 
haloderivatives (310), ethers (311)» esters (312) and 
various sulphur cofflpcunds (313).
Chlorinated camphene (31^) was one of the most 
important of the commercially used insecticides, which 
also included other chlorinated monoterpene hydrocarbons 
(315) and certain thiocyanoacetic ester derivatives (3I6)
Besides the insecticidal compounds within the group, 
the monoterpenoids embrace compounds which possess 
insect-repellent properties. The best known of these is 
citronellal, long used as a mosquito repellent. Various 
synthetic derivatives have also been claimed to possess 
such activity including 2-amino-3~isobornyloxy-2-methyl-1- 
propanol (317) and "citral-malonic acid condensate" (318) 
although pure citrylidene malonic acid (LXI) was found 
to be virtually inactive (3I9). Tests for insect-
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repellancy on other monoterpenoids have been reported
LXI
by Roadhouse (320) and Morton et al. (321),
Some monoterpenoids possess attractive properties 
for insects and geraniol for instance has been employed 
to bait traps for the Japanese beetle, Papilla .iaponlca 
(322).
Antihistaminic Monoterpenoids
Several monoterpenoids have recently aroused a 
certain degree of interest, especially in Russia, on 
account of their reputed antihistaminic properties.
Many of the claims pertain to citral (LXIlO (323)@ 
but geraniol (LXIII), p -ionone, Y -ionone and 
allodcimene (LXIV) are also claimed to possess 
antihistaminic activity (32^), although there is a
CHO
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report that ionone produces allergic skin reactions 
resulting in eczema (325). Because of the structural 
relationship of these compounds to vitamin A, the Russian 
workers have advanced the hypothesis that one of the 
functions of vitamin A in the body is to give rise to 
antihistaminic compounds (326). They further claim that 
alloocimene, Y -ionone, ionylidenecrotonic acid and 
carotene act biologically by activating oxygen and 
peroxide oxygen (327). Because of its antiallergic 
anti-inflammatory and analgesic properties, citral is 
apparently widely used by Russian opthalmologists (328).
Furthermore citral has been reported to possess 
carcinostatic properties (329), as has the closely 
related compound citronellal (330), but the 
thiosemicarbazone, oxime, semicarbazone and bisulphite 
addition product of citral are without carcinostatic 
activity (331).
There is a claim in the literature that citral is of 
benefit in the prevention of alimentary atherosclerosis 
in rabbits (332), but, as it has been shown to produce 
fatty liver infiltrations in rats (333) ? more work is 
needed before a complete evaluation of its potential 
usefulness can be made. The condensation product between
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citral and sulphanilamide is reported to be a potent 
antimicrobial agent (33^)*
In addition to its antihistaminic activity p -ionone 
is claimed to possess potent anti-acetylcholine (335)? 
and anti-thyroid (336) activity,to weakly inhibit 
co-carboxylase (337)j and to slightly prolong the life 
span of mice with Ehrlich ascites tumour (338).
Alloocimene has been shown to be active in promoting 
the formation of coagulation factors in the chick (339).
Other Individual Monote^rpenoids and Their Derivatives
The investigations carried out on other individual 
monoterpenoids and their derivatives are many and varied, 
but in this summary an endeavour will be made to 
emphasize those properties of unusual interest, many of 
which may indicate a degree of structural specificity.
Safranal (LXV) became the centre of considerable 
attention when the startling claim was advanced (3^0) 
that this compound, together with ^-hydroxy-p-cyclocitral 
(LXVI) and its glucoside, picrocrocin, functioned as 
sex-determining factors or termones in Chlamydomonas 
eugametos.
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These claims have since been completely refuted (3^1) 
as have the claims that the carotenoid derivatives, crocin 
and the cis and trans crocetin dimethylesters, acted as 
hormones controlling motility, gamete formation and 
copulation in the same organism. Picrocrocin is of interest 
in another respect, however, in that it is the bitter 
principle of saffron, a drug formerly used medicinally(3^2).
Another monoterpenoid glycoside which has been the 
subject of biological investigations is verbenalin, which 
has been shown to possess structure LXVII (3^3). This
o
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compound is claimed to be a weak parasympathomimetic 
agent and to have a pronounced action on the uterus (3^^)* 
The closely related compound aucubin (3^5) possesses 
antibacterial activity (3^6). Studies of the general 
pharmacology of aucubin have been reported by Ogata and 
Nishioji (3^7), whilst its effect on uric acid excretion 
has been studied by Kato (3^8).
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Nepetalactone (LXVIII) is an extremely interesting
I
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monoterpenoid, being the agent responsible for the 
marked attraction which catmint (Neneta cateria) holds 
for the felids. A dramatic experiment clearly 
demonstrating that this compoimd was indeed the active 
principle was performed upon the lions at the Vilas Zoo, 
Madison (3^9)* Nepetalactone arouses felids from a state 
of lethargy to one of intense excitement in which they 
try to transfer the compound to their fur. The close 
similarity in chemical structure between nepetalactone 
and iridomyrmecin could explain the intense interest in 
ants commonly displayed by cats* Indeed matatabilactone 
which is identical with isoiridomyrmecin (3?0) and the 
closely related monoterpene alkaloid actinidine, both 
of which occur in Actinidia polygama have been shown to 
attract felids (3^0,351 )•
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Because the unsaturated lactone ring is believed to 
play an important role in the activity of the steroidal 
cardiac glycosides, nepetalactone was tested for possible 
inotropic action on the frog heart, but it was found to be 
inactive (352).
Menthol is of some physiological interest as it has 
been reported to selectively stimulate the cold receptors 
of the lingual nerve (353). It is stated to be effective 
as a topical dental anaesthetic but it suffers from the 
great disadvantage that it produces sloughing and 
irritation (35^)* It is also reported to potentiate the 
anaesthetic potency of nupercaine (3?5)* Biochemical 
investigations have shown that menthol inhibits the 
activity of liver and kidney dehydrogenases (356)* 
Considerable attention has been paid to the comparision 
of the pharmacological properties of the stereoisomers 
of menthol (357) and several synthetic derivatives of 
potential pharmacological interest have been prepared, 
including the menthyl ester of cinchophen (358), the 
h3Tpnotic 2-isopropyl-5-inethyl-l-ethynylcyclohexane 
(LXIX) (359)5 the bacteriostat menthylthiocyanoacetate 
(360) and the anti-rheumatic menthyl ether of methyl 
salicylate (361). The bornyl ester of salicylic acid
7 ^ -
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has also been prepared as an anti-rheumatic agent (362), 
and menthyl salicylate has seen use as a constituent of 
suntan cosmetics (363).
Several synthetic derivatives of thymol and carvacrol 
have been the subject of biological investigations.
Among these may be mentioned various simple ethers (364-), 
halogenated derivatives (36?) chloromercuri derivatives 
(366), sulphonamide derivatives (367) and substituted 
carbamic esters. These carbamic ester derivatives are 
cholinesterase inhibitors and possess insecticidal 
activity (368).
The naturally-occurring ^-methoxythymol, like 
thymoquinone (369) is a potent fungicide and is thought 
to be at least partially responsible for the 
decay-resistance of Lebocedrus decurrens (370).
A number of studies have been made on the effect of 
various monoterpenoids on the secretion of bile (371), 
and certain mixtures containing monoterpenoids are claimed
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to be therapeutically useful in dissolving concretions 
in the biliary and urinary tracts (372). Considerable 
attention has been given to the anthelmintic (373) and 
antibacterial (374-) properties of such monoterpenoids 
as geraniol, menthol,1:8-cineole, pinene and p-cymene 
and certain monoterpenoids have been utilized in studies 
of the speed of penetration of compounds through the 
skin (375). Recently studies on the speed of penetration 
of inhaled vapours have been conducted using tritium 
labelled menthol and camphor (376).
Various ozonized monoterpenoids have been investigated 
for antibacterial activity (377)> whilst the ozonide of 
pinene was at one time used clinically in the treatment 
of pulmonary tuberculosis (378). Other oxidation 
products of monoterpenoids have also been shown to be 
toxic to bacteria (379) and helminths (380), and the 
mono and bis epoxides of dipentene have been 
investigated for possible tumour-inhibiting and 
cytotoxic activities (381).
Other individual monoterpenoids which have been 
subjected to detailed pharmacological investigation 
include piperitone (382,383), piperitenone (383), 
carvone (383), carvomenthone (383)5 sabinol (384),
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cineole (385,386), phellandrene (386), ketocineole (387), 
(X-pinene (388), p-pinene (389) and hydroxypinocamphone 
(390). Citral and citronellal were included in a study 
of the effect of aldehydes on blood pressure and found 
to have a depressor action (391). Linalool has been 
claimed to inhibit experimental gas gangrene in rabbits 
(392).
Other monoterpenoid derivatives of interest include 
some terpenyl substituted fatty acids which were prepared 
as potential antibacterial agents (393), 2-diethylamino 
-ethyl fencholate (394) which is a fungicide and various 
monoterpenoid esters (395). Dibornyl sulphide has 
recently been investigated and is stated to have 
pharmacological properties similar to camphor (396).
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SESQUITERPENOIDS
Like the monoterpenoids the sesquiterpenoids are of 
widespread occurrence throughout the plant kingdom and 
show considerable variation in their chemical 
complexity (397,398).
Azulenes
Among the sesquiterpenoids with the simplest chemical 
structure are the sesquiterpene azulene hydrocarbons (399) 
and interest in these compounds from a biological 
viewpoint was first aroused when it was claimed that 
chamazulene (LXX) possessed anti-inflammatory properties
2
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(^00), The earlier work dealing with the biological 
properties of this compound has been reviewed by 
Janistyn (^01) and by Thomas (^02)•
Chamazulene which occurs in camomile oil obtained 
from Matricaria chamomila ( a plant long used in Folk 
medicine and mentioned in the writings of Dioscorides
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and Pliny ) is not strictly a true sesquiterpene but it 
can be regarded as being formally related to S-guaiazulene 
(LXXI) by loss of a carbon atom. Moreover it is believed
LXXI
to arise in nature from a guaianolide precursor by 
oxidative degradation (^03).
Both chamazulene and S-guaiazulene as well as other 
sesquiterpenoid azulenes have been subjected to numerous 
clinical and pharmacological trials (^0^), especially 
in Europe, but the results are conflicting. Whilst some 
workers have concluded that these compounds are without 
any demonstrable antiphlogistic action (^0?), other 
workers have claimed that in addition to possessing 
anti-inflammatory properties, the azulenes are of value 
for treating various allergic disorders (4o6), including 
asthma. It is possible that some of.the discrepancies 
are attributable to variations in dose or the route and 
timing of administration. Others may be explained by the
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claim that, whilst the azulenes are themselves without 
effect, certain decomposition products are active (^07)*
The azulenes have seen clinical trial in the 
treatment of migraine (^C8), radiological dermatitis (4-09), 
eczema (4-10), ultraviolet erythema of the skin (4-11), 
burns (4-12), ulcerative colitis (4-13) and gastritis 
(4-14-). S-guaiazulene has been employed in depilatory 
preparations with the object of rendering them 
non-irritant (415^ ). Various azulenes are also claimed 
to possess bacteriostatic (4-16), cancerostatic (4-17) and 
antiarthritic properties (4-18), although l-isopropyl-5- 
methylazulene has been shown to be devoid of anti-cancer 
activity (4-19). The tumour inhibiting properties of 
S-guaiazulene are thought to result from inhibition of 
succinic dehydrogenase (4-20).
Considerable work has been devoted to studying the 
effect of azulenes on anaphylactic shock induced in 
guinea pigs. Various authors (4-21) state that these 
compounds are without effect, but others maintain that 
although the compounds are without influence on histamine 
shock they prevent anaphylactic shock (4-22) or both 
anaphylactic shock and serotonin-shock (4-23).
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Evidence has been advanced that the azulenes affect 
phagocytosis (4-24-), ajod at one time it was suggested that 
this action was mediated through the release of histamine 
(4-25) in accordance with the theory advanced by Jane so 
(4-26). More recently considerable doubt has been cast on 
this assumption (427). In fact some schools (4-14-,4-28) 
have claimed that the azulenes act by preventing the 
release of histamine, one group going so far as to 
postulate that the histaminé-release is prevented by 
activation of the pituitary-adrenal system with consequent 
release of adrenocorticotrophin or cortisone which in 
turn prevents fibrolysin from causing histamine 
discharge (4-29).
The pharmacology and toxicology of S-guaiazulene have 
been studied by Caujolie and Stanislas (4-30) who also 
investigated the effect of this compound on plants (4-31). 
The interest in the biological properties of azulenes 
has inspired the synthesis and biological screening of 
several synthetic compounds. These include non-isoprenoid 
azulene hydrocarbons (4-32) as well as simple derivatives 
such as sulphonated isoprenoid azulenes (4-33)* The 
azulene aldehyde lactaroviolin (LXXII) has been reported 
to show anti-tubercular activity in vitro (4-34-), and the
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perhydroazulenic alcohol guaiol (LXXIII) is claimed to 
possess insecticidal properties (^35)-
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Guaianolides
Apart from their role as azulene precursors, certain 
guaianolides are of biological interest in their own 
right. Several sesquiterpenoids of the guaianolide type 
have been identified as the bitter principles of various 
plants. Examples are lactucin (LXXIV), geigerin, 
helenalin and tenulin (LXXV). Lactucin is the main bitter
15
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principle of the latex of Lactuca virosa which was 
formerly used in pharmacy under the name of lettuce 
opium, and which enjoyed a reputation as hypnotic.
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Geigerin is obtained from the vermeerbos (Geigeria aspera) 
and is believed to be closely related chemically to the 
active emetic principle vermeeric acid (^36). Helenalin 
and tenulin, which possesses two carbon atoms more than 
the basic sesquiterpenoid skeleton in the form of a 
modified acetate unit, occur in Helenium spp.
The guaianolides are postulated to arise in nature 
from a 10-membered ring precursor (^37) and in this 
connection it is interesting to find that another 
sesquiterpenoid bitter principle cnicin, which occurs in 
Cnicus benedictus L., possesses such a 10-membered 
ring system (b-38).
Tenulin and helenalin were tested as potential 
insecticides but found to be inactive (^39)* Helenalin 
is, however, reported to be an effective fish poison 
(^ *^0). The pharmacology of helenalin has been studied 
in detail by Lamson (4^ -1 ) who also reviewed the earlier 
knowledge of the biological properties of this compound. 
Helenalin has a severe irritant action on mucous 
membrane and produces violent sneezing by reflex action.
Another guaianolide, carpesialactone (LXXVI), has been 
shown to be active as an anthelmintic (4^ -2) and to 
possess muscle-relaxant and central nervous system
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depressant properties in mammals (^^3)- Two further 
guaianolides which have been investigated 
pharmacologically are matricin and artabasin 
which are stated to be similar in their actions on 
intestinal muscle to chamazulene.
An interesting sesquiterpenoid acid which is 
postulated to arise in nature by rearrangement of the 
guaianolide skeleton (^^5) is valerenic acid (LXXVII),
COOH
LXXVII
which shows marked spasmolytic activity (4^ 46).
8^.
Santonin
Perhaps the best known sesquiterpenoid from the 
biological point of view is 1 - -santonin (LXXVIII), 
more commonly known simply as santonin. As well
LXXVI II
documented reviews of the biological properties of this 
drug have been published (^ U-7) it is not necessary to 
consider it in great detail in this review.
Santonin until recently was widely used in the 
treatment of human ascariasis (^^8), having been 
employed for this purpose since Dioscorides. Although 
effective against Ascaris spp. santonin appears to be 
ineffective against other parasitic worms. It has, 
however, been reported to be highly toxic to the leech 
(^ -^ 9). It has been claimed that santonin is only 
effective as an anthelmintic in the presence of base, 
e.g. in the presence of bile salts (4-^ 0), when it exists
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as an alkali-metal santoninate, and this would support 
the report that sodium santoninate is as effective as 
santonin itself against Ascaris (^51)•
The anthelmintic action of santonin has been ascribed 
to its ability to cause pronounced contraction of the 
musculature of the worm (^52), but Baldwin (^53) has 
concluded that santonin acts on the central nervous 
system, a conclusion also reached by other workers (^5^). 
It has been further postulated that this stimulation 
of the nervous system of the worm results in chemotropism 
towards the drug (^55). Another somewhat intriguing 
explanation of the mode of action of santonin is that the 
drug deprives Ascaris of its resistance to hydrogen 
sulphide in the intestine (4-^ 6), although in vitro 
studies showing that hydrogen sulphide in the presence 
of santonin is no more toxic to the worms than is hydrogen 
sulphide alone (4-57) would not support this contention.
Whatever the ultimate mechanism of action of santonin 
proves to be, the demonstration that d-santonin is 
inactive as an anthelmintic and that dl-santonin is 
one-half as active as the naturally occurring l_-form 
(^58) conclusively shows that santonin is a structurally 
specific drug.
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Apart from its action in expelling Ascaris spp. perhaps 
the most interesting biological property of santonin 
is its ability to cause visual disturbances in human 
beings resulting in yellow and violet vision 
(xanthopsia). Taste, smell and hearing may also be 
affected. A detailed study of the effects of santonin on 
vision was made by Marshall (4-59) > who gives a summary 
of the earlier work in this field. The changes in the 
electrical phenomena of the optic nerves in animals, 
which presumably accompany visual disturbances similar 
to those in man, have also been studied (4-60).
Santonin has been shown to exert a mild diuretic 
effect (461) and to increase the concentration of uric 
acid in the urine (4-62). Unlike alantolactone (4-63)? 
another sesquiterpenoid lactone whose chemical 
structure is still incompletely established (4-64-)- 
santonin is reported to have no effect on the urinary 
excretion of sulphate (4-65)*
Several investigations have been concerned with the 
effect of santonin on the concentration of sugar in the 
blood. At one time santonin saw clinical trial in the 
treatment of diabetes (466) but it has been shown that 
the hypoglucaemia produced by prolonged treatment with
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santonin is due to liver damage (4-67) * Single doses of 
santonin have been reported to produce a hyperglycaemia 
(4-68,4-69) or to increase the hyper glycaemia due to the 
administration of glucose (4-70), although other workers 
(4-71) have concluded that, whilst there is no direct 
action on the blood sugar level, phlorhizin glycosuria is 
decreased, presumably by a rise in the renal threshold 
for glucose.
In high doses santonin produces convulsions in various 
species (4-69,472). The symptoms of severe santonin 
intoxication have been described by Binz (4-73) and 
Hernach (4-74-).
Other biological studies with santonin have shown that 
it inhibits the serum cholinesterase of the guinea pig 
(4-75)? that it exerts a slight vasodilator action on the 
frog (4-76), that it relaxes the guinea pig uterus (4-77) 
and the rabbit intestine (478), that it prevents the gross 
oedema induced by ^-phenylenediamine (479 ) and that it 
antagonises the action of veratrine (480).
The bio trans formation of santonin has been well 
studied (481) and has been proposed as a test of hepatic 
function (482).
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The isomeric p -santonin has been compared in its 
pharmacological properties to santonin (^83) and 
synthetic derivatives of santonin have been tested 
biologically (48^). Various naturally occurring 
sesquiterpenoid lactones closely related in chemical 
structure to santonin have also been studied. One such 
compound is v  santonin (LXXIX) (^ -85) which was claimed
LXXIX
to exert an action on the frog heart resembling that of 
the steroidal cardiac glycosides (486) although later 
work employing dogs and rabbits showed negative results 
(487). Other studies have shown that isoartemisin 
produces no immediate effect on the blood sugar level 
of fasting rabbits (488).
Alantolactone (syn helenin) has been investigated 
pharmacologically by Kuribayashi and Hara (489)# Its 
efficacy in ascariasis has been in dispute (490), but 
it is claimed to be toxic to the Schistosome carrier,
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Australorbls glabratus (491). Alantolactone has been 
shorn to have a choleretic effect, being some 20 per cent 
as potent as dehydrocholic acid on a molar basis (492).
Sesgniterpenoid Antibiotics
Our knowledge of this group of sesquiterpenoids is of 
very recent origin and so far two representative members 
would appear to be well established. These are 
trichothecin (LXXX) (493) and fumagillin (LXXXI) (494). 
The alcoholic moiety of trichothecin has been shown to
H
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arise in nature from a true se squi terpenoid precursor by 
a double 1,2-methyl group migration (495) but little 
is known of the biogenesis of fumagillin. Several 
possibilities exist. The alcoholic moiety of fumagillin 
can perhaps be regarded as a substituted isoprenalogue of 
carquejol (496), or as resulting from an irregular 
condensation of isoprene units. There is the third
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interesting alternative that it could arise from 
farnesol if a series of allylic hydroxylations were to 
occur before ring closure. This is illustrated in LXXXII.
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Trichothecin is an anti fungal antibiotic, having no 
action against bacteria (497), and it has shown 
considerable promise in field trials against fungal 
plant diseases (498). Pharmacological experiments have 
demonstrated that it has severe irritant properties 
(499). Several analogues of trichothecin have been 
prepared (499) and it has been demonstrated that 
replacement of the isocrotonyl moiety by the acetyl, 
butyryl or crotonyl radicals does not greatly affect the 
antifungal properties. Tetrahydrotrichothecin is, however, 
devoid of antifungal activity.
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Fiunagillin is a potent amoebicide (5C0) both in vitro 
and in viv  ^and has been shovm to be of use in the 
treatment of T; os etna infection of bees (5C1) although it 
is claimed that a complete cure is not effected (502). 
Various amine salts of fumagillin are also active 
against hosema anis (503)*|— I - i- r ~ ■ Ilf- ..II I—  '
Fu.magillin has been claimed to show promising 
carcinostatic activity against various types of 
carcinoma (5 o 4 )  as has fumagillin alcohol (505)* 
Fumagillin has, however, idthout effect on Crocker 
sarcoma 180 in nice (506).
Other studies have shown that it is toxic to 
spermatozoa (507), that it prevents phage multiplication 
in infected Micrococcus pyrozones var auireus (508), and 
that it is active against Plasm o d i urn gall in a, c e urn in 
chicks (509)* A review of the biological properties of 
fumagillin which emphasises its clinical application and 
tolerance has been published (510).
Pierotoxin
Santonin has on occasion been compared in its 
biological properties with picrotoxin, which is a 
molecular compound of the two substances picrotoxinin
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(LXXXIII) (911) and plcrotin (LXXXIV). Although both
o. A
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picrotoxinin o.nd picrotin have been subjected to 
separate biolop'ical investigations ( 2, 5^1 3), as have
several derivatives from them, nearl^^ all the studies 
have employed picrotoxin. Both picrotoxinin and picrotin 
are  ^compounds and can probably be regarded as 
sesquiterpenoids. An interesting possibility is that 
they could arise in anture from a suitably oxygenated 
cadinene-type precursor, as s ho via in L C^XXV. îm alternative 
biogenetic scheme from farnesol has been proposed by
Cross (51^)
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Picrotoxin has been extremely well investigated 
biologically, there being well over 200 publications 
concerned with its pharmacological and clinical properties* 
The earlier work has been reviewed by Trendelenburg (?15). 
A considerable proportion of the work has been concerned 
with the physiological antagonism between picrotoxin 
and various central nervous system depressant drugs. 
Picrotoxin is a convulsant drug (?16) and acts both on 
the midbrain (Ç17) and on the medulla oblongta where it 
stimulates the respiratory, vasomotor and other autonomic 
centres. The drug does, however, show some depressant 
properties (^18). The similarity between the respiratory, 
convulsive and circulatory changes occurring with 
picrotoxin and those occurring in epileptic attacks . - 
has been remarked upon (519)-
Picrotoxin has been shown to antagonise the narcotic 
effects of chloral hydrate (520,521), paraldehyde (522), 
urethane (523), sodium bromide (5249 and the barbiturates 
(525). The degree of respiratory stimulation produced 
has been found to depend upon the depth of the depression 
originally present (526). It would appear that picrotoxin 
is unable to antagonise the narcotic effects of 
magnesium sulphate (527) or morphine, although it does
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counteract the respiratory and circulatory depressant 
actions of morphine (528). Actually morphine has been 
shown to exert a diphasic action, being able to enhance 
the action of both depressant and stimulant drugs, and 
it has been demonstrated to render subconvulsant doses of 
picrotoxin convulsant (529). The fact that picrotoxin 
shows no antagonism towards the action of myanesin has 
been advanced as supporting evidence that myanesin acts 
selectively on the spinal cord (530).
The ability of picrotoxin to antagonise barbiturate 
narcosis has been utilized clinically and the drug has 
been used as an antidote to barbiturate intoxication (531), 
although its use in this connection is not without 
danger (532) and it has now been replaced by amphetamine 
and p-ethyl-p -methylglutarimide. Conversely barbiturates 
have been employed to control the convulsions produced 
by picrotoxin (533)
Picrotoxin has seen application in the evaluation of 
anti-convulsant drugs (534,535), and has seen limited 
trial in the convulsion treatment of schizophrenia. 
Considerable effort has been devoted in attempts to locate 
the exact site of action of picrotoxin in the central 
nervous system (536), and many of the experiments have 
been essentially of a biochemical nature.For instance,
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investigations have been made on the distribution of 
sympathin in the brain during picrotoxin-induced 
convulsions (537), as well as on the ammonia (538), 
phosphate (539), lactic acid (540), glycogen (541) and 
acetylcholine (542) contents of the brain. Picrotoxin has 
also been shown to inhibit the oxidation of glutamate, 
succinate, fumarate and pyruvate by the cat brain 
in vitro (543) and to produce a marked decrease of the 
acid phosphatase activity in the large cells of the motor 
cortex of the dog (544).
As a result of experiments in which picrotoxin was 
shown to reversibly block peripheral inhibition in 
crayfish muscle (545), it has been postulated that 
picrotoxin competes for receptors with an "inhibitory 
transmitter" and that by analogy, the central action in 
mammals may occur by a similar process. In this connection 
it is interesting that picrotoxin has been shown to be a 
competitive antagonist of tt-aminobutyric acid (546).
An interesting property of picrotoxin which is thought 
to be associated with its convulsant action is its ability 
to induce ovulation in rabbits via an indirect 
stimulation of the hypophysis and release of luteinizing 
hormone (547,548). That the convulsions themselves are 
not sufficient to ensure ovulation has been shown by
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Kasdon (549), who found that although picrotoxin 
undoubtedly can induce ovulation, this action is rather 
unpredictable. It would appear that picrotoxin does not 
provoke the release of luteinizing hormone in rats (550).
Picrotoxin has an antipyretic action (551) which is 
thought to result from stimulation of a cooling centre 
in the diencephalon which is closely related to the 
centres controlling the parasympathetic system (552). It 
has been claimed, however, that picrotoxin at the 
convulsant level can produce an increase in the temperature 
of the skin (553).
Another result of the central action of picrotoxin is 
the production of hyperglycaemia (554), the effects being 
mediated via the splanchnic nerve and adrenal glands 
(555). The increase in the concentration of sugar and lactic 
acid in the various body fluids which is induced by 
picrotoxin has been studied in detail by Hata (556).
There is also evidence that picrotoxin can act directly 
on the adrenal gland itself (557)» Similarly picrotoxin 
is thought to stimulate the rabbit uterus mainly by a 
central action, but there would appear to be a peripheral 
component (558) as well. Other peripheral actions of 
picrotoxin are reported by Ogawa (559) and Radouco-Thomas 
et al. (560).
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Amongst the many other detailed studies with 
picrotoxin may be mentioned those concerned with its 
effects on vasoconstriction (561), on the rhythmic 
activity of leech muscle (562), on the permeability of 
frog skin (563) and on the glomerular filtration and 
tubular reabsorption (564). Picrotoxin also produces an 
increase in the potassium level of the blood (565), as 
indeed do other analeptic agents.
Like camphor, picrotoxin has afforded good examples 
of how the potency of a drug varies with the temperature 
(566), with species and sex (567), with the route of 
administration (568), with age (569) and with dietary 
history (570).
Other compounds which are closely related chemically 
to picrotoxinin and picrotin are coriamyrtin, tutin (571) 
and mellitoxin. The biological properties of these 
compounds are similar to those of picrotoxinin (512).
Thus coriamyrtin appears to have a similar action on the 
central nervous system to that of picrotoxin (521,572) 
and to be able to antagonise the action of barbiturates 
(573) although it is unable to induce ovulation in 
rabbits (548). Many other studies of the pharmacological 
properties of coriamyrtin have been reported (574,575)
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and several of its derivatives have been investigated 
(576).
Tutin has also seen considerable pharmacological 
investigation (575,577) and both tutin and mellitoxin 
show antagonism to barbiturates (578).
Other Sesquiterpenoids
Relatively little biological work appears to have 
been carried out on the other sesquiterpenoids which 
are at present knom.
Two se squi terpenoid alkaloids nupharidine (LXXXVI) 
(579) and nupharamine (LXXXVII) (580) have been isolated 
from the roots of Nuphar ianonicum and pharmacological
LXXXVI
HO
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studies (581) on deoxynupharidine hydrochloride have 
shown that this derivative constricts peripheral blood 
vessels, increases the blood pressure in small doses 
and lowers the blood pressure in large doses. It also
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depresses the respiratory centre and exhibits 
anti-acetylcholine and anti-histaminé activity*
The se squi terpenoids farnesenic acid, fame sal, 
farnesol and nerolidol have been shown to inhibit the 
conversion of acetate (582) and mevalonic acid (583) 
into cholesterol by rat liver homogenates. Although the 
inhibition was probably due to alternative incorporation 
of the preformed sesquiterpenoid in the squalene synthesis 
since farnesyl pyrophosphate is known to be an 
intermediate (584-), these experiments raise the question 
as to whether other se squi terpenoids can be found which 
will be capable of blocking the squalene synthesis 
in vitro • As was pointed out by Robinson (585) such 
compounds might be of value in the treatment of conditions 
like atherosclerosis, although animal experiments would 
tend to show that exogenous and not endogenous 
cholesterol is involved in this affliction (586). A 
demonstration that farnesenic acid itself can show an 
inhibitory anti-metabolite effect was given when it was 
shown to antagonise growth promotion by mevalonic acid 
in Lactobacillus acidophilus (587).
-d-Bisabolol (LXXXVIII) is active in vitro against 
Mycobacterium tuberculosis (588) and possesses
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antiphlogistic (589) and spasmolytic (590) properties. 
Turrnerone (LXXXIX) has seen use as a cholagogue and is
OH
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of interest as it has been stabilised by means of its 
thiourea inclusion compound (591). Humulene (XC) has 
been shorn to depress the nervous system of the frog in 
low dosage and to stimulate it in higher concentrations 
(592) whilst caryophyllene (XCI) exhibits anti-anaemic
XC XCI
activity in the toluenediamine-anaemic rabbit (593)«
Asafoetida, a resin obtained from Foerula spp. was 
at one time used in the treatment of hysteria and as a 
stimulant, expectorant and carminative (59^)* Recent
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work has shown this resin to contain several interesting 
sesquiterpenoid ethers of umbelliferone, a representative 
member being farnesiferol A (XCII) (595)* A similar 
monoterpenoid derivative, auraptene, which is the geranyl 
ether of umbelliferone (596), possesses antibacterial 
activity (597).
HO
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Valeranone (syn jatamansone) (XCIII) (598) is a
XCIII
sesquiterpenoid not obeying the head-to-tail isoprene 
coupling rule and may well result from the rearrangement 
of a precursor in which the isoprene units are arranged
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in the regular manner. It has been claimed to exhibit 
antiarrhythmic and anticonvulsant properties (599)*
Other sesquiterpenoids worthy of mention are the various 
acids showing antibacterial properties (600), nootkatin 
(XCIV), ngaione (XGV) which may be the active principle
OH
XCIV
o
XCV
of the toxic essential oil Myoporum laetum Forst (601), 
and dendrolasin (XCVI) which is the odoriferous principle
XCVI
secreted by the mandibular glands of the ant Dendrolasius 
fuliginosus Latr (602).
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Dimeric Sesquiterpenoids
This group includes the dimeric guaianolides absinthin 
and anabsinthin (603) which are the bitter principles of 
wormwood (Artemisia absinthum) and certain dimeric 
naphthalene compounds (60^) occurring in various species 
of cotton (Gossvnium spp«) which are to be regarded as 
dimeric dehydrocadalene derivatives* The best known of 
these dehydrocadalene dimers is gossypol (XCVII) (605)
CHOCHO 9^ OH
OHHO
OHHO
XCVI I
which is the principle colouring matter of cottonseed.
Gossypol has seen extensive biological investigation 
on account of its toxic properties (6C6) and its 
implication in the poisoning of cattle fed on cottonseed 
meal, although recently work has been published in which 
it is claimed that the free gossypol content of 
cottonseed meal does not completely account for its 
toxicity (607)•
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Fortunately, during the processing of the cottonseed 
meal, which is such a valuable protein foodstuff, the 
gossypol is largely inactivated (6o8) by interaction 
with the free amino groups of the proteins (609)* In 
this connection it has been shown that the compound 
formed between gossypol and glycine is non-toxic (610).
The pharmacology and toxicology of gossypol have seen 
considerable study. In low doses ingestion of gossypol 
produces a loss of appetite and fall in body weight in 
various species (611). As it has been shown that gossypol 
interferes with the in vitro digestion of cottonseed 
globulin by pepsin and trypsin (612) these symptoms of 
starvation in vivo are probably due in considerable 
degree to an inability to absorb proteins from diet. 
Somewhat higher doses induce diarrhoea, intestinal 
haemorrhage and ulceration (613)* These haemorrhages 
have been shown not to be primarily due to 
hypoprothrombinaemia (614), although gossypol does 
induce this condition in rabbits and pigs (6l4), and 
haemolytic anaemia in chicks (615).
In addition to exerting a haemolytic effect on 
erythrocytes, gossypol has been shown to prevent the 
liberation of oxygen from oxyhaemoglobin (6l6), which
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would account for the observation that rats sometimes 
die in a state resembling suffocation (617)* Anoxia of 
circulatory origin has also been observed in pigs (618).
Intravenous or intraperitoneal injection of the 
sodium salt of gossypol produces a fall of blood pressure, 
cardiac irregularities and pulmonary oedema, death 
resulting from circulatory failure (619). Other 
pharmacological studies have shown that gossypol 
stimulates the isolated longitudinal muscle of the small 
intestine (620) and induces paralysis of the limbs with 
myelin degeneration of the nerves (619?621). Attempts to 
discover whether gossypol would inhibit the oxidative 
inactivation of adrenaline were frustrated by its low 
solubility (622).
Gossypol was tested as an insecticide but found to be 
ineffective against the species employed (623). More 
detailed reviews of the biological properties of 
gossypol have been published elsewhere (624).
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DITERPENOIDS
As with the mono- and sesqui-terpenoids, the 
diterpenoids show considerable variation in their 
chemical structure. Excellent reviews of the chemistry 
of diterpenes have recently appeared (398,625)5 including 
one which emphasises their industrial applications (626).
Vitamins A, E and K.
Without doubt the most important diterpenoids and 
diterpenoid derivatives from a biological point of view 
are the vitamins A, E, and K^CZO], but as these 
compounds have been the subject of numerous reviews 
(^9,627) very little need be said concerning them here. 
These compounds can all be formally regarded as being 
chemically related to the acyclic diterpenoid alcohol 
phytol (XCVIII) which has itself been shown to be a 
nutritional lipotropic factor (628). The phytyl radical
XCVIII
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can probably be regarded as being of the nature of a 
supporting moiety in the chlorophyll molecule.
There are several vitamins A, all of which are closely 
related chemically, the most active being vitamin (IC)
IG
in which the double bonds of the side chain all have the 
trans configuration. Neovitamin A^ differs from vitamin 
A^ only in the configuration at 0-1^ - and vitamin A^ 
differs from vitamin A^  by possessing an additional 
double bond in the 3-^ position.
As vitamin A^  is formed by degradation of the o( -, p - 
and TT -carotenes in the liver of herbivores these 
tetraterpenoids are often referred to as provitamins A.
A review of our knowledge concerning the way in which 
the provitamins A are transformed into vitamin A has 
recently appeared (629) and the provitamin A effect of 
carotenoids in relationship to cis-trans isomerism has
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also recently been reviewed (63O).
The vitamins A are the vitamins responsible for the 
maintenance of healthy epithelial tissue and normal 
growth in mammals (63I). They also aid in maintaining 
resistance to infection. Vitamins A^ and A^ have another 
important function in that they are precursors of the
11-cis retinenes (neoretinenes b) which on combination 
with specific proteins of the rods and cones called opsins 
form the visual pigments of vertebrate vision. The first 
symptom of vitamin A deficiency in man and other animals 
is the rise of visual threshold known as night-blindness, 
and continued vitamin A deficiency leads to degeneration 
of the rods and cones. Excellent accounts of the parts 
played by the vitamins A and the 11 -cis retinenes in 
vision are available (632). A detailed account of 
hyperVitaminosis A has also appeared (633).
Numerous modifications of the vitamin A molecule have 
been synthesised in attempts to establish relationships 
between chemical structure and vitamin A activity. Most 
of the work has been concerned with alterations in the 
structure of the side chain although some attention has 
been paid to the ionone ring system, including 
preparation of the cyclohexenyl (63^) and benzene (635)
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ring analogues. A summary of the structural 
modifications of the vitamin A molecule which have been 
tested for biological activity is given by Baxter (636).
Recently it has been shown that vitamin A acid will 
maintain normal groifbh of rats, but will not protect 
them against night-blindness (637). This has led to the 
interesting postulate that vitamin A itself is only a 
storage precursor, giving rise to 11-cis retinene on the 
one hand for the maintenance of normal vision and to 
vitamin A acid on the other for the maintenance of 
normal growth and tissue function. The animal is unable 
to convert vitamin A acid into 11-cis retinene.
The vitamins E or the c<, p , zr ) ^ 6 , y,, and 3
tocopherols have been shown to be essential to the 
fertility of rodents, but it has never been clearly 
demonstrated that they are essential to man, although 
there are reports of women subject to spontaneous 
abortion having experienced successful pregnancies after 
vitamin E therapy. The vitamins E can all be regarded as 
derivatives of phytol and they differ only in the number 
and position of the methyl substituents on the benzene 
ring. The structure of oc -tocopherol is shoim in Fig.C.
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The tocopherols appear to participate as hydrogen 
carriers in the oxidative cycles of muscle metabolism 
(638) and they have been shoim to function as in vivo 
antioxidants for fats (639). The typical symptom of 
E-hypoVitaminosis in animals is muscular dystrophy 
and creatinuria.
As in the case of vitamins A numerous synthetic 
analogues of the tocopherols have been prepared and 
tested. These studies have clearly shewn that the 
structure of the phytyl side chain cannot be altered 
without considerable loss of activity and so provide an 
excellent illustration of the supporting moiety concept 
Key references to vitamin E analogues are to be found 
in the review by Mason (6^0).
Both oc-tocopheryl acetate and phytol are of interest 
from the antimetabolite concept as they impair the 
utilisation of p-carotene as a provitamin A although
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they do not affect the utilisation of vitamin A 
itself (6 +^1).
The vitamins K are the antihaemorrhagic vitamins, 
regulating the synthesis, of prothrombin in the body. 
Actually only two vitamins K, viz; vitamin which 
occurs in plants and vitamin [20] (Cl, n=4) which
C H n --
CH
C H —  C H
Ch
01
occurs in mammalian tissue are diterpenoid derivatives. 
The other vitamins K2 which occur in fish meal and 
mycobacteria are higher isoprenalogues fitting formula C*
The vitamins K are employed prophylactically to 
prevent post-operative bleeding in patients with 
obstructive jaundice. As new-born infants have low 
prothrombin values vitamin K is often administered to 
expectant mothers before birth in order to prevent 
haemorrhage in the child. The vitamins K also find 
application in overcoming the effect of overdoses of 
dicoumarol which is employed as an anticoagulant in
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patients prone to thrombosis.
Considerable work has been devoted to the preparation 
of various vitamin K analogues, especially by Isler's 
school (31,32,642).
An interesting naphthotocopherol (ClI) was synthesised 
by Tishler et al. (64-3) and found to exhibit vitamin E 
activity in moderate doses whereas in large doses it has 
vitamin K-like activity. This compound which incorporates 
structural units common to both series is thus very 
interesting from the point of view of structure-action 
relationships.
Other compounds closely related chemically to the 
vitamins K and E are the tocopherylquinones, Kofler's 
quinone (CIII) and the ubiquinones or coenzymes Q.
OH
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oC-Tocopherylquinone (CIV) is of interest as it has 
recently been claimed to possess hypotensive properties
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which are thought to result from a direct adrenocortical
CIV
inhibition (6^V).
The ubiquinones (6^ -5^ ) can be represented by the 
general formula CV where n- 6, 7, 8, 9? 10.
OCH
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The effects of the vitamins A and E on cholesterol 
metabolism and their usefulness in the treatment of 
atherosclerosis are summarized by Lin and Chen (6^6).
Diterpenoid Bitters
Several diterpenoids have been identified as the 
bitter principles of various plants. Examples are
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andrographolide, marrubin and columbin (CVI). Marrubln
O h
o CVI
is the bitter principle of the horehound (Marrnbium 
vulgare) galenical preparations of which were at one 
time used as an expectorant and laxative (in large doses)
(647). Columbin occurs together with the chemically 
related bitter principles palmarin and chasmanthin in 
Colombo root (Jateorrhlza palmata, Miers) which has seen 
use as a bitter tonic. Columbin is not strictly a true 
diterpenoid, but is thought to arise in nature by 
migration of methyl groups in a diterpenoid precursor
(648). Another bitter tonic prepared from quassia, the 
stem wood of Picroena excelsa, contains the rearranged 
diterpenoids quassin (644) and neoquassin.
The popularity of bitter tonics' stems largely from 
the belief that bitters stimulate appetite and aid 
digestion by increasing gastric secretion. Experiments
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have shovTi, however, that in normal human beings and 
animals bitters actually inhibit hunger contractions 
and abolish hunger sensations (650), and are without 
effect on gastric secretion (651). On the other hand, 
in cachetic dogs they do increase gastric secretion 
(652) and this observation may provide some support for 
their use in anorexic states. It is also conceivable 
that their continued use by healthy human beings sets 
up a conditioned reflex of appetite.
Quassin has seen trial as an insecticide, but it 
proved to be ineffective (439,653). It was also used at 
one time against threadworm infections, and has seen 
limited trial as an alternative to emetine in the 
treatment of amoebic dysentery (654). It slows the beat 
of the isolated frog heart and produces coronary 
constriction in the isolated mammalian heart (655). On 
administration to rabbits quassin produces muscular 
tremor followed by paralysis (656).
Gibberellins
An extremely interesting compound which has been 
postulated (657) to arise in nature by a route involving 
diterpenoid intermediates is gibberellic acid which has 
recently been shown to possess the structure CVI I (658).
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Gibberellic acid is one of at least nine naturally
,OH
COOH
CVII
occurring gibberellins, all of which are closely related 
chemically, and all of which possess growth-promoting 
action on plants. Six of the gibberellins viz: gibberellic 
acid and gibberellins A^ and A^ are
metabolites of the fungus Gibberella fuiikuroi, the 
organism which causes bakanae disease in rice, and the 
other three gibberellins A^, Ag and Ag have been isolated 
from the seeds of the runner bean (659)* Gibberellin A^  
has been positively identified as a constituent of 
certain plants (66C) and numerous crude extracts 
possessing gibberellin-like activity have been prepared 
from other plants (661) so it would appear that the 
gibberellins are natural plant growth hormones.
Qualitatively all the gibberellins appear to exhibit 
the same type of biological activity, but gibberellic
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acid has seen the widest investigation as it can be 
produced in quantity from the filtrates of deep cultures 
of G. fu.likuroi (662).
There is considerable species variation in the action 
of gibberellic acid on plants, but this wLll not be 
discussed here as an excellent, comprehensive and 
up-to-date review has just appeared (663). The practical 
aspects of the use of gibberellins in agriculture and 
horticulture have also been recently reviewed (66^) and 
numerous other reviews are available (665).
Recently there has been considerable interest in the 
effects of gibberellic acid on the biosynthesis of 
natural products, particularly those of medicinal 
importance. For example, it has been shown that 
gibberellic acid depresses the alkaloidal content of 
Datura stramonium (666,667)5 and of Atropa belladonna 
(666), although the alkaloid production is not affected 
in the second year of growth in the case of the second 
plant (668). With Hyo s c yamu s ni g er . however, it is 
claimed that gibberellic acid produces an increase in 
alkaloidal content (669). Other experiments have shown 
that gibberellic acid produces an increase in glycoside 
content of Digitalis nurpurea (67O) and a decrease
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in the rutin content of Fagjonyrum esculentum Moench (671)*
Despite its spectacular physiological effect on 
plants, pharmacological and toxicological studies (672) 
have shoun that gibberellic acid is without any 
pronounced activity in mammals and is virtually harmless. 
It is also without action on bacteria or moulds (673) 
and gibberellin A has been shown to have no effect on 
Ehrlich mouse carcinoma (67^). •
The Gravanotoxins
An interesting series of toxic principles which appear 
to be rearranged diterpenoids occurs in plants of the 
family Ericaceae. These compounds are the grayanotoxins 
I, II and III and the pieristoxins A, B.and C. The most 
widely distributed member is grayanotoxin I (CVIII),
HO
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which is better known by its alternative name
andromedotoxin. It has also been designated asebotoxin,
rhodotoxin and acetylandromedol. Andr omedotoxin has been
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identified as a constituent of various species of 
Andromeda, Kalmia, Leucothoe, Lvonia, Pernettva, Pieris 
and Rhododendron (675)? and is the agent responsible for 
the toxicity of these plants to livestock (676). It is 
also the toxic principle of the Chinese drug Nao-Yang-hua 
(677). Andromedotoxin has been positively identified as 
the compound responsible for the poisonous nature of 
certain honeys (678)5 and as the agent present in 
Rhododendron nectar responsible for the outbreaks of bee 
poisoning (679).
In mammals the symptoms of acetylandromedol poisoning 
are ernesis and purging with severe respiratory 
disturbance and convulsions, followed by death through 
respiratory arrest
The grayanotoxins are of considerable taxonomic 
interest for although diterpenoids and plant sterols 
frequently occur together in nature, diterpenoids and 
true triterpenoids rarely do so. Hence the occurrence 
of the triterpenoid taraxerol (68O), the pieristoxins 
A, B, C (681) and grayanotoxin III (682) in the leaves 
of Pieris jauonica is of some significance.
Andromedotoxin was early subjected to considerable 
pharmacological investigation (683). The results of
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these experiments showed that it was without effect 
on unicellular organisms such as Paramoecium and 
Oualina but that it had digitalis-like action on the 
mammalian and frog hearts and that it depressed the 
excitability of the motor nerves of the frog and rabbit, 
in addition to depressing respiration.
More recently investigations have shown that in 
many ways andromedotoxin has similar activity to certain 
of the Veratrum alkaloids (68^), possessing hypotensive 
properties, and producing both direct and indirect 
positive inotropic effects on the heart. In high doses 
it produces ventricular arrhythmia, the nature of which 
has been investigated in detail (685).
Diteruene Alkaloids
The diterpene alkaloids on present day knowledge 
would appear to fall into four main classes. The first 
class, comprising the Erythrophleum alkaloids are esters 
of diterpene acids with alkanolamines. The second class 
is represented by ryanodine which is an ester of 
pyrrole-cic-carboxylic acid (686) and ryanodol which has 
been postulated to be a diterpenoid of unusual type (687). 
The third class is represented by thelepogine which is 
apparently biogenetically related to manoyl oxide (688).
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The fourth class, which is the largest, is represented 
by the Aconitum. Delphinium, and Garrya alkaloids, and 
in this group the nitrogen atom is bound directly to the 
diterpenoid carbon skeleton as in thelepogine. These 
alkaloids (like the monoterpenoid, sesquiterpenoid and 
steroidal alkaloids) are of considerable interest from the 
biogenetic point of view as they do not possess 
structural fragments recognisably derived from essential 
amino acids as do the vast majority of alkaloids (689). 
Instead the nitrogen atoms are attached directly to an 
isoprenoid skeleton and the term "alcaloida imperfecta" 
has been coined to describe them (690). It is to be 
noted that the absolute configuration of the diterpene 
alkaloids corresponds to the kaurene and steviol type 
and not the phyllocladene type (691).
Within the aconite-delphinium group of alkaloids, 
two main subclasses are recognised. The first consists 
of alkaloids with a C2Q skeleton which are relatively 
non-toxic and the second of the alkaloids characterised 
by a skeleton which are highly toxic. The group 
in turn consists of a heptacyclic perhydrophenanthrene 
group represented by deltaline and delpheline (692) and 
a group with a rearranged hexacyclic perhydrophenanthrene
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skeleton represented by lycoctonine and aconitine.
Comprehensive reviews on the chemistry of the 
Aconitum Garrya alkaloids are available (693)? although 
care must be taken as they employ the mirror image of the 
true absolute configuration of the alkaloids.
*
The Erythrophleum alkaoids, typical members of which 
are cassaine (CIX), norcassaidine, homophleine, 
erythrophleine and coumingine, have been well investigated
c h c o o c h ^c H^ n
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biologically and all would seem to show qualitatively 
similar physiological activity (69^) although there is 
quantitative variation. These alkaloids exert a 
pronounced action on the heart which is similar to that 
shown by digitalis (26,69?). Crude preparations of the 
Erythrophleum alkaloids have been used clinically in the 
treatment of congestive heart failure (696), and in his 
review of the cardiac properties of the Erythrophleum 
alkaloids McCawlay (697) points out that if these 
compounds could be obtained cheaply, they hold promise
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as digitalis substitutes.
In addition to their cardiac activity the Erythrophleum 
alkaloids possess local anaesthetic activity (698), 
increase mammalian blood pressure (both by vaso­
constriction (699) and by their action on the heart 
muscle (700) , and stimulate the isolated rabbit 
intestine (701,702), and uterus (701,703). They also act 
on the respiratory and emetic centres. The statement by 
Tsutsui and Tsutsui (70^) in which they attribute the 
local anaesthetic and cardiac activities of cassaine to 
cassaic acid is an unfortunate error.
Studies with Erythrophleum alkaloids have afforded 
excellent examples of species (70?) and seasonal 
variations (706) in drug response.
Ryanodine is obtained from Ryania speciosa Vahl. and 
crude extracts from this plant are used commercially as 
an insecticide (707) being especially effective against 
the European corn borer (Pyrausta nubilalis) (708) and 
the oriental fruit moth (Grapholitha molesta) (709).
The pure alkaloid was isolated in 19^8 (7IO), and has 
seen considerable pharmacological investigation. Earlier 
work using crude preparations is summarized by Kuna and 
Heal (711 ) and by Procita (712) who, in the course of
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detailed pharmacological investigations, showed pure 
ryanodine to be highly toxic to mammals.
The most remarkable property of ryanodine is its 
ability to induce an irreversible contracture in the 
skeletal muscle of mammals and frogs (713) and in 
mammalian intestinal smooth muscle (71^). This action 
occurs without the resting membrane potential nor the 
ATP-ase activity being affected and is independent of the 
innervation. Oxygen uptake is, however, increased (71?). 
Detailed studies of the influence of temperature upon the 
kinetics of ryanodine-induced contracture have been 
reported, using the rat diaphragm (716).
With insect muscle ryanodine induces a flaccid 
paralysis (717) accompanied by an increase in oxygen 
uptake (7175718). Ryanodine also acts on mammalian 
cardiac muscle (719) with resultant hypotension, but in 
this case there is a depression of contractility without 
contracture. The alkaloid has further been shown to 
block the spontaneous rhythmic contraction of isolated 
skeletal muscle cells in tissue culture (720).
Another interesting action of ryanodine is its ability 
to block mitosis by retarding the anaphase movement of 
chromosomes (721). It has also been shown to inhibit
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development and depress oxygen uptake in developing 
embryos of Amblystoma nunctaturn (722).
Most of the earlier biological work on the aconite 
and delphinium alkaloids employed crude extracts from 
the plant, and presumably the activity was mainly due to 
alkaloids of the group. Such galenical preparations 
were formerly used medicinally as salves in the 
treatment of neuralgia, arthralgia and inflammation (723)) 
and as anodynes, diaphoretics and diuretics. The Chinese 
drugs V/u-T'ou and Ï 'sao-wu-t'on are preparations of 
aconite alkaloids. Preparations of aconite alkaloids 
were also employed as arrow poisons by the ancient 
Chinese and Gauls.
The Aconite and Delphinium alkaloids, appear to possess 
insecticidal properties against a variety of insects 
(724-), although not against all insects (725).
The C^Q alkaloids of which atisine (CX), garryine,
O h
CX
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veatchine, garryfoline and cauchichicine are typical 
examples, have been sho\m to be without significant 
action on smooth muscle, to briefly lower the blood 
pressure of the anaesthetized cat and to produce 
respiratory failure when administered in large doses (726), 
Garryine has also been sho™ to be devoid of antimalarial 
activity (727)* The most interesting property of atisine 
is its ability to suppress the bradycardia accompanying 
adrenaline hypertension whilst increasing the slowing 
of respiration, thus dissociating these two reflex 
actions of adrenaline hypertension (728).
The most intensively investigated alkaloid of the 
group from the biological point of view is aconitine, 
which has been shorn to possess structure CXI (729), and
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vrnhich is one of the most toxic alkaloids knovm. (730).
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Aconitine has anaesthetic properties which produce a 
peculiar sensation of tingling and numbness. It was this 
action of aconitine that led to the use of aconite 
preparations in the treatment of rheumatism and neuralgia. 
The alkaloid also shows pronounced action on the emetic 
centre (731)*
Systematically aconitine slows the heart by central 
vagus stimulation and it was at one time employed 
medicinally ina.sthenic fevers. Toxic doses arrest 
respiration and the heart. Numerous detailed studies of 
the action of aconitine on the heart have been reported
(732,733).
The disturbance in cardiac function induced by 
aconitine are antagonised by antihistamine drugs (73^)5 
and the ability of aconitine to produce auricular 
arrhythmias is utilized in evaluating antifibrillatory 
drugs (735).
Recent studies with aconitine have been concerned with 
its action on intracisternal injection (736), and with 
its effects on aerobic glycolysis (737)9 and the activity 
of muscle membranes (738). The morphological changes 
occurring in acute experimental aconitine poisoning have 
been reported (739). A concise account of the pharmacology
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of aconitine is given by Sollmann (7^0), and a fuller 
account of the early work is given by Boehm (7^1)» Related 
alkaloids such as indaconitine (7^2) and japaconitine (7^3) 
have also been well investigated.
Aconine, which is des-acetyl, de-benzoyl aconitine, 
differs considerably in its activity from aconitine 
(732,7^ +^).
Quaternary salts formed from various alkaloids of the 
lycoctonine group show the curariform activity 
characteristic of quaternary nitrogen compounds in 
general (7^5)*
Other Diterpenoids
Several diterpenoids such as podocarpic acid (7^6), 
ferruginol (7^6), and neoisodextropimaric and 
7-isodextropimaric acids (7^7,7^8), possess antifungal 
properties and various metal salts of abietic acid (CXII)
HOOC"
CXII
are bactericides (7^9) and fungicides (7?C). Ozonised
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polyethenoxy abietate was tested as a bactericide against 
Staphvlococcus aureus, but found to be relatively inactive 
(751 )• Sodium abietate, although active in vitro as an 
anti-viral compound, has been shown to be inactive in vivo 
(752).
An interesting application of a diterpenoid as a 
supporting moiety has been the utilization of several 
amines derived from abietic acid to prepare new penicillin 
derivatives (753) which have an extremely low solubility 
in water, thus leading to prolonged effective blood 
concentrations. These derivatives can be employed as stable 
aqueous suspensions for oral use and several are available 
as proprietary drugs. Penicillin salts with monoterpenoid 
bases have also been prepared (75^)*
Various amines derived from abietic acid showed 
molluscidal activity when tested against Australorbis 
glabratus (755) 9 and 6-aminodehydroabietinol and its 
methylated derivatives were prepared as potential 
morphine-like analgesics (756).
Cafestol (formerly known as cafe sterol) (CXIII), which 
is of considerable chemical interest because the A/B ring 
junction like that of farnesiferol A is antipodal to that 
of the steroids and diterpenes of the abietic acid class
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(757)? aroused biological interest when it was claimed to
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possess oestrogenic activity (758). Later work, however, 
has proved these claims to be erroneous (759)#
Nevertheless oestrogenic activity does occur within
the diterpenoid series., One compound possessing marked
oestrogenic properties is 6-hydroxydehydroabietinol (CXIV)
OH
CXIV
which was prepared by Fieser and Campbell (756) in the 
course of a series of investigations as to the possibility 
of utilizing abietic acid as a raw material for the 
synthesis of physiologically active compounds. 
6-Hydroxydehydroabietlnol does not bear any marked 
structural similarity to the natural oestrogens but
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construction of models shows that the two hydroxyl groups 
can readily assume an intergroup distance ranging from 
ca 7*5 to c^ 10.0 The compound thus supports the 
contention of Schueler (?60) that oestrogenic activity is 
associated with strong hydrogen bond forming groups such 
as hydroxyl groups when separated by an optimum distance 
of ca. 8.5 A 5^ although more recent work (65) would tend 
to place this distance somewhat higher viz: 10.5 A^. 
Subsequently Brandt and Ross (761) prepared podocarpinol 
(CXV) which a ls o  was claimed to possess an oestrogenic 
activity as was 7-isopropylpodocarpinol (762). Other
O H
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diterpenoid oestrogens include certain esters of 
6-aryloxyacyldehydroabietic acid which are claimed to be 
of value in the treatment of hyperchoiesterolaemia (763)#
The effect of cafestol on the metabolism of the rat 
has been studied (764-), and it was at one time recommended 
for the treatment of psoriasis and eczema (765)#
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Several diterpenoid compounds were tested as 
choleretic agents (4-92) and podocarpic acid, 
podocarpic acid 0-propionate and 6-carboxymethoxy-1,
12-dimethyl-1,2,3 j4-,9 j10,11 ,12-octahydrophenanthrene-l- 
carboxylic acid, were found to have potencies very close 
to that of dehydrocholic acid. Abietic acid-maleic 
anhydride adduct was also tested but it showed a lower 
activity. An interesting observation was that these 
compounds all produced a fall in blood pressure 
immediately after injection.
TRITERPENOIDS
As a class the triterpenoids are somewhat less 
interesting biologically than the lower terpenoids when 
consideration of the steroids is omitted. The exact 
function of the triterpenoids in the economy of the plant 
kingdom, like that of the diterpenoids, is not well 
understood. The possibility exists, perhaps, that 
phosphorylated precursors play a role in the transport 
of the water insoluble protective plant waxes to the 
exterior and so fulfil a function somewhat analogous to 
that of the bile salts in animals. Evolutionary 
differences in the ability to reabsorb and recycle the 
phosphorylated compounds could be invoked to explain the
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different ratios of higher terpenoids to paraffins and 
straight chain esters found in different plants.
Squalene (CXVI) has been extremely well studied in
CXVI
connection with its role as a steroid precursor but 
several other interesting actions have been reported. For 
instance it has been assigned a possible role as a 
protective agent in sebum on account of its mild 
fungistatic (766) and antibacterial (76?) properties.
It is also thought that peroxidised squalene may play a 
defensive role against carcinogens (768). Another 
interesting hypothesis is that squalene may be involved 
in the aetiology of baldness (769) for like vitamin A, 
lycopene and carotene it has been shown to have a 
depilatory action on animals (770)♦ Squalene diperoxide 
has been shown not to function as an antimetabolite in 
the biosynthesis of cholesterol (771 ) « A review of the
13*+.
biological properties of squalene has appeared (772),
Various triterpenoid saponins such as hederin (773), a 
glycoside of hederagenin (CXVII), have seen pharmacological
COOH
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study. In general these saponj.ns are bitter and exert an 
irritant action on the mucous membranes. They are also 
haemolytic agents (77^)*
The saponins hydroxyasiaticoside and asiaticoside have 
been reported to possess weak antituberculous properties 
(775) and asiaticoside has seen clinical trial in the 
treatment of leprosy (776). The aglycone, asiatic acid, 
is however inactive (777)» Asiaticoside is further claimed 
to stimulate the reticuloendothelial system and so promote 
wound healing (778), and produce a thickening of the skin 
with increased vascularisation of the connective tissue in 
healthy animals (779). Glycyrrhizinic acid has, however, 
been claimed to decrease function of the reticuloendothelial 
system (78O).
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The adverse effect of high concentrations of 
triterpenoid saponins in the diet on the growth of chicks 
has been demonstrated (78I). This action is believed to 
occur as a result of the interference with cholesterol 
absorption from the intestine. A similar effect is 
observed with trimethyl sterols of wool fat (782).
It has been concluded that triterpenoid saponins play 
an important contributory role in the production of bloat 
in ruminants grazing on legumes (783)5 although a complex 
combination of factors is involved (78^). Work with the 
sapons from alfalfa- (hedicago sativa ) which is known 
to contain triterpenoid saponins (785) would indicate 
that a three-fold mechanism is involved in which 
fermentation by the rumen bacteria (786), interference 
with the mechanism of eructation (787) and the formation 
of froth play a part. Other workers, however, have not 
been able to induce experimental bloat with triterpenoid 
saponins (788). Detailed toxicity studies of the alfalfa 
saponins have shown that they produce congestion of lung 
tissue and inflammation, haemorrhage and hyperaemia of the 
small intestine and abomasum (788). Severe kidney and 
liver damage also result. Other investigations have been 
concerned with the effects of the alfalfa saponins on the
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cardiovascular and central nervous system and on the 
motility of the intestines and ruminant stomach (789).
The report that glycosides of ursolic acid and oleanolic 
acid were responsible for the cardiotonic and diuretic 
action of the leaves of Nerium odorum (790) is obviously 
in error. These properties are attributable to steroidal 
cardiac glycosides which occur both in the leaves (791)
and the bark (792) of the plant.
Similarly the claims that the triterpene acids, 
oleanolic, ursolic and crataegolic acids, have a beneficial 
action on coronary flow (793) appear to be without 
foundation as other workers have found them entirely 
devoid of pharmacological activity (79^)* Glycyrrhetinic 
acid has also been claimed to exert an effect on the 
heart (795)? but once again later work using the potassium 
salt of glycyrrhizinic acid failed to show any positive 
cardioactivity (796).
The role of glycyrrhetinic acid as a potentiator of the 
adrenocorticoid steroids has already been discussed. Other 
investigations have shown that it possesses bacteriostatic 
properties (797). A detailed study of its general 
pharmacology has been made by Tocco-Tocco (798), and a 
further interesting property of the compound is its ability
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to effect detoxification of tetanus toxin (799).
The triterpenoids obtained from Polvnorus betulinus
have been claimed to inhibit the growth of neoplastic
cells (800). Polyporenic acid C (CXVIII) has been shown
to possess antibacterial activity (8C1) and the alkali
COOH,
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metal salts of various triterpenoid acids are reported to 
be highly toxic to fish (802). Oleanolic acid fed to 
Drosophila melanogaster has been reported to lead to a 
marked increase in propagation (803).
Two triterpenoids 5 lantadene A (syn rehmannic acid) and 
icterogenin (CXIX) are of somewhat unusual interest as they
GO o'
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have been shoim to produce liver damage in sheep leading 
to an inability to excrete phylloerythrin (a degradation 
product of chlorophyll formed by microbial action in the 
fore-stomach) with the subsequent production of 
photosensitivity Icterogenin also shows a
paralytic action on isolated rabbit duodenum (BO^).
Various triterpenoids such as the cucurbitacins and 
compounds like limonin (CXX), which are believed to arise
X
cxx
in nature from triterpenoid precursors (806), constitute 
the bitter principles of some plants.
The cucurbitacins are highly oxygenated bitter 
triterpenes belonging to the trimethyl steroid group (807) 
and are of widespread distribution in the family 
Cucurbitacaae where they occur as glycosides.
Various plants of the Cucurbitaceae have been used 
medicinally (BoB) and cucurbitacin E or c<-elaterin is a
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constituent of elaterium which is one of the most drastic 
purgatives known, and which at one time was used in the 
treatment of uraemia. The cucurbitacins are cytotoxins 
and some have been shoifjn. to have a necrotizing effect on 
experimental tumours (809). Toxicity determinations on 
pure cucurbitacins A, B and C have been reported (810), 
and it has been shown that these compounds produce 
acute pulmonary oedema at or near the lethal dose.
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II. Hemisuccinates of Mono-, sesqui- and di- terpenoids 
as potential general anaesthetic agents.
It is now over ICO years since anaesthesia was first 
introduced into medicine by Crawford W. Long in Georgia, 
William T. G. Morton in Massachussetts and James Y. Simpson 
in Edinburgh, but despite the expenditure of much time 
and effort, there is still no completely satisfactory 
explanation as to the precise mechanism of action of 
anaesthetic agents. Of the various theories which have 
been proposed, each suffers from certain shortcomings, 
and in an attempt to further our knowledge it was 
considered desirable to investigate certain hemi-succinate 
derivatives of predominantly lipid-soluble alcohols as 
potential general anaesthetics. The choice of mono-, 
sesqui- and di- terpenoid alcohols for this project was 
influenced by the fact that terpenoids do not appear to 
have been fully utilised in fundamental studies of drug 
action, as has been made clear in the introduction of 
this thesis, and also by the fact that such compounds 
possess molecular weights of a particularly suitable 
order of magnitude as v/ill be apparent from the following 
discussion.
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One of the first attempts to explain the mode of action 
of general anaesthetics was that of Overton and Meyer (1) 
who emphasized the need for pronounced lipid solubility 
in a general anaesthetic agent. Accordingly their ideas 
have become knoivn as the Overton-Meyer Lipid Solubility 
Theory. This theory obviously is unable to take account of 
the activity of certain ions such as Mg'^'*' and Br" without 
some modification, but by and large, the need for lipid 
solubility in an organic general anaesthetic is still 
accepted today. Inorganic ions can be accommodated if one 
considers general anaesthetics to affect the properties of 
cell membranes where certain ions are closely associated 
with a structure showing both ionic and lipid properties. 
Mullins (2) has given a generalised picture of the cell 
membrane, which, even if not a literal representation of 
the actual state of affairs, does permit us to see how 
both ions and lipid soluble molecules can alter the normal 
state of the membrane.
Overton and Meyer further suggested that there was a 
relationship between anaesthetic potency and the distribution 
coefficient of the compound between olive oil or cottonseed 
oil and water and considered that these oils could be 
taken as representative of the brain lipids. Indeed they
25-9.
found a good correlation between anaesthetic activity 
towards tadpoles and the olive oil/water distribution 
coefficient for a limited series of compounds which they 
termed " indifferent chemical agents However, certain 
substances such as camphor which possess favourable 
distribution coefficients are not anaesthetic agents, but 
central nervous system stimulants inducing convulsions. 
Although at first sight these compounds would appear to 
contradict the Overton-Meyer theory it must be borne in 
mind that central nervous system excitation is a property 
of many general anaesthetic agents themselves at low 
dosage levels and that one of the problems confronting 
the anaesthetist is to ensure that the patient quickly 
passes through Stage II of anaesthesia (the excitement 
stage) into Stage III. Again slight structural 
modifications to the side chains of certain barbiturates 
may lead to convulsant and not depressant properties (3)# 
The explanation for the excitement stage in general 
anaesthesia lies in the fact that depression of the 
central nervous system occurs progressively from the 
higher centres d o ™  (5-) and that inhibitory mechanisms 
are paralysed before the mechanisms which they inhibit.
Thus central excitation may in fact result from a selective 
depressant action on the cerebral hemispheres facilitating
250.
functional release of the normally inhibited subcortico- 
diencephalic layer with resultant increase in motor 
activity (5).
The Overton-Meyer theory is probably best regarded^not 
as a theory offering any basic explanation of the 
mechanism of anaesthesia, but rather as an expression of 
the experimentally observed fact that general anaesthetic 
activity is often present in lipid soluble compounds. There 
would seem to be a case for considering lipid solubility 
as related to an ’’affinity’* with a secondary property, 
the ’’intrinsic activity”, determining the degree of 
central nervous system depression evoked by the drug.
Ariens has introduced these concepts to afford a clear 
picture of drug action in other situations including 
action at the neuromuscular junction (6) and at the 
neuro-effector junctions of the parasympathetic system (7)#
An extension of the Overton-Meyer theory was advanced 
in 1939 by Ferguson (8) who treated the problem from a 
thermodynamic standpoint. Ferguson pointed out that if 
narcotic action was primarily dependent upon a suitable 
equilibrium between the concentration of the drug in an 
external phase (e.g. aqueous body fluids) and the affected 
phase (e.g. the brain lipids) then equi-potency should
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result when different narcotic agents were present in
the affected phase in such concentrations that their
thermodynamic activities were the same. Moreover there
is no need to know the exact nature of the affected
phase nor to create artificial models of it, since
provided there is equilibrium between the external and
affected phases the partial molal free energies in each
phase for any given narcotic agent will be identical.
(fe F E x t  -  F bio
and as
and
then
Fext ^  Fo + R T  In o.£:ct
F 8,0 . KT("«8,o
CL fact - ""8/0
where ffxt = partial molal free energy in the
external phase
F6/0 = partial molal free energy in the 
biophase
fo - partial molal free energy in the 
standard state which is taken as 
the pure substance
R = gas constant
T  = temperature in degrees Kelvin
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^Ext = thermodynamic activity in external 
phase
^310= thermodynamic activity in biophase
The value of can be measured from a knowledge
of the partial and saturated vapour pressures where the 
anaesthetic is applied as a vapour (^Sxi = ^ ^  and
from a knowledge of the actual molal concentration and 
the saturated concentration at the same temperature 
where the anaesthetic is applied in solution 
if activity coefficients are ignored.
The basic assumption in Ferguson's treatment, namely 
that true equilibrium pertains in general anaesthesia 
would seem valid in view of the fact that maximum 
physiological effect is rapidly attained and remains at 
the same level of intensity so long as the organism is in 
contact with a constant effective concentration of the 
drug. On removal at any time to drug-free surroundings, 
recovery is rapid. Moreover Ferguson's experimental 
results are in good agreement with his basic premise as 
not only did equipotency of action occur at virtually 
identical thermod^mamic activities for homologous series 
such as n-alkanes, primary alcohols, and certain esters, 
ethers, ketones and amides before cut off was reached due
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to insolubility, but a number of chemically unrelated 
general anaesthetics were equipotent when their 
thermodynamic activities fell within the narrow range 
of 0.01 - 0.07. These compounds included nitrous oxide, 
acetylene, dimethyl ether, diethyl ether, methyl chloride, 
ethyl chloride, ethylene oxide, methylal, dimethylacetal, 
diethyl formal, dichloroethylene, carbon disulphide and 
chloroform.
The diverse chemical nature of these general anaesthetic 
agents has led to several workers (9) classifying 
pharmacologically active compounds into 2 groups, the 
structurally non-specific and the structurally specific. 
With structurally specific drugs minor changes in the 
stereochemistry or electron density are accompanied by 
profound changes in activity - as is often observed with 
individual optical antipodes. For example the 1 form of 
morphine is the active analgesic, the d form being 
entirely devoid of analgesic properties (10). With 
structurally non-specific drugs, such changes in electron 
density and stereochemistry are without appreciable effect 
as evidenced by the general anaesthetics previously 
mentioned. Although structural specificity is properly 
regarded as relating to molecular structure,it so happens
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that structurally non-specific drugs tend to be less 
selective in their actions than structurally specific 
drugs, and they also tend to exert an effect on a wide 
variety of biological phenomena. Complete specificity 
of action is never encountered in drug action, however, 
as is emphasized by the theory of biological relativity 
(11 ).
A number of other theories relating anaesthetic 
activity to physical properties have been advanced.
One such theory seeks to relate hypnotic activity to the 
Van der Waal's volume constant as when the compounds 
studied were listed in order of increasing molecular 
volume, i t was found that hypnotic activity also increased 
in the same order (12,13). Helium and neon apparently 
have too small a molecular volume, as unlike the other 
rare gases, they are inactive as anaesthetic agents.
Other theories of narcosis have postulated that 
anaesthesia results from lowering of surface tension 
(14) or decrease in cell permeability (15) but these 
theories are not considered seriously today. On the one 
hand it has been sho™ (16) that the surface tension 
between a cell -membrane and the water surrounding it is 
already zero so that no further lowering is possible
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and on the other hand decrease in cell permeability is 
not universally observed with narcotics (17).
Several attempts have been made to more closely 
define the sequence of events once the anaesthetic agent , 
has gained access to the biophase and foremost amongst 
these is the theory that production of anaesthesia is 
dependent upon blockade of oxidative carbohydrate 
m.etabolism. Indeed Quastel and his collaborators (5) 
have demonstrated that there is a parallelism between 
the hypnotic potency of certain barbiturates and their 
ability to depress the oxygen consumption of minced 
guinea pig brain, but the question remains as to whether 
such inhibition of respiration in brain tissue is the 
cause or the result of anaesthesia. Not all oxidative 
processes are affected - the main inhibitions occurring 
with glucose lactate and pyruvate - and not all drugs 
which inhibit oxygen uptake are anaesthetics (17)# More 
detailed studies have been concerned with the effect of 
narcotics upon cytochrome oxidase (18), flavoprotein (19) 
the synthesis and release of acetylcholine in the brain 
(20,21) and upon the s^mthesis of ATP (22,23) but the 
overall results obtained have not given rise to any 
clarification of the position.
2 5 6 .
The demonstration that a number of predominantly 
lipid-soluble steroids possessed general anaesthetic 
properties (24) posed the question as to whether certain 
molecules (other than the barbiturate and oxazolidine 
2 ;4 dione type) possessing molecular weights lying between 
those of the simple gaseous anaesthetics and the steroids 
would exhibit structurally non-specific narcotic activity 
if they could be introduced into the central nervous 
system in sufficient concentration. In view of the 
successful clinical introduction of hydroxydlone (21- 
hydroxy pregnane- 3? 20-dione) in which the hemisuccinate 
moiety confers a high initial aqueous solubility on the 
compound before the molecule is rapidly hydrolysed by the 
non specific esterases of the serum permitting the parent 
lipid soluble steroid to cross the blood-brain barrier 
and build up an anaesthetically-active concentration (25) 
it was decided to prepare a number of hemi-succinates of 
representative m.ono-, sesqui- and di-terpene alcohols.
Such terpene alcohols would be expected to be structurally 
non-specific agents and moreover it is well established 
that a number of terpenoids exhibit central nervous system 
stimulation in low doses and depression at higher doses. 
Other terpenoids such as camphor and thujone exhibit 
predominantly stimulant properties. This could be due
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either to a low intrinsic activity or to their being 
present in too low a concentration for depression to be 
evoked. It is to be noted that in the steroid field, 
whilst the majority of steroids act as central nervous 
system depressants - a few such as cortisone produce 
stimulation.
Encouragement was given to the current project involving 
the terpenoid hemisuccinates by the fact that the 
hemisuccinate of Tf hydroxycamphor has been reported to be 
a hypnotic (26).
The terpenoid hemi-succinates were*all prepared by 
refluxing the requisite alcohol with succinic anhydride 
in a basic solvent (pyridine or quinoline). The formulae 
of the compounds studied are shown in Fig.1 together with 
those of several long chain alcohol hemisuccinates which 
were included in the investigation for the purposes of 
comparision.
The compounds prepared were kindly tested by Dr. K. Ahmad 
and found to be inactive as general anaesthetics on 
intraperitoneal injection into rats at dose levels of 
5-10 mg./IOOg of body weight (27).
Hence it would appear that there is not a continuous 
spectrum of structurally non-specific anaesthetic activity
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running from the simple gaseous anaesthetics on the one 
hand to the steroids on the other, and our results would 
support evidence adduced by other workers pursuing entirely 
different lines of investigation.
Thus an extensive investigation of the pharmacological 
properties of the hemisuccinate of glycyrrhetinic acid 
prompted no mention of anaesthetic properties (28) and the 
work of Figdor and his acollaborators (25) has shorn that 
anaesthetic potency in the steroid field is influenced 
both by the nature of the water-solubilising group (esters 
of amino acids shov/ing considerable differences from 
hemisuccinates) and by the nuclear substitution. It is 
possible that the amino esters are not hydrolysed by the 
non-specific serum esterases as are hemisuccinates and 
this could explain the high acute toxicity of these 
compounds. The marked influence of nuclear substitution 
on activity (25) however would perhaps indicate a 
structurally specific mechanism. On the other.hand,the 
influence of stereochemical changes appears to be slight.
Moreover studies on the inhibition of oxidation in 
brain tissue by the anaesthetic steroids would indicate 
that these compounds do not act in the same way as do 
other anaesthetics (29).
Experimental
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(") Menthvl hemisuccinate (10)
(-) Menthol (15.0 g.) in dry freshly distilled 
pyridine (150 ml.) was refluxed with succinic anhydride 
(10.0 g.) with exclusion of moisture. After 6 hrs. the 
pyridine was distilled off, the menthyl hemisuccinate 
taken up in ether and the ethereal solution washed once 
with water and once with dilwte hydrochloric acid. The 
product was then extracted with cold aqueous sodium 
bicarbonate and the solution carefully acidified with 
dilute hydrochloric acid and extracted with ether. The 
ethereal solution was dried and after removal of the 
solvent the product was sublimed and recrystallised from 
ether (10.2 g., with m.p. 64° [hit., (31) 62°;
(32) 6^1
(+) Bornyl and cltronell.yl hemisuccinates
(+) Borneol (15.4 g.) and (+) Citronellol (12.6 g.) 
were converted into their corresponding hemisuccinates 
by refluxing for 6 hr s. with 10.0 g . and 8.0 g. succinic 
anhydride respectively, in redistilled quinoline (150 ml.), 
followed by standing overnight. Isolation in the usual 
manner gave :-
(+) Bornyl hemisuccinate (33) m.p. 60-67° (11.6 g., 45.6^) 
[Lit., (33) 61-2“] and
Citronellyl hemisncclria.te m.p. 60-70“ (5*99 g. , 2-9. )fO
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Fenchyl hemisuccinate
As preparation of fenchyl alcohol by direct catalytic 
hydrogenation of fenchone in acetic acid with a platinum 
catalyst in the presence of perchloric acid proved 
unsatisfactory5 the follomng procedure was adopted.
Fenchone (15.0 g*) was refluxed with lithium aluminium 
hydride (11.0 g.) in 4oo ml. of anhydrous ether for 6 hr s. 
Excess lithium aluminium hydride was destroyed by careful 
drop wise addition of water and the fenchyl alcohol 
reclaimed from the ether. This was converted to the 
hemisuccinate by refluxing with succinic anhydride (10.5 g.) 
in quinoline (1 50 ml.) and the product (10.3 g. , 
recrystallised from benzene with m.p. 115-120^.
Arachidvl-. eru.cyl-, and dodecyl- hemisuccinates
These three straight chain esters were prepared by 
refluxing the alcohol (1 mole) with succinic anhydride 
(1 mole) in freshly distilled quinoline and isolating the 
products as previously described.
Arachidyl hemisuccinate (52.5 5) had m.p. 88-96° ; 
erucyl hemisuccinate (38 5) had m.p. 45-54 and dodecyl 
hemisuccinate (39 f ) had m.p. 66-74° .
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Farnesyl hemisuccinate
Refluxing fame sol (4.4 g.) with sue c ini c anhydride 
(1.9 g*) in freshly distilled quinoline (1^0 ml.) yielded 
a dark oil (3.1 g. , 44 %) which could not be induced to 
crystallise. The sodium salt was semi solid.
Two diterpenoid alcohols prepared by reduction of the 
carbonyl functions of podocarpic acid and dehydro abietic 
acid were converted into their hemisuccinates. The acids 
as their methyl esters were reduced by refluxing with 
lithium aluminium hydride (2-3 g.) for 6 hrs. in anhydrous 
ether. Excess lithium aluminium hydride was destroyed by 
dropwise addition of water and the products were extracted 
with ether.
The alcohols, podocarpyl (2,8 g.) and dehydroabietyl 
(3.4 g.) were then converted to the hemi succinates vrlth 
succinic anhydride (1.1 g. and 1.19 g* respectively) in 
150 ml. quinoline and crystallised.
Podocarnyl hemi succinate (1.9 g., 4^.? ^) with m.p. 205-1?^ . 
Dehydroabietyl hemisuccinate (3-0 g. , &S ^
The infra red spectra of the hemi succinates innujoL 
showed broad absorption bands between the region 
3400-3180 cm* and sharp peaks at 1734 cm"' , and 1250 cm 
characteristic of both the ester and carboxylic acid 
functions.
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All the hemisuccinates s^mthesized in the above 
manner were converted to their sodium salts by treating 
them with equimolecular proportions of sodium bicarbonate 
in aqueous solution and shaking vigorously for 30 mins. 
The aqueous solutions were treated with ether to remove 
impurities, separated from the ethereal layer and 
evaporated to complete dryness. The sodium salts were 
obtained as white powders, freely soluble in water.
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nr. utilization of the Bornane Skeleton as a Rigid 
Molecular Framework for the Investigation of 
Acetylcholine-13ke action.
Acetylcholine as a neurohormone
Perhaps the greatest single fundamental advance in 
the science of Pharmacology was the establishment of the 
fact that conduction and translation of nerve impulses 
involves the intercession of "chemical transmitters" or 
neurohormones, as thj.s discovery enabled the action of a 
large number of drugs to be rationally interpreted in terras 
of their interference with the normal physiological 
functioning of these neurohormones. The existence of 
chemical mediators in nervous conduction was first 
suggested by Elliot (1) who postulated the existence of 
sympathin to explain transmission at the sympathetic 
neuroeffector junction. The same concept was subsequently 
applied to parasympathetic innervation by a number of 
workers. At first muscarine was thought to be the 
parasympathetic transmitter, although Hunt and Taveau 
(2) and Dixon (3) had early appreciated the similarities 
between the effects of acetylcholine and those of 
parasympathetic stimulation. Following the thorough 
examination of the pharmacological properties of
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acetylcholine by Dale (4) and Loewi (5) acetylcholine 
correctly became considered the parasympathetic transmitter, 
and in 1936, Dale, Feldberg and Vogt (6) were able to 
demonstrate the existence of acetylcholine in the 
perfusion fluid from the mammalian neuromuscular 
junction following stimulation of the motor nerve.
In addition to sympathin (which is actually a mixture 
of noradrenaline and adrenaline) ,.and acetylcholine whose 
role as neurohormones In the peripheral nervous system is 
now well established, three other compounds, histamine, 
5-hydroxytryptamine and'^r-aminobutyric acid have been 
postulated to act as chemical transmitters (7) but so far 
unequivocal proof that these compounds are indeed 
neurohormones has not been forthcoming.
VJhereas sympathin appears to be involved in only three 
situations in the body viz,, in the central nervous system, 
at the neuroeffector junctions of a number of nerves 
belonging physiologically to the sympathetic division of the 
autonomic nervous system and as a secretion by the cells 
of the adrenal medulls released into the blood stream, 
acetylcholine is knovjn to be involved in seven separate 
situations. These are
1 . In the brain where its exact role is still not fully 
ascertained.
P 6R
2. At the spT).ap5GS of the ganglia of the syonpathetic 
nervous system.
3. At the synapses nf the ganglia of the parasympathetic 
nery/eus system.
4. In the cells of the adrenal medulla which are in 
actual fact modified ganglionic cells.
5. At the ncuroeffcctor junctions of all post-ganglionic 
nerve fibres belonging to the para.sympathetic nervous 
system.
6. At the nGuroeffGdtep junctions of certain
post-ganglionic nerve fibres belonging anatomically to the 
sympathetic nervous system, notably those innervating 
the sweat glands and certain vasculo.r beds of the skin.
7. At the neuroeffector junctions of the voluntary^ 
nervous system, i.e. at the neuromuscular junctions*
In order to illustrate the precise role of acetylcholine 
in nervous transmission, one can consider the emission of 
a nerve impulse from the central nevYOv.s system along a 
fibre belonging to the parasympathetic system. With the 
arrival of the nerve action potential at the terminals 
of the preganglionl c axon, acetylcholine is liberated from 
an intr a-axonal storage site, and acts initially^ at the
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same presynaptic terminals to bring about the liberation 
of more acetylcholine. The secondarily released, increased 
amount of acetylcholine then acts at the post synaptic 
site to initiate transmission in the post ganglionic fibre,
i.e. the acetylcholine crosses the narrow s^/naptic cleft 
and combines with receptor groups on the ganglion cell 
membrane, causing a localized non-propagated depolarization, 
knovm as the post-synaptic potential. This in turn initiates 
electrogenically a nerve action potential, which is 
propagated along the peec ganglionic fibre. The polarized 
state of the post synaptic membrane is restored with the 
rapid destruction of the synaptic transmitter by the enzyme, 
acetylcholinesterase (8). then the post ganglionic impulse 
arrives at the neuroeffectmr junction acetylcholine is 
again liberated, crosses the gap between nerve terminal 
and the effector cell, affects the resting potential of 
the latter and brings about the characteristic response 
of the effector cell.
A similar situation pertains at the neuromuscular 
junction of voluntary nerve which has been studied in 
great detail. Thus^ histological studies of the 
neuromuscular synapse have revealed an intensive branching 
of the motor nerve prior to its termination (9), and a
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lack of direct cytoplasmic continuity between nerve endings 
and the muscle fibre (10). The presence of vesicles in 
the terminal portions of the motor neurons has also been 
established (11), and it is presumed that these store the 
bound acetylcholine.
The process of liberation of acetylcholine is however 
neither fully understood nor easily investigated (12) but 
it is known to be influenced by the concentration of 
certain cations in the environment (13). Moreover a 
spontaneous and intermittent release of discrete quanta of 
acetylcholine occurs at rest (lb) continually eliciting 
minute changes in the potential of the post junctional 
membrane and it is only the symchronous release of a 
large number of quanta of acetylcholine which is sufficient 
to excite the muscle.
This excitatory depolarizing effect produces alterations 
in the permeability of the membrane to inorganic ions (15) 
and produces the so called "spike" action potential 
propagating in both directions along the membrane of the 
muscle fibre inducing contraction.
An excellent summary of present day knowledge of events 
at the neuromuscular junction has been given by Muir (16).
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Drugs Interferjnr wi th the Function of Acetylcholine.
Drugs capable of interfering with the action of 
acetylcholine may act in one of several ways : - 
1 , By blocking the symthesis of acetylcholine e.g. 
the hemicholiniums (17)-
2. By preventing the liberation of acetylcholine from 
its bound storage form,e.g. botulinum toxin (18).
3* By interference with the formation of the complex 
between acetylcholine and its receptor e.g. tubocurarine 
and décaméthonium. These two drugs represent two different 
modes of action, one, tubocurarine being termed a 
"competitor" and the other a "depolariser". These different 
mechani.sms of action have been rationalised in terms of 
intrinsic activity values (19), i.e. the depolarisers 
mimic the action of acetylcholine and the competitors 
antagonise it.
4. By blocking the response to acetylcholine through 
occupation of receptors other than those utilized by 
acetylcholine itself e.g. the "non-competitive" 
neuromuscular blocking agents, prodeconium (20).
5. By preventing the destruction of acetylcholine by 
acetylcholinesterase thus allowing the acetylcholine to 
accumulate and exert its effect in an exaggerated manner,
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e.g. neostigmine, eserine.and various organic phosphate 
esters.
At first sight it would perhaps appear that drugs 
capable of interfering with the normal function of 
acetylcholine might do so at all the seven sites in the 
body where acetylcholine is implicated but in practice a 
certain degree of selectivity is observed. Complete 
selectivity for site of action does not occur, however, 
as is emphasized in the theory of biological relativity 
(21 ) and it is found that druga which act by interference 
with acetylcholine at the neuromuscular junction often 
interfere with acetylcholine at the autonomic ganglia.
The fact that drugs blocking the action of acetylcholine 
at the synapses of the sympathetic ganglia also usually 
block the action of acetylcholine at the synapses of the 
parasymipathetic ganglia is one of the drawbacks to attempts 
to treat hypertension clinically by blockade of the 
sympathetic ganglia.
Nevertheless by and large it is possible to distinguish 
separate classes of drugs which act by interfering with 
the action of acetylcholine at different sites.
Thus the pharmacologist classifies drugs knovm to 
interfere with the action of acetylcholine a.s follows : -
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1 • r'uscarini c
This group embraces those drugs such as the alkaloid 
L(+)-muscarine (I) (22) which mimic or intensify the action
of acetylcholine on smooth muscle and the exocrine glands 
i.e. at the parasympathetic neuroeffector junctions and 
certain s%nnpathetic neuroeffector junctions.
Many attempts have been made to interpret the 
requirements for muscarinj.c activity in terms of 
structural modification, of the acetylcholine molecule and 
these are summarized by Barlow (23); who considers the 
acetylcholine molecule as divisible into h parts, the 
cationic head, the alkamine chain, the acyl group and 
the ester group (II). The cationic head is essential for
'CHj
■CH3
II.
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muscarinic activity but it need not be an ammonium ion 
as activity is also present in sulphonium, phosphonium 
and arsonium compounds, although the potency is greatly 
dimini shed (2V ).
It has long been kno-vn that replacement of the N-methyl 
groups of the acetylcholine molecule by ethyl or higher 
radicals causes decrease in its stimulant properties (25) 
and Ing (26) has stressed the importance of the size of 
the cationic head. He has pointed out that if the molecule 
is pictured as being adsorbed at a surface (Fig. 1 ) then 
only half the head is actually involved in the process, 
the other half wi 11 be free. Replacement of one methyl 
group attached to the nitrogen atom will lower the 
adsorbability^ and hence the potency^ because the probability 
of the head being in the right position for adsorption 
(with both methyl groups presented to the surface) m i l  
not be unity. Replacement of another methyl group, will be 
disasterous, as there m i l  no longer be even half a "head” 
which fits the receptor surface.
The alkamine chain of 2 carbon atoms in acetylcholine 
is of optimal length for muscarinic activity and 
lengthening or shortening it leads to reduced potency.
The introduction of methyl groups has pronounced effects.
/•
N
CH,
/\; ; <^«3/
' ^ CHg CH3 - -- - - — ---
B
Fig.1.
A. At hemihedral cavity. B. At a planar surface
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Thus acetyl o<- methylcholine (III) has (23) only 1/20 th
— n (c H3)3
CH3
III
of the muscarinic activity of acetylcholine and acetyl p 
methylcholine (IV) has half the muscarinic activity of
CH3C0 0  *-CH -.CHg— N ^ H3j,
IV
acetylcholine.
The acetyl group appears to be the optimal acyl group 
for muscarinic activity as replacement by other acyl 
radicals leads to a pronounced loss of potency (27). It is 
to be noted, houever, that choline, tropine and 1-methyl-3- 
piperidylmethanol, in which the acyl group is completely 
absent show some muscarinic activity. Very low muscarinic 
activity is present in phenylacetylcholine and 
phenylpropionylcholine (28).
The ester link of acetylcholine can be replaced by 
certain other groups with retention of muscarinic properties 
Thus the n-butyltrimethylammonium ion and the
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n-amyltrimethylammonium ion show acetylcholine-like action 
on certain heart preparations (29) and the ethoxyethyl- 
trimethylammonium ion has potent muscarinic properties.
The compound F2268 (V) (30) has 10-50 times the muscarinic
V
activity of acetylcholine itself.
It would also appear that the presence of an ether 
oxygen or thioether sulphur atom favours muscarinic 
activity (31).
In an attempt to briefly summarize the molecular 
requirements for muscarinic activity several workers (32) 
have proposed the 5-stom rule which states that for 
muscarinic activity there should be 5 atoms in a chain 
bearing a cationic head. This rule has been applied to 
explain why compound (VI) shows strong muscarinic properties
CH3-
5 •0^2 2^
 ^ 3
VI VII
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whereas cnmpeund (VII) does not.
Other workers have attempted to express the molecular 
requirements for muscarinic activity in terms of a 
detailed representation of the muscarinic receptor. Recently 
Waser (33) has reviewed these attempts to picture the 
receptor in terms of the structure of muscarine and its 
derivatives (Fig.2) (22). The potency of muscarine is 
considerably higher than acetylcholine which may be due to 
the absence of the ester linkage rendering the compound 
immune to hydrolysis by cholinesterase. The receptor is 
considered to enter a 3-point attachment with the 
muscarine molecule, which involves the OIÏ group, the ether 
oxygen and the cationic head. It has been shown (3^) that 
stereo isomers of muscarine are several hundred times less 
active than the natural alkaloid and it appears that steric 
hindrance of the approach of the ether oxygen or the OH 
group, to the receptor leads to a pronounced reduction in 
activity. The larger the stericali.y interfering group, 
the less potent is the compound.
The (-) ) isomers of acetyl- oC- and acetyl-p-methyl­
choline are about 10 and 250 times more potent as 
muscarinics respectively than their corresponding 
enantiomorphs (22). If the quaternary nitrogen group and
HHO*'
Fig.2.
1. Anionic cavity negatively charged to accommodàte 
quaternary nitrogen.
2. Positively charged point accommodating ether linkage 
of muscarine.
3. Positively charged area to accommodate OH of 
muscarine *
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the ether oxygen of muscarine, lying almost in a plane, 
form the two main centres for drug receptor association 
(the hydroxy group acting as a secondary association site), 
then association with the receptor must involve the lower 
surface of the molecule. Inversion of the methyl group 
would then produce a steric barrier against such 
association. Replacement nf this methyl group by a hydrogen 
atom considerably reduces activity probably because of a 
reduction in the electron density on the ether oxygen atom 
rather than by reduction in,the availability of van der 
Waal's forces for hording (35)*
Certain muscarone derivatives (3^) are more potent than 
muscarine and its derivatives and exhibit strong stimulating 
and blocking effects at both ganglionic synapses and the 
neuromuscular junctions. In atropinized animals, higher 
doses block the sympathetic ganglia and the end plates in 
a curare-like fashion. Here stereospecificity appears to be 
less important as the different isomers possess more or less 
comparable activity in contrast to muscarine and its 
derivatives. Thus conversion of the hydroxyl group in 
muscarine to the carbonyl group in musearone exerts 
pronounced changes in the properties of the molecule. From 
the steric p^int of view, the oxygen of the carbonyl group
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lies in the ring plane so is less influenced by 
substituents on either side of the ring. Moreover, the 
carbonyl group has a marked polar character which enables 
it, like the electrophilic carbon atom in an ester group 
to form a bond with a basic group in the receptor. Such 
bond formation which is not possible in muscarine (35) has 
been proposed by Wilson (36) to account for the binding of 
acetylcholine to acetylcholinesterase.
The proposals just summarised emphasize the steric and 
electronic requirements for muscarinic activity but there 
are many anomalies and the diverse chemical structures of 
the three best established muscarinic agents muscarine (I) 
itself, arecoline (VIII) and pilocarpine (IX), serves to
/C^CO0CH3
■CH-»— n----N
CH3
VIII IX
underline the shortcomings of approaches to structure-action 
relationships such as those outlined above.
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2. Atropinic
This group embraces those drugs which antagonise the 
action of acetylcholine at the parasympathetic neuroeffector 
junctions and at certain s^npathetic neuroeffector junctions 
i.e. it consists of the drugs which antagonise the 
muscarinic effects of acetylcholine. Characteristic of the 
group is the possession of bulky molecules such as are 
represented in the series atropine, homatropine, eucatropine 
and the dialkylaminoalkanol esters of tropic, mandelic, 
atrolactic, diphenylacetic, benzilic and cycloalkylmandelic 
acids. These dialkylaminoalkanol esters can be regarded 
as derivatives of the acetylcholine molecule in which the 
acetyl group has been replaced by acyl groups possessing 
at least one ring system. A large number of heterocyclic 
ring derivatives have also been studied and a summary of 
the thiophen compounds of this class has been given by 
Martin-Smith and Reid (37).
The atropinic group includes a large number of quaternary 
ammonium derivatives (38), Including higher alkyl trimethyl 
ammonium salts (39).
A detailed picture of the requirements for atropinic 
activity in terms of the muscarinic receptor has been given 
by Lands and hi s colleagues;(4Ô).
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3 • Niontirie
The alkaloid nicotine has the ability to first 
stimulate and then depress ga.nglia and skeletal muscle so 
the selection of this agent as pharmacological prototype 
has been rather unfortunate insofar as a more precise 
division of drugs into ganglion stimulants, ganglion blockers, 
neuromuscular stimulants and neuromuscular blocking agents 
would represent a more fundamental classification. In 
practice such a division tends to be used today, and 
nicotine can be regarded as a drug showing a considerable 
lack of specificity.
Nicotinic action has been discussed in terms of the 
molecular structure of acetylcholine by Barlow (23) in an 
analogous fashion to his treatment for muscarinic activity. 
Thus replacement of the acetyl group of acetylcholine by the 
propionyl, benzoyl, phenylacetyl, phenylpropionyl or 
trimethyl acetyl radicals exaggerates the nicotinic 
properties of the neurohormone (27) at the expense of the 
muscarinic properties. Carbamylcholine shows both 
muscarinic and nicotinic properties.
Changes in the ester linkage of acetylcholine may also 
lead to increased nicotinic activity relative to the 
muscarinic properties as in acetyl p - methyl-thiocholine,
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and In the biitoxyeth];-! tr ime thylammonium ion. Dicholine 
esters of dicarboxylic acids also show nicotinic activity 
especially at the neuromuscular junction. Nicotinic 
properties are also present in a number of aromatic ethers 
of choline. These compounds have been studied in detail by 
Hey (41).
A further series of nicotinic compounds are afforded 
by certain aliphatic ketones bearing a quaternary 
trimethylammonluni substituent where the nitrogen atom and 
the carbonyl group are in 1 relationship (42). It is of 
some interest that acetyl oL - methylcholine although 
possessing only 1/20 th of the muscarinic activity of 
acetylcholine exhibits roughly the same nicotinic potency, 
whilst acetyl p - methylcholine is devoid of nicotinic 
properties, yet shows pronounced muscarinic activity.
It has been suggested that the ideal requirements for 
nicotinic properties are a cationic nitrogen atom bearing 
three methyl substituents and an atom bearing a partial 
positive charge 3 atoms removed from the nitrogen atom.
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Gan g 1 j on 31 n c ir j n f: ents*
These compounds antagonise the action of acetylcholine 
in the autonomic ganglia and are usually characterised 
by the possession of a single quaternary nitrogen atom, 
or tertiary sulphur atom as in trimetaphan. However, certain 
bis quaternary compounds induce ganglionic blockade j, (e. g, 
bexamethonium) as do certain hindered secondary or tertiary 
amines such as mecamylamine (X) and pempidine (XI). It is
NHCHaHCt
V XI
also of interest that the acetylcholine analogue in which 
ethyl radicals replace two of the N-methyl groups, is a 
ganglion blocking agent.
2G4.
Neuromuscular Blocking
These are the compounds which induce paralysis of 
skeletal muscle through interference with the function of 
acetylcholine at the neuromuscular junction. They are 
customarily divided into two classes, the depolarisers 
and the competitors (43) of which the depolarisers can be 
regarded as strictly nicotinic as they first stimulate 
and then block, neuromuscular conduction. Examples of 
depolarisers are décaméthonium and succinylcholine, whilst 
^-tubocurarine is an example of a competitive neuromuscular 
blocking agent. Unfortunately the classification of 
neuromuscular blocking agents as depolarisers and 
competitors is unsatisfactory due to variation in the 
response of different species (44) and of different muscles 
within the same species (45) to a particular neuromuscular 
blocking agent. Moreover certain compounds induce a 
two-phase block (46). Neuromuscular blocking properties 
are associated with onium functions as was first 
recognized by CrumBrown and Fraser in 1869 (47) and tend 
to be very pronounced in molecules possessing 2 or more 
onium functions, leading to the concept of pharmacologically 
’’bivalent molecules" (23) and by inference "polyvalent 
molecules". There are exceptions to the need for an onium
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centre however e.g. the tertiary base p- erythroidine.
A detailed picture of the acetylcholine receptor at 
the muscle end plate has been given by Waser (48) and recent!/ 
Ehrcnpreis (49) has isolated a protein thought to be the 
acetylcholine receptor from the electric tissue of the 
electric eel.
The fact that drugs interfering with the neurohormonal 
function of acetylcholine can be divided into the broad 
groups just outlined has by inference been mainly 
attributed to the varying abilities of the drugs concerned 
to cross permeability barriers in the body and so reach 
the various sites at which acetylcholine is involved. Thus 
the absence of a membrane barrier surrounding the 
neuromuscular junction (50) has been involved to explain 
the ready access of the ionic neuromuscular blocking 
agents to their site of action, where—as these compounds 
do not pass the blood-brain barrier for example to exert 
central effects.
There is however, another possible reason why drugs 
capable of mimicking or opposing the action of acetylcholine 
should fall into these catagories. It is conceivable that 
the receptors for acetylcholine at its different sites of: 
action may be considerably different in their nature.
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Acetylcholine is a conformationally non-rigid molecule 
and so theoretically capable of existing in an infinite 
number of conformations. It is possible therefore, that 
the different receptors are such as to permit interaction 
only with different conformational isomers of the 
neurohormone whilst it may not be energetically favourable 
for the different groups of drugs just discussed to 
achieve suitable geometry for interaction with all receptors.
It, therefore, seemed a worthwhile project to prepare 
a series of rigid acetylcholj.ne-like molecules which 
would be incapable of conformational isomerism for 
pharmacological testing on different tissue preparations 
in order to ascertain whether there were marked differences 
in the activity of these isomers at the different 
acetylcholine receptors, and hence throw more light on the 
intimate nature of these various receptors. Even if little 
or no difference in activity on preparations such as 
perfused ganglia, the frog rectus abdominis, the chicken 
gastrocnemius, the rat diaphragm, the guinea pig ileum etc. 
■were to be detectable the investigation would still be of 
value in-so-far as it would be the first indication that 
conformational isomerism played no part in the interaction 
of acetylcholine with its receptors.
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I t  is of considerable interest that Feliman and Fujita 
(51) have very recently put forward evidence to show that 
in solution acetylcholine exists in the cyclic conformation 
( X I I ) .  Their conclusions were based on infrared measure­
ments and on the high rate constant for the acylation
CH3
X I I
of hydroxyl ami ne by acetylcholine as compared to the rate 
constants observed with 3-dimethylaminopropyl acetate 
methiodide and 4-dimethylaminobutyl acetate methiodide 
indicating a high electron deficiency on the carbon atom 
of the carbonyl group in acetylcholine such as would 
result from the quasi 6-membered ring conformation ( X I I ) .  
Similar quasi ring conformations would not be expected 
to be energetically favourable for 3-dimethylaminopropyl 
acetate methiodide and 4-dimethylaminobutyl acetate 
methiodide by analogy with the fact that 7 and 8 membered 
cyclic transition states are well knov/n to be unfavoured.
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The infrared spectrum of acetylcholine measured in 
absolute ethanol showed strong ester carbonyl absorption 
at 1760 cm"”^ with a less intense absorption at lower 
frequency whilst 3-bimethylaminopropyl acetate methiodide 
and 4-dimethylaminobutyl acetate methiodide showed split
^-1
peaks of approximately equal intensity at 1752 cm" and 
1732 cm"^ and 1748 cm"^ and 1728 cm"^ respectively. In all 
3 cases the lower frequency peak con be interpreted as 
resulting from intermolecular hydrogen bonding between the 
ester molecules and ethane1 molecules as hydrogen bond 
formation is well Inovn to l.ower the frequency of ester 
carbonyl absorption (52). Thus the quasi 6-membered ring 
(XII) greatly decreases the ahili ty of acetylcholine to 
hydrogen bond to ethanol giving further indication of its 
stability. At the same time the high value of the non 
hydrogen bonded absorption in acetylcholine at 176O cm  ^
probably indicates a greater degree of rigidity in the 
C - 0 bond in acetylcholine than is present in the higher 
homologues.
Fellman and Fujita quote as further evidence the fact
that cis 2-dimethylamiinocyclohexyl acetate methiodide
absorbs at 17.53 cm" whilst trans 2-dimcthylaminocyclohexyl
—1
acetate methiodide absorbs at 1740 cm" in ethanol. Since 
quasi 6-membered ring formation from the cis (axial.
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equatorial) and the trans in the equatorial equatorial chair 
conformations should be equally facile, the exact 
significance of these values is by no means clear.
It is to be borne in mind however that there is no 
justification for supposing that the thermodynamically 
most stable conformation of acetylcholine in solution is 
necessarily that actually adopted at the receptors.
The bornane skeleton appeared to offer the ideal rigid 
molecular framework or supporting moiety (53) on which to 
base certain of the desired inflexible acetylcholine-like 
molecules as the bj.cycle heptane [2,2,lJ system permits of 
no flexibility whatsoever. In particular the ready 
availability of D (+) camphor whose absolute configuration 
■was shown to be (XIII) by Freudenberg et al (5^) afforded 
a compound giving easy access to the desired derivatives, 
since it is readily converted to D-3-ondoamino camphor (XIV).
XIII
NH
XIV
D-3-Fndoamino camphor w-^ uld then afford, after the 
appropriate synthetic steps, both 3-Gndodimethylamino-2'
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endo-acetoxybornane methiodide (XV) and 3-endodimethylaminO'
2-exo-acetoxybornane methiodide (XVI), in which the
V XVI
trimethylarnmonium and acetoxyl functions are in the fully 
eclipsed (XVII) and eclipsed (Will ) conformations
XVII Will
respectively, thus giving two extreme conformations to the 
incorporated acetylcholine unit.
Compounds (W) and (WI) are completely rigid molecules 
unlike the cis and trans cyclohexane and cyclopentane 
acetylcholine-like molecules prepared by Friess and his 
colleagues (56). The cyclohexane compounds can suffer 
ready conformational isomerism as in Fig.3? and the
cyclopentane derivatives although not
A c O
y1
OAfi.
CIS
A tO -
N(CH3)3
nCCH3)3
A
OAc-
V
A
A cO __
V
t r a n s
Fig-3.
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subject to such extreme conformational isomerism as the 
6-mem.bered ring compounds, can nevertheless be expected 
to exist in multiplanar conformations as veil as in the 
planar conformation (57)* These cyclic derivatives of 
Friess and his colleagues have been tested for their ability 
to function as substrates of acetylcholinesterase (56), 
and for activity on the kitten phrenic nerve diaphra.gm 
preparation (58), but they do not appear to have been 
tested on ganglia, or on smooth muscle.
In both the cyclohexane and cyclopentane series the 
cis derivative vas found to be more readily hydrolysed by 
acetylcholinesterase and to be more active on the kitten 
phrenic nerve diaphragm preparation. Similarly the cis 
alcohols (XIX) and (XX) vere found to produce greater
OH
XIX
f t
OH N ^ 3):
XX
inhibition of acetylcholinesterase than their trans isomers
On the other hand certain vorkers have emphasized the 
need for a degree of flexibility in acetylcholine like 
molecules. Thus Schueler (59) emphasized the flexibility
2Q2.
of tvo cyclic analogues of acetylcholine (XXI and XXII).
CH3 CH3
XXII
Gill (60) has postulated that completely rigid molecules 
should prove inactive due to variability in the receptors. 
This generalization which rests on the absence of 
ganglion-bleding activity in an extremely limited number 
of compounds such as the completely rigid N,N,N,N- 
tetramethyl-p-phenylenediamine dimethiodide (61), and 
certain virtually rigid furan derivatives still retaining 
a limited degree of rotational flexibility (62) certainly 
requires further substantiation before it can be 
unqualifiedly accepted especially as other receptors 
appear to accept rigid molecules as evidenced by the 
activity of the natural oestrogcns and androgens.
Compounds (XV) and (X/I) therefore achieve a further 
significance in-so-far as they have direct bearing on
Gi11  ^s hypothesis.
It is also of some interest that introduction of an 
acetylonic bond into certain acetylcholine-like molecules
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gives a marked Increase in potency (63) and this effect 
has been discussed in terms of the increased rigidity in 
such molecule s.
Construction of models shows that for both compounds 
(}f/) and (XVI) when the acetyl and quaternary nitrogen 
functions are laid on a planar surface the bulk of the 
molecule in no way interferes. Hence it can probably be 
assumed that utilization ^f the bornane skeleton as a 
supporting moietiT will not introduce steric hindrance to 
the approach of the molecule to the acetylcholine receptors.
Measurements made on Dreiding and Bartonian models
show that the CH3C— o______ ^ fcH I3 distance in compound
(XV) is 2.56 and in compound (X/I) is 3-6 A^.
These distances can be comnared with the N
interatomic distances in the cyclic compounds of Friess 
and his colleagues where data for the cis - trans alcohols 
in both cyclohexane and cyclopentane series were interpreted
to indicate an enzymatically preferred N  o separation
with a maximum distance of a.bout 2.5 A^ between anionic 
and esteratic sites on the surface. But with the substrates 
i.e. the cis - trans acetates the N — >0 separation 
distance was considered not necessarily to mirror the 
distance between sharply defined adsorption regions on the
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enzyme, because the possibility exists that the esteratic 
site binds the — Oco— entity as a single locus of overall 
high electron density rather then concentrating its binding 
capacity on a single atom of the group. In the former 
event the average distance between catalytic adsorption 
regions f^n the enzyme most probably would be reflected 
in the d:i stance between the quaternary nitrogen and that 
geometrical portion of the — •OCO~' function characterised 
as the centre of highest electron density.
It is of interest that the bornane skeleton has been used 
as a rigid supporting moiety in a number of other biologically 
active molecules. For instance two isomeric 2-hydroxy-3- 
methylaminobornanes whose configurations were not 
established; exert a pronounced action on the respiratory 
centre of rabbits (6^ f) and a 2,3-dihydroxybornane and its 
monocarbamate cxlnibit central nervous system depressant 
properties (65)-
II - ( 2Ahydroxy-f-methyl -2'-phenyle thy 1 ), N -me thylc amphor
sulphonamide (XXIII) was found to be a potent analeptic
C H 2S O 2 — N — C H — C H  — P k  
.0
XXIII
29^.
(66) ; and esters of camphor-tranS" Tf-carboxylic acid of 
type (XJvIV) were fonnd to be antitussives thus supporting
XXIV
the contention of Ka.se and. Yuizono (67) that the 
piperidino group possesses the ability to function as an 
active antitussive moiety. Derivatives similar to those of 
type (XXIV) in which the piperidine ring was replaced by a 
morpholine ring or a piperazine ring were prepared as 
potential anti-hypertensive agents (68). Such anti­
hypertensive activity is present in trimethyl-d-bornyl- 
ammonium iodide (XXV) (69) and one of the intermediates
^ ^ N ( c H 3 ) a
X]CV
utilized in the present project, 3-endoaminocamphor in the 
form of its hydrochloride, exhibits feeble neuromuscular
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blocking action and transiently lowers blood pressure (70).
Pronounced local anaesthetic properties have been shown 
to be present in 2-benzoyloxy-?-diethylaminobornane (XXI/I) 
(71) and a number of 3-dialkylaminoacyl camphors like
.OCOPk
XXVI
diethylaminoethylhornyl ether exhibit smooth muscle and 
central depressant properties (72).
Various 3-ami.no-2-hydroxybornanes were prepared as 
potential antimalarial agents (73) and the benzoic ester 
of cis aminoborneol inhibits smooth muscle (7^)#
The 2,3-secobornane skeleton has also seen utilization 
as a supporting moiety in such compounds as (XXVII) which
OOCH2-CH2-N4fe
XXVII
is active as a neuromuscular blocking agent and in the 
mercurial diuretics mercaptomerin and mercurophylline.
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In addition to compounds (X^ /) and (XVI ) it was 
originally planned to include compounds of type (}CXVIII) 
and (}C(IX) i.e. isomeric 2-acetomy-5“trimethylammoniuin
OCOCH H
OCOCHs
XXVIII XXIX
bornanes in the present studies. Although these compounds 
are not strictly acetylcholjne-ljke in structure as 
^ carbon atoms separate the substituent groupings, they 
might be expected to throw more light on intergroup
distances. For instance the N   -OcoCHj distance
in (XyCVIII) is 3*^ -^  as measured on Dr ei ding models, 
which lies between the distances of 2.56 in (XV) and 
3.6 in (Xi'I).
The fully opposed conformation for acetylcholine itself 
gives a separation of 3.8 A*^ . In ’ : (XXIX) the separation
is 4.8 .
However the low yields obtained of the key intermediates 
required for this project, either D (+) -2-endoacetoxy-5- 
oxobornane or dl-2-benzoyloxy-5-oxobornane, on chromic 
oxide oxidation of the corresponding bornyl esters by the
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procedures in the literature proved an insurmountable 
obstacle to the completion of this project.
In the search for a more satisfactory method of 
preparation of a bornane derivative possessing oxygen 
functions in both the 2- and 5~ positions a preliminary 
investigation was made of the action of molecular oxygen 
on D (+) camphor in the presence of ascorbic acid, the 
sodium salt of ethylenediamine tetraacetic acid, ferrous 
sulphate and a phosphate buffer.
The rationale for this approach lies in the observation 
of Brodie and his co-workers (75) that molecular oxygen' 
in the presence of ascorbic acid, sodium ethylenediamine 
tetraacetate and ferrous sulphate in a phosphate buffer is 
able to mimic a number of biological oxidations involved 
in the bio transformat ion of aromatic compounds in the body 
to phenolic compounds. As 5-hydroxycamphor is known to be 
one of the end-products of the metabolism of camphor by the 
animal body (76), it was considered worthwhile investigating 
whether camphor would afford an acceptable yield of this 
oxidation product when exposed to the same reaction 
conditions. In the event oxidation of the camphor did occur 
as was evidenced by the uptake of oxygen but no pure 
5-hydroxy camphor could be isolated from the reaction 
mixture.
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Approach to the STOthesis of the Rigid Molecules.
The key starting material for the preparation of 
compounds (XV) and (XVI) was D 3-endoamino-camphor (XIV) 
which was prepared by the method of Duden and Pritzkow^
(77) from D isonitrosocamphor which is readily obtainable 
from D (-)') camphor (XIII) by the action of isoamyl nitrite
(78).
The configurational assignment of the compound as the 
3-endoamino derivative follows from the work of Van Tamelen 
et al (55) and is in accord with the knoun greater 
stability of the endo configuration in the bornane series, 
where groups in the exo configuration suffer non bonded 
interaction with the methyl groups on the 1 ,4 methylene 
bridge.
The conversions of 3 “-en do amX no camphor into both
3-endoamino-2-endohydroxybornane (X]CXI) and 3-endoamino-
2-exohydroxybornane (XIXTI) (Chart 1.) have been reported 
in the literature (79) and the N - p - nitrobenzoyl 
derivative of (XXXI) was sho-vjn to undergo smooth 
acyl migration under the influence of dry hydrogen chloride 
in dioxan. In the present work, however, attempts to 
achieve similar n -^o  acyl migration on _D 3-endoacetamido-
2-endohydroxybornane (:X5[XIV) prepared by sodium and wet
XIII XXX
O h
XXXI
XIV
XXXI
Chart. 1.
3 0 0 .
ether reduction of D 3-endoacetamidocamphor (XXXIII)
(Chart 2.) were unsuccessful and so it was decided to 
achieve N - dimethylation before reduction of the carbonyl 
function. The choice of sodium and wet ether to effect 
transformation of (XXXIII) into (XXXIV) was based on 
analogy with the formation of 3-endoamino-2-endohydroxy- 
bornane by sodium and wet ether reduction of
3-endoaminocamphor (79) whereas sodium and alcohol 
reduction of 3-endoaminocamphor gives the 3-exohydroxy 
compound (79)* That compound (XXXIV) was indeed
3-endoacetamido-2-endohydroxy bornane was shown by the 
infrared spectrum of the compound in carbon tetrachloride 
solution at dilutions (0.0005 M and 0.0015 M) sufficient 
to ensure the absence of inter-molecular hydrogen bonding.
A
The broad peak with maximum at 3518 cm" showing 
intra-molecular hydrogen bonding proved the endo 
configuration of the hydroxyl group. Similar utilization 
of infrared spectra to assign configurations in the 
bornane-2,3-biol series has been reported by Angyal and 
Young (80).
The route followed to the desired compounds was 
therefore, that shovm in chart 3*
D-3-Endoaminocamphor was dimethylated by a slight 
modification of the procedure described by Duden and
N H ;
XIV
N H C C X H ,
XXXIII
NHCOCHs
O H
JIfy HCi
XXXIV
Chart. 2.
X IV
Rtdu-ttîow-
OH
XXX V I
i
0C0CH3
XXXVIII
XV
X XXV
XXXVII
X X X IX
'COCH
XVI
Chart, 3*
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Pritzkow (81) to afford (XXXV) whose infrared spectrum
—1
showed strong peaks at 2800 and 2770 cm" characteristic 
of the dimethylamino group (Fig,4).
Reduction of (X20CV) by means of lithium aluminium 
hy/dride in dry ether afforded an oily mixture of the cis 
and trans isomers (7JŒVI) and (XXXVII) clearly showing 
the presence of both free and intramolecularly hydrogen 
bonded hydroxyl groups when the infrared spectrum of the 
crude product was examined in carbon tetrachloride solution, 
at dilutions sufficient to ensure the absence of 
intermolecular hydrogen bonding. The presence of the 
cis isomer (XXXVI) was also indicated by the formation of 
a purple colouration (chelate formation) with copper 
sulphate solution. Chromatography of the mixture over 
alumina yielded the pure trans isomer (XXXVII) in ^0 % 
yield, but the cis isomer could not be eluted from the 
column, presumably on account of chelate formation.
The cis isomer (XXXVI) was obtained in 55 a yield 
from the mother liquors after preferential crystallisation 
of the trans isomer from the mixture in light petroleum 
and in pure form by the following procedure. The crude 
reduction product was acetylated by the action of ketene 
and the mixture of acetyl derivatives chromatographed
1 5  I 1 51 5 . 2
Fig.H.
Infrared spectrum of D-3“Endo-dimethvlamlnocamphor 
taken as a film showing absorption bands characteristic 
of the dimethylamino group.
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over alumina (Woelm grade I neutral). The cis acetate
eluted vfith light petroleum and the trans acetate suffered
hydrolysis to the parent am.inoalcohol which eluted with
ether. Hydrolysis of the pure cis acetate (XHXVIII) then
afforded the pure cis alcohol OGDTVI), which showed
intra-molecular hydrogen bonding in dilute carbon
tetrachloride solution (infrared, broad absorption with
—1
maximum at 3^ -^ 0 cm" ) and gave a purple colouration with
copper sulphate solution. The pure trans isomer (X/QCVII)
showed no hydrogen bonding when its infrared spectrum in
dilute carbon tetrachloride solution was examined (OH
—1
stretching peak at 3620 cm" ).
It is of interest to compare this ratio of exohydroxy 
(^0 /:>) to endohydroxy (55 50 resulting from the lithium 
aluminium hydride reduction of 3-endodimethylaminocamphor 
with other results reported in the camphor field, where 
reduction of both camphor and epicam.phor with lithium 
aluminium hydride is knov/n to give predominantly exo 
alcohol (82) as is catalytic hydrogenation. Similarly 
reduction of camphorquinone with lithium aluminium 
hydride has been found to yield predominantly the cis
di exo glycol (XL) (83)
OHHO
XL
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The higher ratio of the endo hydroxy compound observed 
in this work is presumably attributable to the bulk of the 
endo dimethylamino group which would be expected to hinder 
the rearward anionic attack of the keto group by the 
complex aluminiumhydride ion from the endo side. Such 
steric hindrance at the endo side is absent in camphor 
itself where the steric hindrance to rearward attack on 
the exo side due to the gem-dimethyl groups on C - 7 ,can 
be presumed to give rise to the preponderance of exo 
product, although this isomer is the thermodynamically 
least stable; i,e. kinetic control - not product control 
operates (840.
Reduction of 3-Gndodimethylaminocamphor (}[XXV) by 
sodium and alcohol as previously described by Duden and 
Pritzkow (85) gave after alumina chromatography a 70 % 
yield of the trans isomer. The early workers reported a 
m.p, of ca 80  ^ for their product and since the pure trans 
isomer was found in the present work to melt at 120^, it 
must be concluded that their material was contaminated 
with cis isomer.
Reduction of 3-endodimethylaminocamphor (XXXV) by means 
of sodium and wet ether gave a mixture of isomers and 
after alumina chromatography a 30 % yield of the trans
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alcohol was obtained. The reaction mixture was not worked 
up for its content of cis isomer, but in view of the fact 
already established that the cis isomer does not elute 
from an alumina column, it can be assumed from the above 
results that reduction of 3-Gndodimethylaminocamphor 
(JJQCI) with sodium and wot ether gives predominantly the 
endo hydroxy compound whilst reduction with sodium and 
alcohol gives predominantly the exo hydroxy compound.
These results are in good accord with the results obtained 
by the 2 methods of reduction on 3-endo amino camphor (79).
It is of some interest to compare these results with 
those already reported for camphor and epicamphor. Thus 
reduction of camphor with sodium and alcohol gives 
predominantly the endo alcohol (i.e. borneol) (86) as 
does reduction of epicamphor under the same conditions (87) 
It is to be noted that togyal and Young (80) obtained the
2-endo, 3-endo, the 2-exo, 3-Gndo and the 2-endo, 3-exo 
bornanediols by catalytic hydrogenation procedures.
hhilst there can be no doubt as to the structure of
3-en do dime thylamino-2-endohydr oxybornane (XXXVI) since it 
displays the expected intramolecular hydrogen bonding, 
there exists a small chance that the compound described 
as 3-endodimethylamino-2-exoh,ydroxybornane (XXXVII) is
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in fact the rearranged camphane derivative (XLII) formed 
by a classical Wagner-Meerwein shift as sho-v/n in chart 4, 
where the 1,6 bond being trans and antiparal].el to the 
exobond originating from the 2 position, migrates with 
extreme ease to form the tertiary carbonium ion (XLI). 
However as such Wagner-Weerwein shifts are to be expected 
under acid conditions it does not seem likely that sodium 
and alcohol, sodium and wet ether or lithium aluminium 
hydride which are all basic reducing agents would effect 
such a resri*angement •
Less certainty exists however with respect to the effect 
of the alumina columns used to purify this non 
intramolecularly hydrogen bonded dim.ethylaminohydroxy 
derivative and which produce hydrolysis of its acetate, 
and it is in this that any doubt concerning structure 
(}CHn/II) arises, although the complete identity of the 
material eluting from alumina columns with that obtained 
by repeated direct crystallisations from light petroleum 
of the mixture of products from the lithium aluminium 
hydride reduction would tend to indicate that no 
rearrangement had in fact taken place on the columns.
As the usual procedures for acétylation proved 
uusatisfactorv when apnli ed to compounds (XXXVI) and
5OH
XLI
XXXVII
OH
XLlI
Chart. 4".
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(yO'DCVII ) both D-2-endo-acetoxy-3-endodlmethylaminobornane 
(XXyvVIIT) and D-2-exo-acetoxy 3-endodiinethylamlnobornane 
(X)DC[X) were prepared by the action of ketene. in anhydrous 
ether on D-3-endodimethylamino-2-endohydroxybornane 
(H'lXVI ) and D-3-endo dime thylamino-2-exohydr oxybornane 
(]COn/II) respectively. Conversion of these compounds to 
the quaternary methiodides (XV) and (X V I)  was achieved 
by means of methyl iodide.
In the case of the trans compound ()CVI ) it was found 
that huTdrolysis of the acetyl function was exceptionally 
facile and the reaction was best performed in dry benzene. 
Both products were extremely h%/groscopic.
As a sideline to the main problem the reduction of 
D camphor imine (88) (XIV . ) (Chart ?.) by means of 
lithium and ethanol in liquid ammonia was investigated 
since Ourisson and Rassat (89) had shown that reduction 
of camphor under these conditions gave 20 % of isoborneol 
(exo) whereas caesium in liquid ammonia gave % of
isoborneol and it seemed worthwhile to establish whether 
similar selectivity existed \r±th respect to the imine. 
However the mixture of isomeric bornylamines formed 
could not be separated by chromatography. That reduction 
had taken place was shown by the complete absence of
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c = N absorption in the infrared spectrum at c^ 
1 700 cm” "'.
Experimental.
108.
D ( + )-oC- Tsoni trosncamnhor (XXX) was prepared by 
slightly modifying the method of Claisen and Menasse (^0),
D (+) camphor (40.0 g.) was dissolved in 200 ml. dry 
ether in a 2 ].itre flask. Freshly prepared sodium, wire 
(6.1 g.) was added followed immediately by the slow and 
careful dropwise addition of a small quantity of 
i soamylnitrite.
harming on the steam bath with concurrent scratching 
of the sodium by means of a glass rod ensured commencement 
of the reaction, as was evidenced by the solution turning 
yellow and the production of slight foaming.
Once reaction had set in, the reaction flask was placed 
in an ice bath. Further quantities of isoamylnitrite were 
added carefully with swdrling at intervals (at such a 
rate that the reaction did not become too vigorous) until 
a total of 31*0 g. had been added.
The total time taken for the addition of the 
isoamylnitrite i^ras 35-4o min.
The reaction mixture in which some sodium isonitroso- 
camphor had separated was allowed to stand for 1 hr. and 
then carefully treated with ice water whereby the sodium 
salt dissolved with the production of a red colour. The
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solution V7S.S extracted twice with ether to remove traces 
of camphor and borneol and air was then blown through the 
aqueous solution to remove residual ether. On treatment of the 
aqueous solution with acetic acid (25 ml. ) the crude 
product separated and was taken into ether. Removal of the 
organic solvent yielded an oily semi-crystalline mass of 
cd-isonitrosocamphor (29.0 g. , 57 /O , which was used in 
the next step without any further purification.
P G d   ^+ 170.0° [ c  = 0.81+ in chlorofori^[Lit., (91 ) 172.9^ 
in chlofoformj.
D  (-)- 3 - Rndo-amino camnhor. (X I V )
This compound can be prepared from oc-isonitrosocamphor 
by reduction with either zinc and sodium hydroxide or zinc 
and acetic acid as reported by Duden and Pritzkow (77). 
Comparison of the two procedures showed that a higher yield 
resulted from the zinc and sodium hydroxide method (7? % 
as against 55 u from the zinc and acetic acid reduction ).
ct- Isonitrosocamphor (16.0 g.) was dissolved in 33 ^ 
sodium hydroxide solution (64 ml.) and water (64- ml.). To 
the solution powdered zinc (19*2 g.) was added in small 
quantities at intervals with warming on the steam bath 
so that the temperature of the reaction mixture remained 
in the range 5C-60^C. As the reaction proceeded a thick
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yellow oil separated, then the reaction vias complete (1 hr.) 
the mixture was diluted with water (4-00 ml.) and extracted 
with ether. Removal of the organic solvent afforded a 
yellow waxy mass (12.0 g. 75 m) with indistinct m.p. The 
compound was therefore isolated as the carbonate salt 
which was obtained by passing carbon dioxide gas through 
a wet ethereal solution of the crude product. tJhite crystals, 
feathery plates (11.0 g., 91.3 <) of m.p. 117-118?
The amine hydrochloride from acetone as needles had 
m.p. 22C-22f [lit., (17) 223-2.2f] .
(Fotind ; C, 59.28; H, 8.95. Calcd. for C^gH^gMOCl ;
C, 58.95; II, 8.90 f).
The free base had hi D~-18.9^ (0=1.32 in chloroform)
Harper in Redd(9z)states that this compound hasgjD +60° but it
not clear from where he quotes this value.
The constitution of the amine as the 3-Gndoamino 
derivative of camphor follows from the work of Van Tamelen,
T ou signant and Peckhs.m (55).
D (-^ )-3-En.do-dimethy.^1 amlnocamphor (XXXV) . This compound 
was prepared by a modification of the method of Duden 
and Pritzkow (81). 3-Endoamino-camphor carbonate (4-.0 g.) was 
suspended in 30 ml. ether in a 100 ml. flask and to the 
flask was added a sni'ijtion of sodium hydroxide (2.6 g.) in 
30 ml. of water. ! ethyl iodide (5*8 g. , 4- moles) was added
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and after firmly stoppering the flask, the mixture was 
shaken overnight on a mechanical shaker. Separation of 
the ethereal layer and removal of solvent afforded the 
crude product of D (+)-3-Gndo-dimethylamino camphor as a 
yellow coloured oil. (3.I g., 77*5 5^ ). Chromatography 
over alumina (Woelm, grade I, neutral) in petroleum ether 
(b.p. 4-0-60 )^ removed the colour and treatment with 
hydrogen chloride in ether afforded the hydrochloride. 
Colourless needles from acetone had m.p. 220-224-° jbit. ,
(81 ) 220-222°] .
(Found ; C, 61.35; H, 9.71- Calcd. for C^2^22^^^^^ *
C, 62.18; H; 9.57 5').
[c<] D = + 3^. 8° (C = 1 .0 in chloroform) [hit., (46 ) + 50°
in ethanolJ .
The infrared spectrum of the free base taken as a film
showed strong absorption bands characteristic of the
^ c %  group (93) at 2800 cm"^ and 2770 cm"^ in addition
—1
to the peak at 1734- cm" characteristic of the five 
membered ring carbonyl group (Fig. 4- ).
D (-) - .3 - Endomethylaminocamphor.
To a suspension of D-3-ondo-amino camphor carbonate 
(4-.0 g. ) in ether (25 ml.) in a 100 ml. quickfit flask 
was added a solution of sodium hydroxide (2.04- g.) in
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water (20 ml.) and methyl iodide (2.8 g., 2 moles). The
flask was firmly stoppered and shaken for 16 hr. on a
mechanical shaker. Separation of the ethereal layer and 
removal of the solvent afforded the crude product
(2.8 g. , 70 %) which was converted to the hydrochloride
by treatment with hydrogen chloride in ether. Several 
recrystallisations from acetone gave colourless needles 
with m.p. 225-228° Lit., (94) melts and decomposes at 
228°] .
(Found : C, 60.22; H, 9-45. Calcd. for C^  ^ H^gNOCl :
C, 60.67; H, 9.25 ^^ ).
The infrared spectrum of the free base taken as a
film showed 2 split peaks at 1580 and 1 54-0 cm"^ and a
—1broad band below 3300 cm" indicative of the secondary 
amino function as well as a band at 173^ cm"^ characteristic 
of the carbonyl group in a five membered ring.
The free base h a d H D  = -26.8° (C = 1.1 in chloroform).
D ( + ) - 9 - Endodimethylamino - 2 - endo - hydroxvbornane(>!6<^ •)
This compound was formed in admixture with D (+) - 3 “ 
endo dime thylamino - 2 - ex6 - hydroxy bornane by the 
action of lithium aluminium hydride on D (+) - 3 - 
endo dime thylaminoc am.phor and was first obtained in the 
pure form after a multi-stage process. This involved 
acétylation of the crude reaction product and passage
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of the resulting mixture of acetylated derivatives in
I
ether over neutral alumina which effected preferential 
hydrolysis of D (-)-3-endo-dimethylamino-2-exo-acetoxy- 
bornane and gave a clean separation of the cis D (-)-3- 
endo-dimethyl-2-endo-acetoxybornane from the trans D (+)- 
3-ondodimethylamino-2-exo-hydroxybornane. Finally hydrolysis 
under vigorous conditions of the D (-)-3-endodlmethylamino-
2-endo-acetoxybornane gave the cis hydroxy compound.
D (+)-3-Cndo-dimethylaminocamphor (1.8 g.) was dissolved 
in 50 ml. of anhydrous ether and lithium aluminium hydride 
(1*3 g*) added in small portions to avoid too vigorous a 
reaction. After all the lithium aluminium hydride had been 
added the mixture was refluxed overnight with exclusion 
of moisture by means of a calcium chloride tube. On cooling 
the excess lithium aluminium hydride was decomposed by 
careful addition of several drops of water and the mixture 
of products obtained from the ethereal solution as a waxy 
solid with indefinite m.p. The mixture gave a purple 
colouration with copper sulphate indicative of chelation 
by the cis isomer. The infrared spectrum of the mixture 
in carbon tetrachloride solution at a dilution sufficient 
to ensure the absence of inter molecular hydrogen bonding 
(0.000508 M and 0.00253 M) showed 0— H stretching
— 1 — i
absorption at 3620 cm" and between 34?0 - 3330 cm"
indicating that both the intra molecularly hydrogen bonded 
cis isomer and the non-bonded trans isomer were present.
Chromatography of the mixture (1.8 g.) in ether over 
alumina (Woelm neutral grade I) resulted in the elution 
of only 720 mg. (4o /O of the material and this proved to 
be identical with trans D (+)-3-ondo-dimethylamino-3- 
exo-hydroxybornane prepared as described below. Presumably 
the cis isomer had chelated to the alumina and could not 
be eluted.
In a separate experiment the crude reaction product 
from the lithium aluminium hydride reduction was 
acetylated by treatment with ketene (95).
The mixture of the two isomers (2.0 g.) was dissolved 
in anhydrous ether (50 ml.) and a continuous stream of 
ketene prepared as described later, passed through the 
solution for 2 - 3 hrs.
At the end of the reaction, on evaporation of the 
solvent a crude dark brovm oil was obtained. On 
chromatography over alumina (Woelm, grade I neutral) the 
cis compound eluted in petroleum ether (b.p. 40-60°),
(1.2 g. , 50%3, and the trans suffered hydrolysis to the 
corresponding alcohol which eluted with ether, (0.5 g *,
25 5)* The identity of this latter compound was confirmed
915.j
by its infrarod spectrum and m.p.'s of the free base 
and its hydrochloride which showed no depression in 
admixture with authentic material.
The cis compound (1.2 g.) was hydrolysed by treating 
with sodium hydroxide solution (2.9 g. , in 20 ml.) with 
stirring and re fluxing for 2 hr s. The hydroxy compound 
was obtained as an oily semi crystalline mass.
The infrared spectrum in carbon tetrachloride solution 
at dilutions sufficient to ensure the absence of inter 
molecular hydrogen bonding (3-9 mg. in 50 ml. and 2.74- mg. 
in 5 ml.) showed the position of the 0 — H stretching as a 
broad band between 34-60 - 3510 cm" with a maximum 
absorption at 3440 cm"^.
[o c ]d  = + 27. 7^ (C = 0.8 in chloroform)
It was characterised as the hydrochloride prepared by 
treatment with dry hydrogen chloride in, ether. Recrystalli­
sation from ethanol gave feathery needles with m.p. 253-55  ^
(Found : C, 61.62: H, 10.12; ^12^^24^^^^ requires
C, 61 .64; Î-I, 10.34 ^).
It was later discovered that the cis hydroxy compound 
could be separated from the mixture of the two isomers 
obtained bir lithium aluminiumi hydride reduction (2.0 g.) 
by treatment with hot petroleum ether (b.p. 40-60^) from
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which the trans isomer crystallises out leaving the cis 
isomer in solution. Identification of the isomers follows 
from their infrared spectra and the m.p. of the trans 
isomer.
Cis - (1.1 g., 55 5) Trans - (0.8 g. , 40 %).
D ( + )- I-Endo-dimethy 1 am 1 no-2-exo-hvdroxvbornane (XXXVII)
(a) D (+)-3-Sndodimethylaminocamphor (1.0 g.) dissolved 
in ethanol (50 ml.) was treated under reflux with sodium 
metal (3.0 g.) added at intervals in small aliquots.
Re fluxing was continued for 4 hr . when the reaction 
mixture was taken to dryness under reduced pressure. The 
reaction product was extracted from the sticky residue by 
addition of water (70 ml.) followed by extraction with 
ether. Removal of the solvent from the ethereal solution 
gave an oily mass slowly turning to a solid with indefinite 
m.p. (0.7 g.? 70 On chromatography over alumina
(Woelm, neutral, grade I )  in ether eluted 92.8 % of the 
material applied to the column. Recrystallisation from 
petroleum ether (b.p. 40-60°) gave colourless needles with 
m.p. 120° [Lit., (85) Ca 80° presumably contained some cis 
isomer] .
(Found : C, 72.82; H, 11.2; Calcd. for :
C, 73.04; H, 11.74 5).
[cC] D = + 36° (C = 0.84 in chloroform)
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It was converted to the hydrochloride and characterised 
as such. Colourless needles from acetone/ethanol had
m.p. 277-280°.
(Found : G, 61 .90; H , 1 0. 56; C2""24^'^01 requires 
C, 61,64; II, 10.34 /).
(b) D (-r) “3-Sndo-dime thylaminoc amphor (1.0 g.) was 
dissreived in ether saturated with water (50 ml.) contained 
in a throe necked flask equipped with a dropping funnel 
and an ej'ficiont reflux condenser. î'etallic sodium (3*0 g.) 
in small aliquots was carefuJJi/ added at intervals whilst 
the mixture was kept under reflux. From time to time a 
few drops of water were added from the dropping funnel to 
ensure steody dissolution of sodium. Refluxing was 
continued for 4 hr. After cooling the ethereal solution 
was washed with water, dried and the solvent removed. 
Chromatography of the product in ether over alumina 
(hoelm, grade I, neutral) gave 300 mg. (30 /) of the 
trans - hy/droxy compound.
This was recrystallised from petroleum ether (b.p. 40- 
60^) as needles with m.p. 120^.
There wns no mixed m.p. depression wi th the material 
obtained by alumina chrcmatography of the mixture of 
products obtained by lithium aluminium hydride reduction
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of D (+)-3-endo dimethylamino camphor described above 
and the infrared spectra were identical.
The trans configuration i.e. the 3-endo dimethylamino-2- 
exo-hydroxy configuration, was assigned to this compound 
as it gave no colouration on treatment with copper sulphate 
solution indicative of chelate formation, and as the 
infrared spectrum in carbon tetrachloride solution at 
dilutions sufficient to ensure the absence of inter- 
molecular hydrogen bonding (5.3 mg. in 5 ml. and 2.55 mg. 
in 50 ml.) showed the position of the 0— H stretching 
absorption to be at 3620 cm"^ proving that there was no 
intramolecular hydrogen bonding.
D  (-.)-2-Exo-acetoxy-3-endo-dimethylaminobornane <XXXIX)
Conventional methods of acétylation of 3-endo- 
dimethylamino-2-exo-hydroxybornane proved unsatisfactory, 
so this compound was prepared by the action of ketene on 
the parent alcohol.
3-Endo-dimethylamino-2-exo-hydroxybornane (1.0 g.) was 
dissolved in anhydrous ether (50 ml.) and a continuous 
stream of freshly generated ketene passed through the 
solution for 2 hr. At the end of this time removal of the 
solvent afforded the crude acetyl derivative as a dark oil. 
Dissolution in petroleum ether (b.p. 40-60^) followed by
919.
filtration afforded the product as a colourless oil.
The infrared spectrum of the free base in thin film
*1 *1
showed sharp absorption peaks at 1734 cm" and 1206 cm" 
characteristic of the acetate residue. There was no 
absorption in the 3600 - 3300 cm" region.
= -24^ (C = 0.9 in chloroform)
The acetoxy compound was characterised as its 
hydrochloride, needles from acetone had m.p. 265-270*^
(Found : G, 60.42; II, 9*11 C^i^R^gO^FCl requires 
C, 60.96; II, 9.5 5").
D ( - ) - 2 -Fn do - a c e t o X V - 9 - e n do - d i m e t h^ r 1 am i n o bn r n an e (XXXVIII )
This compound was obtained by direct acétylation of 
the mixture of 2-hydro>y^-3"cndo-dimethylaminobornanes 
resulting from lithium aluminium hydride reduction of
3-endo-dimethylamino camphor by means of ketene, followed 
by chromatography over basic alumina as previously described.
The free base in thin film showed absorption in the
—1 —  1infrared spectrum at 1734 cm and 1260 cm but no peak
between 3600 and 3300 cm" indicating complete acétylation.
|c] D = -68^ (C = 1 .26 in chloroform)
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The acetoxy compound was characterised as its 
hydrochloride 5 needles from benzene had m.p. 24-5-24-7^
(Found : C, 61.42: H, 8;8 4^26^2^^^^ requires
C, 60.96; H, 9.5 /).
D (4-)-2-Fxo-acetoxY-9-endo-dimethylaminobornane methiodide (XVI
'D (-)-2-Exo-acetoxy-3-cndo-dimethylaminobornane 
(350 mg. ) was dissolved in dry benzene (30 ml.) and treated 
wMth excess methyl iodide (8.0 g.) and left overnight, 
when crystals of the methiodide had scpara^ted as colourless 
cubes, of m_.p. 250-252  ^ (I60 mg. , 31 *3 w)
(Found : C, 4y.06; ÎI, 8.O8. c-H^gO^NI requires
c, 47.24; n, 7.40 5).
= + 62.5° (C = 0.9 in ethanol).
D ( -) -2-Endo-acetoxy-f-eodo-di methyl am i n o b o m a n  e methiodide 
(XV)
D ( -)-2-Endo-acetoxy-3-endo-dimethy1aminobornane 
(500 mg. ) dissolved in anhydrous ether (30 ml.) was 
treated with a ].arge excess of methyl iodide (10.0 g.) 
and allowed to stand overnight when crystals of the
3 2 1 .
methiodide separated. These were collected by filtration. 
Colourless needles, extreme 1]^  hygroscopic of m.p. 219-221^, 
without further purification (250 mg., 38 /)
(Found : C, 46.93; H, 6.9?» 5^^28^2^^ requires
C, 47.24; H, 7.40 /).
Mj)= -25.4  ^ (C = 0.92 in chloroform)
922.
D (+)-9"Endo-acetamidocamnhor QGCCTTT).
D (-)-3-Endo-aminocamphor (1.3 g O  Ir acetic acid 
(5 ml.) was re fluxed with acetic anhydride (5 ml.) for 
1 hr. At the end of this time the mixture was concentrated 
to less than one half the original volume and poured 
into cold Vrater. The crystalline material which separated 
was filtered, dried and recrystaJJ.ised from petroleum 
other (b.p. 60-80^) as colourless feathery plates 
(1.0 g., 63 3) m.p. 122° [Lit., (97) 121-122°].
(Found : G , 69-15; H, 9-12 Calcd. for 2 -^^  ^ 2^^ ' *
C, 68.66; II, 9-15
The infrared spectrum in nujol showed peaks below 
3200 cm"^ and at 1 734 cm"^ , 1 64o cm"^ and 1 570 cm"^ . The 
last two being characteristic of a monosubstituted amide. 
[o<Jd - + 50.5^ (C = 0.88 in chloroform)
D ( - ) - 2 -End o -hy d r o xy - 9 - on dn -a c e t am i. d o bornane (XXXIV).
This compound was formed in low 3^ 1 eld by sodium metal 
reduction of 3-endo-acetamido camphor.
D ( + )-3-Endo-acetamido camphor (0.5 g -) was placed in 
a 2-necked 250 ml. flask fitted with a reflux condenser 
and a dropping funnel and dissolved in wet ether (100 ml.), 
freshl^r prepared sodium in re (1.5 g- ) was then added to 
it and re fluxed on a steam bath for 2 hr s. with dropwise
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addition of water till all the sodium went into solution.
The ethereal extract was evaporated to dr^mess and the 
impure compound vras chromatographed over alumina (Woelm, 
neutral grade I) in ether / methanol ( 50 : 1 ), to 
elute the desired product. Extensive variation of 
conditions (sodium in wet ether, sodium in ethanol, sodium 
shot in xylene / ethanol) failed to raise the i/ield of 
pure material above 20 /.
In all cases the crude product from the reaction 
required chromatographic purification. Colourless feathery 
plates from petroleum ether (b.p. 60-80^) or ethanol had 
m.p. 208-210
(Found : C, 68.31, K, 10.75* 2^21^2^^ requires
C, 68.20; H, 10-01 5).
M  D = -56° (C = 0.82 in chloroform).
Assignment of the endo configuration to the hydroxyl group 
follows from a study of the infrared spectrum in carbon 
tetrachloride at a dilution (0.0005 M and 0.0015 M) 
sufficient to ensure the absence of inter-molecular hydrogen 
bonding. The broad peak between 354-0-3480 cm"^ with 
maximum at 3518 cm"^ showed the presence of intramolecular 
h^rdrogen bonding thus proving the compound to be the cis 
isomer (i.e. 2-hydroxyl group endo).
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All attempts at N — > 0 ac%/l migration by treatment 
wi th hydrogen chloride in dry dioxane ( cf the successful 
N 0 acyl migration of p-nitrobenzamide of p-aminoborneol 
to |3 -aminohernyl p-nitrobenzoate hydrochloride achieved 
by van Tamelen and his collaborators (55 were 
unsuccessful.
Ill
D ( +)-9-Endo-(222-t^i chi oro-1-hydroxvethyl ) am.ino camphor.
In an attempt to prepare D-3-endo-formylaminocamphor 
by the method of Blicke and Chi-Jung Lu (48), D (-)-3- 
endo-aminocamphor (2.0 g.) was dissolved in chloroform 
(1C0 ml.) in a 3-necked, 250 ml. flask equipped with 
stirrer, dropping funnel and condenser to which was 
attached a calcium chloride tube to exclude moisture. To 
the stirred mixture cooled in an ice bath, chloral 
(freshly prepared by distillation of equal weights of 
chloral hydrate and concentrated sulphuric acid)
(1.6 g., 1 mole) was added dropwise. When all the chloral 
had been added stirring was continued for 4 hr. at room 
temperature and the mixture then refluxed for 30 min. 
Removal of the solvent under reduced pressure followed by 
crystallisation from petroleum ether (b.p. 60-80^) gave 
needles m.p. 108-113° •
(Found : C, 45.65; H, 5*88. 2^1 8^2^^^^3 requires
;25-
c ,  45. 78; H ,  5.76 5 0 .
W  D = + 30.8 (C = 0.68 in ethanol).
The compound resisted all attempts to eleminate the 
elements of chloroform and generate the desired N - formyl 
derivative.
126.
D~(+)-Bornyl acetate was prepared by heating D (#) 
borneol (50.0 g.) and acetic anhydride (40.0 g.) for 2 
hrs. at 145'° (72.9 g-, éS ?0, it had b.p. 99-100°* [hit., 
(91) 99-100°}
M d  = +4-3° (0=1.16 in chloroform) L^it., (103) 44.3'
D ( + )"2~enho-acetnyy-^-oxoborr]ane.
To a 3 necked 2 litre flask, fitted v/ith a reflux 
condenser and a mechanical stirrer, was added bornyl 
acetate (^O.O g.) in acetic acid (75 ml.). The flask was 
half immersed in an electrically heated oil bath, the
O O
temperature of which was maintained at 14-0 (±5 )• V/ith 
vigorous stirring powdered chromium trioxide (125.0 g.) 
was added in spoonfuls down the condenser. With each 
addition, a violent frothing occurred and between each 
addition about 10 ml. acetic acid was poured down the 
condenser. This prevented blocking of the condenser and 
used in all about 250 ml. acetic acid. The total time of 
addition of chromium trioxide and acetic acid was 40 mins. 
approximately. After all the chromiujn trioxide had been 
added, heating and stirring was continued for another 
30 mins. Thereafter the solution was cooled, dissolved in 
2 litres of water, neutralized with sodium bicarbonate 
and extracted with ether. Evaporation of the ether yielded
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a residue consisting of a mixture of camphor, unreacted 
starting material and the product. The mixture was 
distilled under vacuum and the fraction boiling at 
97-117  ^a.t 0.7 mm was collected. This fraction crystallised 
on standing and rubbing with petroleum ether (b.p. 60-80*" ). 
Crystallisation from petroleum ether (b.p. 60-80°) gave 
colourless rods (5 g. , 10 )t) with m.p. 76-77^[lit., (^^) 
76-771
|k] D -I- 11 3 (C = 1.12 in chloroform) 
dl Bornvl benzoate was prepared (|00) by dissolving racemic 
borneol (15.0 g.) in dry pyridine and adding benzoyl 
chloride dropwise with careful exclusion of moisture. The 
reaction flask was kept in ice and stirred throughout the 
addition of the benzoyl chloride, the latter being added 
over a period of 30 mins. After the addition was complete 
the mixture was left for 2 hrs. After addition of water 
(250 ml.) the solution was acidified v/ith dilute 
hydrochloric acid and extracted with ether.
The ethereal extract vms washed once with water and 
once with dilute sodium hydroxide solution to remove traces 
of benzoic acid. The product was obtained as an oily liquid,
(9.0 g., 38 5).
1 2 8 .
dl 2-endo-»benzoyloxv-5-oxobornane was prepared in 
analogous manner to that described for the preparation of 
D-2-endo-acetoxy-5-oxobornane. Crystallisation of the oily 
product from petroleum ether (b.p. 60-80*^  ) gave colourless 
needles with m.p. 115^- Despite minor modifications of the 
procedure the yield was always less than 5 r.
dl-2-endo-hydroxy-5-oxobornene.
Treatment of dl-2-endo-benzoyloxy-5-oxo-bornane (1.0 g.) 
with excess potassium hydroxide in ethanol under reflux 
for 2 hr. and removal of solvent gave after extraction of 
the residue with ether, dl-2-endo-hydroxy-5-oxobornane. 
Crystallisation from petroleum ether (b.p. 60-80°) gave 
colourless needles (500 mg., ~lS %) m.p. 23^ -24-4- [lit.,
(U) 238-246°] .
The infrared spectrum in nujol showed peaks at 3200 cm 
for the hydroxyl and 1734- cm" characteristic for five 
membered ring carbonyl.
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D (+) Camphor oxime. (XLIII)
D (+) camphor (30.0 g.), sodium hydroxide pellets 
(45.0 g.) and ethanol (400 ml. ) were refluxed with 
hydroxy lamine (30.0 g.) in water (200 ml.) for 2 hrs.
On cooling the reaction mixture was diluted by the addition 
of 1 500 ml. of water and made acidic by the addition of 
acetic acid. The product separated as a crystalline mass 
which was collected by filtration. Crystallisation from 
petroleum ether (b.p. 60-80^) gave rods (26.0 g., 87 5 ) 
with m.p. 119 "^ [lit. , (101) 119'] .
1^ ] D = ^ 47  ^ (C = 0.84 in chloroform) [lit. , (fo|)
42. 4^  in ethanolJ .
D camphor nitrimine. (XlIV)
This compound was prepared by the method of Houben and 
Pfanlmch ( 88). D ( + ) camphor oxime (25.0 g. ) was dissolved 
in ether (250 ml.) in a 1 litre separating funnel and a 
solution of sodium nitrite (25.0 g.) and concentrated 
sulphuric acid (15*0 g.) in I60 ml. of water added and the 
mixture shaken. The by-product of camphor imine nitrite 
which separated, was removed by filtration (5*0 g. , 20 w) 
and the ethereal layer concentrated under reduced pressure 
in the absence of heat in order to avoid decomposition of 
the product. Colourless needles subliming at 26 0 ° without
330.
melting* The material was used in the next step without 
further purification.
D (-) Camnhor imine (XIV. )
D-Camphor nitrimine as isolated in the previous step 
was treated with sufficient ether to ensure complete 
lio^uifaction and 100 ml. of *880 ammonia added. After 
shaking the mixture vigorously it was allowed to stand 
overnight. Extraction mth ether followed by removal of 
solvent gave the desired product which was converted to 
the hydrochloride as plates (14.0 g . , a) with m.p. 210^.
m.p. nf free base 93-94^^ [lit. , ( 1^ 4 ) 95 
The free base hadIKI D = -22° (C = 1.16 in chloroform).
The infrared spectrum of the hydrochloride in n u j o l  showed 
a strong C = N peak at 1700 c m"\
D-borny]nmine and D-i sobernvlamine (XLVI)
D (-) camphor imine hydrochloride (3*5 g . ) and 
ammonium chloride (1.0 g. , 1 mole) were added to 100 ml. 
of liquid ammonia in a 250 ml. 3-necked flask fitted with 
stirrer and air condenser. Then small pieces of metallic 
lithium were added until the solution became permanently 
blue. The blue colour was carefully destroyed after some 
time with solid ammonium chloride which was dropped dov/n 
the condenser and the solution was left until the ammonia 
had evaporated off completely. Water and ether were then
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added and the mixture transferred to a separating funnel*
The ethereal layer yielded a white crystalline solid
which was soluble in ethanol and petroleum ether (b.p*
60-80° ). The derived hydrochloride v/as obtained as a white
0
pov/der which melted and sublimed at 244 . The infrared 
spectrum of the free base in nujol confirmed that complete 
reduction of the imine had taken place but the m.p. was 
not sharp (160-175^)* The product was in fact a mixture 
of the isomers bornyl and isobornyl amine. Attempts to 
separate the isomers by chromatography over alumina 
(Brockman grade III) in petroleum ether (b.p. 60-80°) 
were unsuccessful.
Generation nf Ketere. (uj_g q)
Ketene v/as prepared according to the method of Williams 
and Hurd by passing acetone vapour over an electrically
heated chromel filament suspended from the top of a 
ground glass joint.
The filament. A,v/as prepared from a 175 cm length of 
B and S gauge 24 chromel A v/ire an alloy of nickel (80 /O 
and chromium (20 by stretching the spiral obtained by 
v/rapping the v/ire around a 3 mm. diameter rod to a length 
of 70 cm. The filament so obtained v/as supported on 
platinum hooks, B, 15 mm. in length and sealed into a pyrex 
supporting rod. Tv/o more platinum hooks, B^  supported the 
filament at the bottom of the rod.
The ends of the filament v/ere connected to tungsten 
leads of B and S gauge 24 v/ire by means of nickel sleeves, 
C^IO mm. long and of 3*5 mm. internal diameter equipped 
v/ith tv/o set screws. These tungsten leads were sealed into 
the glass, and to them were soldered B and S gauge 24 
copper v/ires (insulated by 6 mm. glass tubing held in 
place by the cork stopper D ) v/hich v/ere connected to a 
source of.220 volts through a variac Rheostat.
The filament v/as contained in a chamber E, constructed 
from a 25 cm. length of glass tubing of 70 mm. internal
KtTtnc
»fo RK.t,o.t«-t
Fig.5.
Ketene generator.
A - Filament; B - Platinum hooks; C- Nickel sleeves;
D - Cork stopper; E - Filament chamber; F - Connecting tube; 
G - Side arm; H - Reflux return tube; I - Double spiral 
condenser; J - Single spiral condenser; K - Liquid trap ;
L - Round bottomed flask for acetone.
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diameter. The connecting tube at the bottom F, was 12 mm. 
tubing, the side arm G, near the top of the filament 
chamber was 15 mm. tubing and reflux return tube H, from 
side arm was 6 mm. tubing.
One condenser I, which was connected to the side arm 
of the filament chamber was a double spiral 50 cm. long, 
and the second condenser J, was a single spiral condenser 
90 cm in length. The two were connected at the top. The 
liquid trap K, connected to the lower end of the single 
spiral condenser was provided with a stopcock for removal 
of liquid from the trap.
Operation - - Acetone was placed in the round bottomed
flask L, which v/as attached to the lamp by means of a
rubber stopper. The introduction into the flask of 
sufficient glass v/ool to extend a few cm. above the surface 
of the liquid served to prevent bumping. After the outlet 
tube had been connected to the reaction flask through a 
glass tube, the stopcock on the liquid trap was closed, 
and the liquid in the round bottomed flask was heated by a 
heating mantle until it refluxed gently from the condenser 
above. About 5 mins. refluxing v/as allowed to drive the
air from the filament chamber. The current was then passed
through the filament, which v/as heated to a dull red glow
11.4.
(temperature 700-750^) to pyrolise the acetone.
After starting the operation the apparatus needed 
little attention. Occasionally condensed liquid had to he 
removed from the trap. If the condensers allow too much 
acetone to pass, a trap surrounded by ice water may be 
placed between the outlet for ketene and the reaction 
fla sk.
At the end of a run the following operations were 
carried out rapidly 1. The source of heat was removed,
2. the filament current was turned off and 3* the stopcock 
on the trap v/as opened.
In order to ensure that ketene was being generated, a 
steady and effluent stream of the gas was passed through 
excess aniline to ensure that crystals of acetanilide 
appeared immediately.
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